 Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
GDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in DRB3*02:02
patients with multiple sclerosis
Planas, Raquel; Santos, Radleigh; Tomas-Ojer, Paula; Cruciani, Carolina; Lutterotti, Andreas; Faigle,
Wolfgang; Schaeren-Wiemers, Nicole; Espejo, Carmen; Eixarch, Herena; Pinilla, Clemencia; Martin,
Roland; Sospedra, Mireia
Abstract: Multiple sclerosis is an immune-mediated autoimmune disease of the central nervous sys-
tem that develops in genetically susceptible individuals and likely requires environmental triggers. The
autoantigens and molecular mimics triggering the autoimmune response in multiple sclerosis remain in-
completely understood. By using a brain-infiltrating CD4<jats:sup>+</jats:sup> T cell clone that is
clonally expanded in multiple sclerosis brain lesions and a systematic approach for the identification of its
target antigens, positional scanning peptide libraries in combination with biometrical analysis, we have
identified guanosine diphosphate (GDP)–<jats:sc>l</jats:sc>-fucose synthase as an autoantigen that is
recognized by cerebrospinal fluid–infiltrating CD4<jats:sup>+</jats:sup> T cells from HLA-DRB3*–
positive patients. Significant associations were found between reactivity to GDP-<jats:sc>l</jats:sc>-
fucose synthase peptides and DRB3*02:02 expression, along with reactivity against an immunodominant
myelin basic protein peptide. These results, coupled with the cross-recognition of homologous peptides
from gut microbiota, suggest a possible role of this antigen as an inducer or driver of pathogenic autoim-
mune responses in multiple sclerosis.
DOI: https://doi.org/10.1126/scitranslmed.aat4301
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-158835
Journal Article
Accepted Version
Originally published at:
Planas, Raquel; Santos, Radleigh; Tomas-Ojer, Paula; Cruciani, Carolina; Lutterotti, Andreas; Faigle,
Wolfgang; Schaeren-Wiemers, Nicole; Espejo, Carmen; Eixarch, Herena; Pinilla, Clemencia; Martin,
Roland; Sospedra, Mireia (2018).
GDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in
DRB3*02:02 patients with multiple sclerosis. Science Translational Medicine, 10(462):eaat4301.
DOI: https://doi.org/10.1126/scitranslmed.aat4301
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
1   
 
GDP-L-Fucose Synthase As A Novel CD4+ T Cell-Specific Autoantigen in DRB3*02:02 
Multiple Sclerosis Patients 
 
 
 
Authors:  Raquel Planas1, Radleigh Santos2, Paula Tomas-Ojer1, Carolina Cruciani1, Andreas 
Lutterotti1, Wolfgang Faigle1, Nicole Schaeren-Wiemers3, Carmen Espejo4, Herena Eixarch4, 
Clemencia Pinilla2, Roland Martin1, Mireia Sospedra1* 
 
Affiliations: 
1 Neuroimmunology and MS Research (nims), Department of Neurology, University Zurich, 
Frauenklinikstrasse 26, 8091 Zürich, Switzerland 
2 Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway Port St. Lucie, FL 
34987, USA. 
3 Department of Biomedicine, University Hospital Basel, Hebelstrasse 20, 4031 Basel, 
Switzerland 
4 Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall 
d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain; 
Universitat Autònoma de Barcelona, 08193 Bellaterra, Cerdanyola del Vallès, Spain. 
 
 
*Corresponding author: 
Mireia Sospedra, PhD 
Neuroimmunology and MS Research (nims) 
Department of Neurology 
University Hospital Zürich 
Frauenklinikstrasse 26 
8091 Zürich 
Switzerland  
Tel. +41442553905 
Fax. +41442558864 
e-mail: Mireia.SospedraRamos@usz.ch 
 
 
One Sentence Summary: Using a brain-infiltrating T cell clone that is clonally expanded in 
multiple sclerosis brain lesions and positional scanning peptide libraries in combination with 
biometrical analysis, we have identified GDP-L-fucose synthase as a putative autoantigen that 
is recognized by cerebrospinal fluid-infiltrating CD4+ T cells from HLA-DRB3*-positive patients. 
 
 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
2   
ABSTRACT 
Multiple sclerosis is a CD4+ T cell-mediated autoimmune disease of the central nervous system 
that develops in genetically susceptible individuals and likely requires environmental triggers. 
The autoantigen/s and molecular mimic/s triggering the autoimmune response in multiple 
sclerosis remain incompletely understood. By using a brain-infiltrating T cell clone that is 
clonally expanded in multiple sclerosis brain lesions and an unbiased approach for the 
identification of its target antigens, positional scanning peptide libraries in combination with 
biometrical analysis, we have identified GDP-L-fucose synthase as a novel autoantigen that is 
recognized by cerebrospinal fluid-infiltrating CD4+ T cells from HLA-DRB3*-positive patients. 
Significant associations were found between reactivity to GDP-L-fucose synthase peptides and 
DRB3*02:02 expression, along with reactivity against an immunodominant myelin basic protein 
peptide. These results, coupled with the cross-recognition of homologous peptides from gut 
microbiota, suggest a possible role of this antigen as inducer or driver of pathogenic 
autoimmune responses in MS. 
 
 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
3   
 
INTRODUCTION 
Multiple sclerosis (MS) is considered a demyelinating autoimmune disease of the central 
nervous system (1-4). The inflammatory infiltrate in demyelinating brain lesions, the intrathecal 
production of oligoclonal immunoglobulin G, the genetic trait consisting of multiple immune-
related genes (5, 6), the positive effect of immunotherapies targeting B and T cells, and the 
similarities with the animal model experimental autoimmune encephalomyelitis, all support that 
MS is an immune-mediated disease. The dominance of CD8+ T cells in MS brain lesions and 
the predisposition conferred by the HLA-A*03:01 allele and protection by HLA-A*0201 (6, 7) as 
well as evidence in experimental animal models (8) hint at a relevant role of these cells in MS 
pathogenesis. However, the fact that the HLA-DR15 haplotype is by far the strongest genetic 
risk factor associated with MS and that immunization with myelin components induces relapsing 
or chronic demyelinating disease models, which can be transferred by myelin-specific CD4+ T 
cells to naive animals, underscore that autoreactive CD4+ T cells play a central role in MS 
pathogenesis (1). Although myelin protein/peptides are considered relevant autoantigens in MS 
(9), the full spectrum of target antigen(s) driving the immune response in this disease has yet to 
be defined. 
The etiology of MS involves both a complex genetic trait with more than 100 quantitative trait 
loci (5, 6) and several environmental risk factors including vitamin D, smoking (10), viral 
infections (11) and gut microbiota (12). Several studies have reported distinct fecal microbial 
community profiles in MS patients compared to healthy controls (13-16), which might affect 
autoimmune responses by regulating permeability of the blood brain barrier (BBB), by 
modulating the maturation, activation and function of immune cells (12, 15-17), or by controlling 
the maturation and function of microglia (18) and astroglia (19). In order to be able to cross the 
BBB and infiltrate the brain, autoreactive T cells first have to be activated outside the CNS. 
Cross-reactivity between autoantigens and peptides from pathogens or gut microbiota, i.e. 
molecular mimicry, has been considered a putative trigger of the autoimmune reaction in MS. 
The identification of autoantigen/s and molecular mimic/s targeted by pathogenic CD4+ T cells 
in MS may improve our understanding of disease mechanisms, help in diagnostic classification 
of MS patients and enable the development of antigen-specific immunotherapies (20). In the 
past, the search for candidate autoantigen/s in MS has concentrated on myelin components 
based on the fact that demyelination is a hallmark of MS brain lesions. Furthermore, 
immunological research in MS patients focused on studying myelin-specific T cells from the 
peripheral blood, since the target tissue, i.e. brain and spinal cord, is rarely available for 
immunological studies. Autoimmune diseases like primary biliary cirrhosis can be exquisitely 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
4   
organ- or tissue-specific, and nevertheless T cell autoreactivity be directed against ubiquitous 
autoantigens such as pyruvate dehydrogenase (21). Thus, the focus on myelin-specific CD4+ T 
cells and on cells circulating in the peripheral blood has had limitations in the search for 
candidate autoantigen/s and molecular mimic/s in MS. Non-myelin target antigens should 
therefore also be considered in MS. To overcome these limitations, we (a) applied the unbiased 
identification of stimulatory peptides using positional scanning peptide libraries (22, 23) and 
biometrical analysis (24, 25), and (b) concentrated on putatively disease-relevant T cells that 
infiltrated brain lesions and were clonally expanded locally. We focused on T cell clone (TCC) 
21.1, a CD4+ TCC that was identified in active pattern II demyelinating brain lesions from a 
secondary progressive (SP) MS patient using deep T cell receptor (TCR) β-chain sequencing 
and that was isolated from autologous cerebrospinal fluid (CSF)-infiltrating cells as previously 
described (26). The release of Th2 cytokines and the ability to help B cells (26) supports a 
pathogenic role of this TCC in pattern II demyelination that is mediated by antibodies and 
complement (27). Using the above methodological approach, we have identified GDP-L-fucose 
synthase as the main specificity of TCC21.1. Reactivity against this protein as well as against 
myelin and putative molecular mimic/s has then been examined more broadly in CSF-infiltrating 
CD4+ T cells from MS patients and led to the identification of a novel target autoantigen in MS. 
 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
5   
RESULTS 
Peptide mixtures to identify the specificity of a brain-infiltrating TCC 
TCC21.1 is a CD4+ TCC isolated from CSF-infiltrating cells and clonally expanded in two active 
white matter demyelinating MS lesions (LI and LIII) from a SPMS patient (1154SA) with pattern 
II demyelination (26). TCC21.1 releases Th2 cytokines and helps proliferation and antibody 
production by autologous B cells upon unspecific activation. TCR α- and β-chain sequences of 
TCC21.1 are: TRAV12-2, TRAJ42*01, CDR3α CAVNEGSQGNLIF and TRBV11-2*01, TRBJ1-
2*01, TRBD1*01, CDR3β CASSGRGPSYGYT, respectively. In order to study the peptides 
recognized by this TCC of unknown specificity using a decapeptide positional scanning library, 
we first identified the HLA class II molecule used by TCC21.1 to recognize the peptide mixtures 
(28). Since patient 1154SA was homozygous for the DR15 haplotype, we tested TCC21.1 
initially only with the mixtures with amino acids (AAs) defined at position 5, presented by EBV 
immortalized BLS B cells (BCL) transfected with different single autologous HLA DR/DQ 
molecules (DRA*01:01/DRB5*01:01, DRA*01:01/DRB1*15:01 and DQA1*01:02/DQB1*06:02).  
As readout of T cell activation we used GM-CSF production (29), since TCC21.1 releases this 
cytokine after unspecific stimulation with anti-CD3 and PMA (26). Only mixtures presented by 
BCL expressing DRB1*15:01 class II molecules were stimulatory (Fig. 1A). We then tested 
TCC21.1 with the complete decapeptide positional scanning library (200 mixtures), presented 
by BCL expressing DRB1*15:01 class II molecules. GM-CSF release in response to the 
complete library is shown in Fig. 1B (black histograms). Next, we generated a biometrical 
analysis scoring matrix by assigning numerical values to the stimulatory potential of each of the 
20 defined AAs in each of the ten positions of the decapeptide library as previously described 
(24). Here, the values were calculated as the log base 10 of the median GM-CSF (pg/ml) 
secretion of three independent experiments in the presence of mixtures, minus the secretion in 
the absence of mixtures (Fig. 1C). Based on a model of independent contribution of individual 
AAs to peptide antigen recognition, the predicted stimulatory score of a given peptide is the sum 
of the matrix values of each AA contained in the peptide at each position (24). This scoring 
approach was applied to rank, according to their stimulatory score that is predictive of their 
stimulatory potency, all natural overlapping 10-mers peptides of the protein sequences within 
the UniProt human protein database (30). Based upon these predicted values, we synthesized 
and tested at 5 µg/ml the 50 predicted human natural peptides with highest scores (Table S1). 
Unexpectedly, none of the peptides was clearly stimulatory (Fig. 1D). The predictive capacity of 
the above approach combining positional scanning library and biometrical analysis was lower 
for this TCC than for others in previous studies (25). 
To further explore this unusual discrepancy between the mixture activities and the lower than 
expected activity of the peptides described above, we first noted that TCC21.1 also released 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
6   
high levels of IL-10 after unspecific stimulation with anti-CD3 and PMA (26). TCC21.1 was then 
tested with the complete decapeptide positional scanning library using IL-10 production as 
readout (Fig.1B, white histograms). A similar but not identical response pattern was obtained 
with both readouts. The most stimulatory mixtures with both approaches are shown in Fig. 1C. 
Interestingly, these mixtures have identical defined AAs in consecutive positions, suggesting a 
possible recognition of one AA motif in multiple frames. To confirm this observation, a set of 22 
dual-defined mixtures (i.e. positional scanning mixtures with two defined positions) was 
designed, synthesized, and tested (Fig. 1E); the results confirmed the presence of a unique 
recognition motif (LHSXFEV) with different flanking residues (Fig. 1F). In order to apply this 
recognition motif in the two frames to the original GM-CSF-derived matrix and perform 
biometrical analysis, we used the harmonic mean model (HM) (31) to integrate the stimulatory 
responses of some of the dual defined mixtures (Fig. 1E, Frame 1/2-HM mixtures) into the 
original matrix (Fig. S1). Using the new “harmonic boost” frame 1 and frame 2 matrices, all 
natural overlapping 10-mers peptides in the protein sequences within the UniProt human 
database were scored and ranked as before. The 50 predicted natural peptides with highest 
scores for both matrices were synthesized and tested for GM-CSF release (Table S1). These 
two matrices allowed us the identification of three clearly stimulatory peptides (Fig. 1G). The two 
most stimulatory peptides, NVLHSAFEVG predicted with harmonic boost frame 1 and 
DNVLHSAFEV predicted with harmonic boost frame 2, belong to GDP-L-fucose synthase 
encoded by the TSTA3 gene, and overlap by 9 AAs. The third stimulatory peptide 
(KLLLHSGVEN) was predicted with harmonic boost frame 2 and belongs to a transmembrane 
protein (FLJ37396). 
GDP-L-fucose synthase as the main autoantigen for a brain-infiltrating TCC 
In order to identify autoantigens recognized by TCC21.1 in the two autologous brain lesions 
within which TCC21.1 was known to be clonally expanded (LI and III (26)), the harmonic boost 
frame 1 and frame 2 matrices were then used to score and rank, according to their stimulatory 
score, all natural overlapping 10-mer peptides in the protein sequences within a brain-protein 
sub-database created with RNASeq-based transcriptome data from these two lesions 
(GSE60943). Of the 40 predicted natural brain peptides with highest scores for the frame 1 
matrix, 38 peptides were already predicted from the unbiased UniProt human database. For 
frame 2 matrix, the top 40 peptides were previously predicted (Table S1). The two new peptides 
for frame 1 were synthesized and tested. NVLHSAFEVG (GDP-L-fucose synthase 96-105) and 
DNVLHSAFEV (95-104) were the only peptides from proteins transcribed in autologous brain 
lesions found to stimulate TCC21.1 (Table S1). 
Transcript level, expressed as reads per kilo base of exon model per million mapped reads 
(RPKM), of GDP-L-fucose synthase in the autologous brain LI and LIII is shown in Table 1. 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
7   
Transcript values for other brain-specific genes are also shown as quality control of the samples 
and as reference for genes expressed at high (myelin basic protein (MBP), myelin proteolipid 
protein 1 (PLP1)), and medium (myelin-associated glycoprotein (MAG), myelin-associated 
oligodendrocyte basic protein (MOBP) and oligodendrocyte myelin glycoprotein (OMG)) level. 
Seventeen GDP-L-fucose synthase peptides were identified in white and grey matter brain 
tissue from other MS patients and non-MS controls by proteomic analysis. The peptide 
sequences are listed in Table 1 as well as the peptide spectrum matches (PSM) in the different 
samples. The percentage of the GDP-L-fucose synthase AA sequence covered by identified 
peptides was 56%. Analysis of other brain-specific proteins as reference is also included (Table 
1 and Table S3). 
Characterization of GDP-L-fucose synthase recognition by a brain-infiltrating TCC 
As mentioned above, the two GDP-L-fucose synthase peptides recognized by TCC21.1 overlap 
by 9 AAs. We synthesized and tested on DRB1*15:01-expressing BCL nine additional 10-mer 
peptides overlapping by 9 AAs and identified an additional peptide, VLHSAFEVGA (97-106), 
which induced GM-CSF release (Fig. 2A). Peptide NVLHSAFEVG (96-105) gave the optimal 
response with an EC50 of 0.2 µg/ml (Fig. 2B) and was presented by DRB1*15:01 and 
DQB1*0602 molecules (Fig. 2C). As we demonstrated previously, the cross-reactivity and 
cross-restriction of TCC21.1 might facilitate its activation (32, 33). The common AAs of the three 
stimulatory GDP-L-fucose synthase peptides are VLHSAFEV (97-104).  Single alanine (A) 
substitutions of these three overlapping peptides revealed that the substitution of H99 and S100 
abrogated the T cell responses, suggesting that they are the primary AA involved in TCR or 
HLA interaction. The substitution of V97, L98, F102 or E103 for A in the most active peptide 
NVLHSAFEVG (96-105) resulted in peptides with some stimulatory activity, in contrast to the 
two other overlapping peptides in which their substitution resulted in non-stimulatory peptides. 
Thus the residues V97, L98, F102 and E103 appear to be secondary TCR or HLA contacts (Fig. 
2D). 
Next, we characterized the response of TCC21.1 to GDP-L-fucose synthase peptides presented 
by autologous irradiated peripheral blood mononuclear cells (PBMCs) and BCL. GDP-L-fucose 
synthase peptides presented by the two types of APCs were able to induce proliferation, 
although PBMCs were more efficient (Fig. 2E). We also analyzed the functional phenotype of 
this response (Fig. 2E). TCC21.1 displayed a Th2 phenotype, releasing mainly Th2 cytokines 
and lower levels of IL-22 and IL-10. Unexpectedly, when peptides were presented by 
autologous BCL, they induced higher levels of IFNγ. In addition, TCC21.1 also released GM-
CSF and IL-3 in response to GDP-L-fucose synthase peptides (Fig. 2F). The release of these 
two cytokines seems to be a specific feature of this TCC compared with other Th1, Th1* or 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
8   
Th1/2 TCCs that our laboratory had generated from patients with different conditions. 
Intracellular cytokine staining confirmed the Th2 functional phenotype of TCC21.1 in response 
to GDP-L-fucose synthase (96-105) (Fig. 2G). More than 60% of TCC21.1 cells were IL-4+ after 
stimulation with GDP-L-fucose synthase (96-105), while only around 12% were IFNγ+. Around 
60% of the cells were GM-CSF+ and 47.7% of these also IL-4+. Further characterization of 
TCC21.1 demonstrated expression of CD28 and the chemokine receptor CRTh2 (Fig. 2H). 
Recognition of GDP-L-fucose synthase by CSF-infiltrating CD4+ T cells from patient 
1154SA 
Sixty-two 15-mer peptides overlapping by 10 AAs and covering the entire GDP-L-fucose 
synthase protein (Table S2) were synthesized and tested for their ability to induce TCC21.1 
proliferation when presented by autologous PBMCs. Seven immunodominant/encephalitogenic 
myelin peptides (34), CEF (cytomegalovirus, EBV, influenza virus and tetanus toxoid) peptide 
pool and control beads were tested in parallel (Table S2 and Fig. 3A). TCC21.1 only recognized 
two overlapping GDP-L-fucose synthase peptides, 91-105 and 96-110, containing the three 
stimulatory decapeptides (95-104, 96-105 and 97-106) that we identified previously. Bulk CSF-
infiltrating CD4+ T cells after short and long phytohaemagglutinin (PHA) expansion (see M&M) 
were tested with the GDP-L-fucose synthase-, myelin- and CEF peptides (Fig. 3A). Long- but 
not short-PHA-expanded CSF-infiltrating CD4+ T cells proliferated in response to three GDP-L-
fucose synthase peptides suggesting a low frequency of specific TCCs in the initial CSF 
infiltrate and a preferential expansion with enrichment of some TCCs, including TCC21.1, during 
the long PHA expansion. Proliferation of long-PHA-expanded CSF-infiltrating CD4+ T cells to 
peptides 91-105 and 96-110 was mainly mediated by TCC21.1 since Vb21+ (that included 
TCC21.1) but not Vb21- CSF-infiltrating CD4+ T cells proliferated in response to this peptide 
(Fig. 3B). Interestingly, the third GDP-L-fucose synthase peptide recognized by long-PHA-
expanded CSF-infiltrating CD4+ T cells (191-205) was not recognized by TCC21.1 (Fig. 3A). We 
generated a T cell line (TCL) from these proliferating cells (TCL39, Fig. 3C), and its TCR 
sequencing confirmed the existence of three TCCs other than TCC21.1. Although we have not 
been able to identify the TCC responsible for GDP-L-fucose-specific response, it is interesting 
to note that two of these TCCs were clonally expanded in active brain lesion III and ranked in 
positions 51 and 56 regarding their frequency (Fig. 3D (26)). Functional phenotype analysis of 
responses to peptides 91-105 and 191-205 showed a Th2 response for peptide 91-105, 
confirming activation of TCC21.1, but a Th1/Th2 response for peptide 191-205 supporting 
activation of other TCCs (Fig. 3E). Bulk CSF-infiltrating CD4+ T cells did not recognize either the 
myelin peptides or the CEF peptide pool. 
Recognition of GDP-L-fucose synthase by CSF-infiltrating CD4+ T cells from CIS/MS 
patients. 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
9   
In order to find out how frequently specific recognition of GDP-L-fucose synthase occurs in 
CSF-infiltrating CD4+ T cells in CIS/MS patients, we developed a new protocol to expand fresh 
CSF-infiltrating CD4+ T cells to high numbers in a single round to minimize variations in the 
original T cell repertoire (see M&M). Resting PHA-expanded CSF-infiltrating CD4+ T cells from 
31 CIS/MS patients were tested in quadruplicate with the 62 overlapping GDP-L-fucose 
synthase peptides presented by autologous irradiated PBMCs, as well as with the seven myelin 
peptides, CEF peptide pool and control beads. All SIs (except control beads) were pooled and 
SI values less than one were treated as having unit value. Cluster k-means analysis was 
performed to determine the optimal cut-off to differentiate responsive SI values from non-
responsive in this patient population. K-means clustering resulted in a cut-off value of 1.455 to 
differentiate positive responses from negative. Subsequently, for each patient, all peptides 
having a median SI (of the quadruplicate wells) greater than 1.455 were identified as positive 
responses (Table S4A). Notably, a follow-up study of the negative control well SI values using 
Monte-Carlo bootstrapping indicated that the 1.455 cut-off showed a 0.26% false positive rate 
when applied to simulated medians of quadruplicate negative values. 
Next, patient scores were constructed by calculating the sum of each responsive peptide 
median SI, weighted by the number of total patients that responded to that peptide.  In this way, 
both the SI values themselves for each peptide, as well as the relative immunogenicity of each 
peptide, were factored in. Three-cluster k-means analysis was performed on base 10 patient 
scores and clearly grouped patients into three categories: “nonresponders”, “moderate 
responders”, and “high responders” (Table S4A). Nineteen patients (61.3%) were therefore 
characterized as nonresponders to GDP-L-fucose synthase (Fig. S2A), six (19.35%) as 
moderate, and six (19.35%) as high responders (Fig.4A). No significant differences between the 
three groups were found for CEF responses or for the positive or negative controls (Fig. S2B). 
Immunodominant peptides were defined as peptides able to induce positive responses in at 
least three patients. The 14 GDP-L-fucose peptides achieving this criterion are shown in Figure 
4B. Functional analysis of the strongest responses to some immunodominant peptides revealed 
a Th1 phenotype with mainly production of IFNγ (Fig. 4C). 
T cell responses to immunodominant GDP-L-fucose synthase peptides are associated 
with reactivity against MBP 83-99 
In order to judge better the reactivity of CSF-infiltrating CD4+ T cells in CIS/MS patients against 
GDP-L-fucose synthase peptides, we compared it with reactivity against the seven 
immunodominant/encephalitogenic myelin peptides, which had previously been shown to be the 
targets of high avidity T cells in MS (34) (Fig.5A). Four out of six (67%) of the high responder 
patients to GDP-L-fucose synthase also responded to myelin peptides, while only one of the six 
(17%) moderate responders and two of the 19 (11%) nonresponders did (Fig.5A). This 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
10   
association is significant (p=0.0138, Fisher’s exact test). When comparing the recognition of 
immunodominant GDP-L-fucose synthase peptides and specific myelin peptides (Fig.5B), we 
found a significant association between recognition of peptide MBP 83-99 and three 
immunodominant GDP-L-fucose synthase peptides (1-15 – p=0.0122, 156-170 – p=0.0122, and 
256-270 – p=0.0481, Fisher’s exact tests with Bonferroni-Holm correction) (Fig.5B). 
T cell response to GDP-L-fucose synthase is associated with DRB3* alleles 
Table 2 summarizes demographical and clinical characteristics of the CIS/MS patients and their 
designation as nonresponders, moderate responders, or high responders to GDP-L-fucose 
synthase peptides. No significant differences between groups could be identified regarding 
disease course or clinical presentation, gender, age, CSF IgG index or number of CSF-
infiltrating cells. HLA class II typing is also summarized in Table 2. Interestingly, all six of the 
high responder patients are DRB3*02:02, while only one of the six (17%) moderate responders 
and four of the 19 (21%) nonresponders express this class II molecule. This association is 
significant (p=0.0006, Fisher’s exact test). Further, when looking only at the difference between 
moderate responders and nonresponders, an additional significant association was observed; 
three of the six (50%) moderate responders are DRB3*01:01 while only one of the 19 (5%) 
nonresponders is (p=0.0312, Fisher’s exact test). The predicted binding affinities of positive 
peptides to DRB3*01:01 and DRB3*02:02 are summarized in Table S4B. 
Cross-recognition of human and bacterial GDP-L-fucose synthase peptides by CD4+ CSF-
infiltrating T cells 
GDP-L-fucose synthase is a cytosolic enzyme that converts GDP-4-keto-6-deoxy-D-mannose 
into GDP-L-fucose that then is used to fucosylate oligosaccharides (35) including sugars and 
glycoproteins on mucosal intestinal cells. Gut microbiota use a mammalian-like pathway of 
fucosylation to colonize the mammalian intestine (36). GDP-L-fucose synthase is an 
evolutionarily conserved protein (37). In order to search for molecular mimics that might induce 
or perpetuate GDP-L-fucose synthase-specific T cells, we therefore compared the protein 
sequence of human GDP-L-fucose synthase with several bacterial GDP-L-fucose synthase 
sequences. We focused on bacterial species that have been reported to be altered in gut 
microbiota of MS patients and for which GDP-L-fucose synthase sequences were available, 
further on bacterial species present in gut microbiota without association with MS, and also 
some pathogens not present in gut (Table S5). Sequence comparison of the four main 
immunodominant peptides is shown in Table S6A.  The most immunodominant human GDP-L-
fucose synthase peptide, 161-175, showed the highest homology with bacterial sequences, and 
particularly with those associated with MS, with which it shares at least 40% homology. Eight 
15-mer bacterial peptides with at least 40% homology with the human 161-175 peptide and 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
11   
shared by different bacteria species were synthesized as 15- and 10-mer (overlapping in 5 AAs) 
peptides (Table S6B). Reactivity of CSF-infiltrating CD4+ T cells against these bacterial peptides 
was tested in eight CIS/MS patients. Six of these patients were patients from our previous 
cohort from whom autologous PBMCs were available (748UR, 1005ME, 1129RE, 1173DI, 
718MA and 776JE). Five of them (748UR, 1129RE, 1173DI, 718MA and 776JE) had a positive 
response to human peptide 161-175, while patient 1005ME did not respond to this peptide and 
was included as control (Fig. 4A). Two additional patients (1440AM and 1489HE), from whom 
autologous PBMCs were not sufficient to test all GDP-L-fucose synthase peptides and who 
were not included in the previous cohort, were also identified as high responders to GDP-L-
fucose synthase peptides, including peptide 161-175, after testing with a selection of six 
immunodominant peptides (Fig. S3A). Both patients were also DRB3* (Fig. S3B). 1489HE was 
DRB3*02:02 and 1440AM expressed DRB3*03:01 with high homology with DRB3*02:02 (38). 
CD4+ CSF-infiltrating T cells from four of these patients (1489HE, 1173DI, 748UR and 776JE) 
proliferated in response to different bacterial peptides (Fig. 6). Interestingly, the four patients 
showed reactivity against peptides 3 and 4, which show the highest degree of homology 
(53,3%) with the human peptide (Fig. 6). Blast (NCBI) analysis of these bacterial peptides (Fig. 
S3C) revealed that peptide 3 was shared by bacteria from the genera Akkermansia and 
Prevotella, which both have been reported to be altered in MS patients (14). Peptide 4 is also 
shared by different bacterial genera present in gut microbiota and belonging to the phylum 
Bacteroidetes, the second most abundant phylum, after Firmicutes, in gut microbiota. 
 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
12   
DISCUSSION 
Assuming that MS is a CD4+ T cell-mediated autoimmune disease it is crucial to elucidate the 
target antigens responsible for inducing CD4+ T cell activation to understand MS pathogenesis. 
In addition, it is a prerequisite for developing antigen-specific tolerization strategies. Using 
positional scanning peptide libraries in combination with biometric analysis, we have identified 
GDP-L-fucose synthase as the main specificity of TCC21.1, a brain-infiltrating and clonally 
expanded TCC from a SPMS patient with pattern II demyelination (26). In pattern II lesions, 
demyelination is mediated by deposits of antibody and complement in addition to macrophages 
and T cells (27). TCC21.1, in addition to be clonally expanded in active MS lesions, was able to 
release Th2 cytokines and help B cells after unspecific activation, characteristics that strongly 
support its putative pathogenic role in pattern II demyelination. Here, we confirmed a clear Th2 
functional phenotype of TCC21.1 in response to GDP-L-fucose synthase peptides presented by 
autologous PBMCs and the expression of the chemokine receptor CRTh2, a marker of human 
Th2 cells. Furthermore, in response to GDP-L-fucose synthase peptides, TCC21.1 also 
released GM-CSF, which is considered relevant in MS pathogenesis (39, 40), and IL-3, reported 
to promote Th2 responses (41, 42). Reactivity against GDP-L-fucose synthase peptides was 
also identified in bulk CSF-infiltrating CD4+ T cells from the same patient after long but not short 
PHA expansion. TCC21.1 and at least one other GDP-L-fucose synthase-specific CD4+ TCC 
were responsible for this response further supporting a putative role of GDP-L-fucose synthase 
as autoantigen. The inability to detect GDP-L-fucose synthase-specific CSF-infiltrating CD4+ T 
cells after short PHA expansion suggests a low frequency of these cells in the CSF. The fact 
that TCC21.1 and most likely also the TCC specific for peptide 191-205 were clonally expanded 
in the most active lesion III (26) suggests that these TCCs might be retained in the brain 
parenchyma and recirculate through the CSF compartment to a limited extent. The long PHA 
expansion that we performed to obtain sufficient cell numbers to isolate brain-infiltrating clonally 
expanded TCCs (26) resulted in enrichment of some TCCs that allowed us to identify at least 
one additional CSF-infiltrating TCC specific for GDP-L-fucose synthase. 
The identification of TCC21.1 specificity using positional scanning libraries was less efficient 
than in previous studies (23, 25) due to recognition by this TCC of peptides with identical 
binding/contact motif but variable flanking C- and N-terminal AA. MHC-class II molecules have 
open binding grooves and are able to present peptides with a highly variable length rendering 
TCR binding very flexible (43). However, at present it is unclear why the recognition of a TCR 
motif in different frames influenced the results for TCC21.1 more so than other TCCs. Further 
development of quantitative approaches to both detect and account for frame shifting within 
scoring matrices based on the results of TCC21.1 are currently in development. The number of 
stimulatory peptides identified for TCC21.1 was unusually low compared with previous studies 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
13   
(23, 25). The limited cross-reactivity of TCC21.1 might underlie the special features of this TCC 
recognition profile of the decapeptide positional scanning library. 
Analysis of bulk CSF-infiltrating CD4+ T cells from other CIS/MS patients after a single PHA 
expansion demonstrated reactivity against GDP-L-fucose synthase in 40% of patients. Fourteen 
immunodominant peptides were identified that unexpectedly induced a Th1 response excluding 
a firm association between GDP-L-fucose synthase reactivity and pattern II demyelination. 
Interestingly, a significant association between recognition of GDP-L-fucose synthase and 
myelin has been found between the immunodominant GDP-L-fucose synthase peptides 1-15, 
156-170 and 256-270 and the myelin peptide MBP 83-99, and all patients reacting to both GDP-
L-fucose synthase peptides and MBP 83-99 were high responders. The putative cross-
recognition of these peptides by CSF-infiltrating CD4+ T cells might play a relevant role in MS 
pathogenesis, since CD4+ T cells specific for MBP 83-99 not only are able to induce a 
demyelinating disease similar to MS in experimental animal models, but also to exacerbate the 
human disease (44-48). Further studies are needed to determine whether single TCCs are able 
to cross-recognize MBP 83-99 and GDP-L-fucose synthase peptides, whether the recognition of 
one of these peptides facilitates the release of the other and the novo activation of new 
autoreactive T cells, a phenomenon known as epitope spreading (49), or whether these 
responses co-develop from as yet unknown reasons. 
HLA typing of the CIS/MS patients demonstrated reactivity against GDP-L-fucose synthase in 
DRB3*-positive patients and particularly strong reactivity in those expressing DRB3*02:02. The 
HLA DRB1*03 and the DRB3* haplotype most likely appeared via gene duplication of a 
common DRB1* gene in that locus, and in consequence DRB3* has been considered a 
secondary redundant locus (50). However, the ability of DRB3* molecules to present a distinct 
pattern of peptides and the existence of DRB3*-restricted T cells in peripheral blood have been 
demonstrated (51). Here, we found that the GDP-L-fucose synthase peptide 51-65, the only 
peptide stimulatory in all high responder DRB3*02:02 patients, showed the highest predicted 
binding affinity to this class II molecule, suggesting DRB3*02:02-restricted T cell recognition of 
this peptide. The DRB3*02:02 allele has been associated with MS in Korean children (52) and 
also with neuromyelitis optica (NMO) (53). Interestingly, DRB3*02:02 was over-represented in a 
cohort of NMO patients, in whom aquaporin 4-specific T cells cross-recognized a peptide from 
Clostridium perfringens, a normal component of gut microbiota (54).  
The cytosolic enzyme GDP-L-fucose synthase converts GDP-4-keto-6-deoxy-D-mannose into 
GDP-L-fucose, which is then used by fucosyltransferases to fucosylate all oligosaccharides 
(35). Synthesis of GDP-L-fucose from free L-fucose represents a minor route. In mammals, 
fucosylated glycans play important roles in many biological processes including blood 
transfusion reactions, host-microbe interactions, and cancer pathogenesis (55, 56). Fucosylated 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
14   
glycans are highly expressed in brain tissue, and quantitative glycan profiling of human CNS 
myelin demonstrated an unusually rich variety of Lewis-type antigen containing fucosylated 
glycans compared with other tissues (57). Brain fucosylated glycans have been implicated in 
the molecular mechanisms that underlie neuronal development, survival and function (55, 58-
60) as well as in modulating immune responses. The encephalitogenic MOG is decorated with 
fucosylated glycans that support recognition by DC-SIGN on microglia and DCs. This 
recognition results in a tolerogenic signal characterized by IL-10 secretion and decreased T cell 
proliferation, while reduced fucosylation results in immunogenic signals (57). Reduction of brain 
fucosylated glycans as a consequence of T cell reactivity against GDP-L-fucose synthase might 
directly affect neurons and facilitate MS development by inducing a pro-inflammatory immune 
response. Fucosylated glycans are highly expressed also in gut tissue, where they play a 
crucial role in the host-microbe interaction (61). Fucosylation is less common in prokaryotic 
organisms, and it seems to be involved in adhesion, colonization, and regulation of the host 
immune response. In addition, a putative role of fucosylated glycans as mechanism to mimic the 
host and evade the immune system has been suggested in these organisms (56). Such a 
mechanism might be very beneficial for pathogens colonizing highly fucosylated tissues like the 
gut. In this context, the putative cross-reactivity of human and gut microbial GDP-L-fucose 
synthase peptides may represent a new role of gut microbiota in MS pathogenesis. Supporting 
this hypothesis, we demonstrated that CSF-infiltrating CD4+ T cells from four CIS/MS patients 
that were reactive against the human GDP-L-fucose synthase peptide 161-175 also recognized 
two gut microbial GDP-L-fucose synthase peptides from bacterial genera that have been 
associated with MS (13-16, 62-65) and that in addition showed the highest homology with the 
human peptide. However, since demonstration of cross-reactivity at single TCC level is missing, 
further investigation is required to clarify the putative involvement of gut-microbiota via this 
mechanism in MS pathogenesis. Recently, molecular mimicry between a specific β-cell 
autoantigen and a bacteroides integrase peptide has been demonstrated in mice. Diabetogenic 
CD8+ T cells specific of the pancreatic peptide were able to cross-recognize the microbiota 
derived peptide and suppress colitis (66). 
In conclusion, using positional scanning peptide libraries and biometrical analysis we identified 
GDP-L-fucose synthase as the main specificity of a brain-infiltrating clonally expanded TCC 
most likely involved in MS pathogenesis. This putative autoantigen is widely recognized by 
CSF-infiltrating CD4+ T cells from DRB3*-positive MS patients. The significant correlation 
between myelin and GDP-L-fucose synthase reactivity in DRB3*02:02 patients as well as the 
putative cross-recognition of homologous peptides from gut microbiota, support a role of this 
antigen as potential inducer or driver of relevant immune responses in MS. Further studies are 
needed to confirm the existence of DRB3*02:02-restricted TCCs able to cross-recognize myelin, 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
15   
human and bacterial GDP-L-fucose synthase peptides that might provide the basis for a role of 
molecular mimicry in the development of MS. 
 
 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
16   
MATERIAL AND METHODS 
Patient Material 
Patient 1154SA: CSF-derived mononuclear cells and PBMCs were obtained from a SPMS 
patient with pattern II demyelinating lesions as previously described (26). HLA-class I and II 
types of this patient were: A*32:01, A*33:01, B*14:02, B*51:01, DRB1*15:01, DRB5* 01:01, 
DQB1*06:02 and DQA1*01:02. 
CSF from diagnostic lumbar puncture and paired peripheral blood were collected from 31 
untreated MS patients: 8 patients with clinically isolated syndrome (CIS), 20 patients with 
relapsing-remitting (RR) MS and 3 patients with SPMS. Demographical and clinical 
characteristics of the patients are summarized in Table 2. Patients were recruited from the inims 
outpatient clinic and day hospital at the University Medical Center Hamburg-Eppendorf and the 
nims section, Neurology Clinic, University Hospital Zurich. MS diagnosis was based on the 
revised McDonald criteria (67). All CIS patients had CSF-specific oligoclonal bands detected by 
isoelectric focusing (IEF). Patients, who had not received steroids at least 4 weeks prior to 
enrolment or any immunomodulatory or immunosuppressive agent during the last 3 months, 
were considered untreated and included in the study. Fresh CSF cells from these patients were 
expanded in vitro (see below). PBMCs were freshly isolated from EDTA-containing blood tubes 
by Ficoll density gradient centrifugation (PAA, Pasching, Austria) and cryopreserved. 
The Ethik Kommission der Ärztekammer Hamburg, protocol No. 2758 and the Cantonal Ethical 
Committee of Zurich, EC-No. of the research project 2013-0001, approved the study 
procedures. Informed consent was obtained from all patients or relatives. 
Brain autopsy tissue from 13 MS patients (7 SPMS, 5 primary progressive (PP) MS and 1 
primary relapsing (PR) MS) and 7 non-MS controls were obtained from the UK Multiple 
Sclerosis Tissue Bank (UK Multicentre Research Ethics Committee, MREC/02/2/39). 
Demographical and clinical characteristics of MS patients and non-MS controls are summarized 
in Table S7. 
Transcriptomic and Proteomic Analysis 
Transcriptomic analysis of brain lesions was performed as previously described (26). The data 
discussed in this paper was deposited in NCBI's Gene Expression Omnibus and are accessible 
through GEO Series accession number GSE60943. 
For proteomic analysis, pressure-assisted protein extraction was performed with a barocycler 
(2320EXT, BioSciences, Inc, South Easton, MA) (68). Reduction and alkylation was applied on 
the homogenate before samples were digested with Lys-C and trypsin. Peptides were desalted 
on solid phase extraction columns (C18 Finisterre, Wicom Germany), vacuum dried, re-
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
17   
dissolved and measured (Nanodrop 1000, spectrophotometer (Thermo Scientific, Wilmington, 
DE, USA). Resulting peptides were purified and separated by hydrophilic interaction 
chromatography (HILIC, Agilent LC1200 equipped with a column Polyamin II 250 x 3.0 mm 120 
Å, 5µm) before they were injected on a nano liquid chromatography system Easy-nLC linked to 
an Orbitrap Fusion instrument (Thermo Fisher). Data analysis was performed with MASCOT 
software using a human UniProtKB/Swiss-Prot protein database (March 22, 2016 with 40912 
entries). Search parameters were 0.05 Da fragment mass tolerance and 10ppm precursor 
mass, minimal number of peptides 2, and FDR (false discovery rate) of 0.1%, allowing 2 mis-
cleavages on trypsin fragments. Carbamidomethylation at cysteine was set as a fixed 
modification, and oxidation of methionine, n-terminal acetylation as variable modifications. 
Positional Scanning Peptide Libraries and Individual Peptides 
A synthetic N-acetylated, C-amide L-amino acid (AA) decapeptide combinatorial library in a 
positional scanning format (200 mixtures) and twenty-two dual defined mixtures were prepared 
as previously described (69). Individual peptides (Table S1 and S2) were synthesized by 
Peptides and Elephants GmbH (Potsdam, Germany). 
Cells and culture conditions 
Bulk CSF-derived mononuclear cells from patient 1154SA were expanded as previously 
reported (26). Briefly, 2000 cells per well were seeded in 96-well U-bottom microtiter plates 
together with 2 x 105 allogeneic irradiated PBMC (45 Gy), 1 µg/ml of PHA-L (Sigma, St Louis, 
MO) and IL-2 supernatant (500 U/ml) (IL-2 hybridoma kindly provided by Dr. Sallusto, Institute 
for Research in Biomedicine, Bellinzona, Switzerland). Medium consisted of IMDM (PAA) 
containing 100 U/ml penicillin/streptomycin (PAA), 50 µg/ml gentamicin (BioWhittaker, 
Cambrex), 2 mM L-glutamine (Gibco, Invitrogen, Carlsbad, CA) and 5% heat-decomplemented 
human serum (PAA). Additional IL-2 was added every 3-4 days. After two weeks, cells were 
pooled (short expansion) or expanded by eight rounds of restimulation. In each round, 2000 
PHA-pre-expanded cells per well were seeded in 96-well U-bottom microtiter plates together 
with 2 x 105 allogeneic irradiated PBMC, PHA-L and IL-2. IL-2 was added every 3-4 days. After 
16 weeks, eight rounds of two weeks, cells were pooled (long expansion). CSF-infiltrating CD4+ 
T cells were positively selected from short and long PHA-expanded bulk CSF-derived cells 
using anti-CD4 magnetic beads (CD4 Micro Beads human MACS, Miltenyi Biotec Inc, CA, USA) 
and restimulated once again with PHA-L, IL-2 and allogeneic irradiated PBMC.  
TCC21.1 was established from CSF-infiltrating cells as previously described (26). TCL-39 was 
generated from CSF-derived CD4+ T cells (long PHA expansion) that responded to GDP-L-
fucose synthase peptide 191-205. Positive wells underwent five rounds of restimulation with 
PHA and allogeneic irradiated PBMCs and IL-2. Additional IL-2 was added every 3-4 days. 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
18   
The approach used to expand CSF-derived CD4+ T cells from the 31 CIS/MS patients was an 
adaptation from a method previously reported (70). Fresh bulk CSF-derived mononuclear cells 
were mixed with 5 x 106 allogeneic irradiated PBMCs and CD4+ T cells were positively selected 
with anti-CD4 magnetic beads. CD4+ fractions were then seeded at 1500 cells per well in 96-
well U-bottom microtiter plates together with 1.5 x 105 allogeneic irradiated PBMC, 1 µg/ml of 
PHA-L and IL-2 supernatant. Medium consisted of RPMI 1640 without Hepes (Pan-Biotech, 
Aidenbach, Germany) supplemented with 2 mM glutamine (Pan-Biotech), 1% (vol/vol) 
nonessential amino acids (Gibco), 1% (vol/vol) sodium pyruvate (Gibco), 50 µg/ml penicillin-
streptomycin (Corning, NY, USA), 0.00001% β-Mercaptoethanol (Gibco) and 5% human serum 
(Blood Bank Basel). Additional IL-2 was added every 4 days. Growing wells were transferred to 
48 well plates and finally to 75 cm3 flask until cells were fully rested (20-25 days). Cells were 
highly expanded in a single round of stimulation.  
An autologous B cell line (BCL) from patient 1154SA was generated by Epstein–Barr virus 
(EBV)-transformation. Bare lymphocyte syndrome (BLS) cells transfected with single HLA class 
II molecules, DR2a (DRA1*01:01, DRB5*01:01), DR2b (DRA1*01:01, DRB1*15:01) and DQw6 
(DQA1*01:02, DQB1*06:02) were kindly provided by Dr. Nepom and Dr. Kwok (University of 
Washington, Seattle). 
T cell stimulation 
TCC responses to single/dual defined peptide mixtures or individual decapeptides were tested 
by seeding in duplicate 2 x 104 T cells and 5 x 104 irradiated BLS cell lines or autologous BCL or 
1 x 105 irradiated PBMC (as indicated) with or without combinatorial peptide mixtures or 
individual decapeptides. 2.5 µg/ml PHA and 10-7 M PMA (Sigma), 1 µg/ml of surface-coated 
anti-CD3 (OKT3, Ortho Biotech Products, Raritan, NJ) and 0.5 µg/ml of soluble anti-CD28 
(Biolegend, San Diego, CA), and a T Cell Activation Kit (anti-CD3, anti-CD28, anti-CD2 beads) 
(Miltenyi Biotec) served as positive controls as indicated. 
The response of PHA-expanded CSF-infiltrating CD4+ T cells to GDP-L-fucose synthase, myelin 
and CEF peptides (Table S2) was tested by seeding in quadruplicate 6 x 104 T cells and 2 x 105 
irradiated autologous PBMCs with or without peptides. For EdU experiments BLS DRB1*15:01 
were used as APCs. T Cell Activation Kit was used as positive control.  
Cytokine measurement 
Cytokines in the supernatant of stimulated and unstimulated TCC21.1 or expanded CSF-
infiltrating T cells were measured after 48 h of culture using the Human T Helper Cytokine Panel 
LEGENDplex bead-based immunoassay (Biolegend), GM-CSF ELISA (BD Biosciences, 
Franklin Lakes, NJ) and IL-3 ELISA (Biolegend) according to the manufacturer´s instructions. 
The amount of each cytokine released by TCC21.1 or expanded CSF-infiltrating T cells to 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
19   
specific or unspecific stimuli was normalized by subtracting the amount of the corresponding 
cytokine released by T cells in absence of stimulus (negative control). For cytokines defining 
functional phenotypes, i.e. IFNγ for Th1, IL-4 for Th2, IL-17A and -F for Th17, IL-9 for Th9 and 
IL-22 for Th22, a threshold for positivity was defined based on published data (33, 71-73) to 
facilitate functional classification of TCC21.1. 
For intracellular cytokine staining, TCC21.1 was analyzed 48 h after stimulation. After 5 h in 
presence of GolgiStop protein transport inhibitor (BD Biosciences), T cells were labeled with 
Live/Dead® Aqua (Invitrogen). Following fixation and permeabilization with Cytofix/Cytoperm 
(BD Biosciences), cells were stained with antibodies against CD4 (APC-Cy7, Biolegend), IFN-γ 
(FITC, Biolegend), IL-4 (PE, BD Bioscience), GM-CSF (APC, Biolegend) and IL-3 (PE, 
Biolegend) in PBS containing saponin and BSA, and analyzed by flow cytometry.  
Proliferative Responses 
Proliferation was measured 72 h after stimulation by 3H-thymidine (Hartmann Analytic, 
Braunschweig, Germany) incorporation in a scintillation counter (Wallac 1450, PerkinElmer, 
Rodgau-Jürgesheim, Germany). The stimulatory index (SI) was calculated as follows: SI = 
Median (replicates cpm peptide) / Median (replicates cpm without peptide). 
Proliferation was also measured using a Click-iTTM EdU Flow Cytometry Assay Kit (APC, 
Molecular Probes, Invitrogen) following manufacturer’s instructions. Cells were stained with the 
following antibodies anti-CD3 (PE-Cy-7, e-Bioscience, San Diego, CA) and anti-TRBV-21 
(FITC, Beckman Coulter, Brea, CA) and analyzed by flow cytometry. 
Surface receptor expression 
Resting TCC21.1 was stained with antibodies against CD4 (PE-Texas Red, Thermo Fischer, 
Waltham, MA), TRBV21 (FITC, Beckman Coulter), CD28 (PE-Cy7, BioLegend), CCR4 (APC, 
BioLegend), CCR6 (BV785, BioLegend) and CRTh2 (PE, BioLegend) and analyzed by flow 
cytometry. 
Flow Cytometric Analysis 
Sample acquisition was conducted using a LSR Fortessa Flow Cytometer (BD Biosciences) 
with Diva software, and data were analyzed with FlowJo (Tree Star, Ashland, OR). 
RT-PCR and Sequencing of TCR Rearrangements 
RNA extraction, reverse transcription and TCRα/β-chain (TRA/BV) sequencing of TCC21.1 and 
TCL-39 was assessed as previously reported (26). TCR gene designations are in accord with 
IMGT nomenclature (ImMunoGeneTics, www.IMGT.org). 
HLA 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
20   
Individuals were typed for HLA-class I and II molecules at Histogenetics LLC, NY, USA. 
Isolation of DNA from whole blood with a final concentration of 15 ng/µl was performed with a 
standard DNA isolation protocol using a Triton lysis buffer and Proteinase K treatment. The 
samples were typed for HLA class I (A* and B*) and HLA class II (DRB1*, DRB3*, DRB4*, 
DRB5*, DQA1* and DQB1*) using high-resolution HLA sequence-based typing (SBT). 
The MHC class II binding predictions were made using the IEDB analysis resource Consensus 
tool (74, 75). 
Statistical analysis 
Three-cluster k-means analysis was performed on patient scores to group patients into three 
categories.  Associations between response levels of peptides, patients, and HLA status were 
all performed using Fisher’s Exact Test with Bonferroni-Holm correction applied as appropriate, 
with 5% significance. 
 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
21   
SUPPLEMENTARY MATERIALS 
Supplementary Figures 
Figure S1. Integration of stimulatory responses from testing dual-defined mixtures into the 
original scoring matrix  
Figure S2. Response of CSF-infiltrating CD4+ T cells 
Figure S3. New CIS/MS patients and phylogeny of bacterial species sharing GDP-L-fucose 
synthase peptides 
Supplementary Tables 
Table S1. Summary of human decapeptides predicted with the biometrical approach, 
synthesized and tested for stimulatory capacity 
Table S2. GDP-L-fucose synthase, myelin and CEF Peptides 
Table S3. Peptides from brain proteins identified by proteomic analysis in brain tissue. 
Table S4. Patient classification and HLA binding 
Table S5. Bacteria selected for GDP-L-fucose synthase comparison 
Table S6. Sequence homology between human and bacterial GDP-L-fucose synthase peptides 
Table S7. Demographical and clinical characteristics of MS patients and non-MS controls 
 
 
 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
22   
REFERENCES 
 
1.   
M.   Sospedra,   R.   Martin,   Immunology   of   multiple   sclerosis.   Annual   review   of   
immunology   23,   683-­‐747   (2005).   
2.   
A.   Nylander,   D.   A.   Hafler,   Multiple   sclerosis.   The   Journal   of   clinical   investigation   
122,   1180-­‐1188   (2012).   
3.   
C.   A.   Dendrou,   L.   Fugger,   M.   A.   Friese,   Immunopathology   of   multiple   sclerosis.   
Nature   reviews.   Immunology   15,   545-­‐558   (2015).   
4.   
C.   Baecher-­‐Allan,   B.   J.   Kaskow,   H.   L.   Weiner,   Multiple   Sclerosis:   Mechanisms   
and   Immunotherapy.   Neuron   97,   742-­‐768   (2018).   
5.   
C.   International   Multiple   Sclerosis   Genetics,   A.   H.   Beecham,   N.   A.   Patsopoulos,   
D.   K.   Xifara,   M.   F.   Davis,   A.   Kemppinen,   C.   Cotsapas,   T.   S.   Shah,   C.   Spencer,   D.   
Booth,   A.   Goris,   A.   Oturai,   J.   Saarela,   B.   Fontaine,   B.   Hemmer,   C.   Martin,   F.   Zipp,   
S.   D'Alfonso,   F.   Martinelli-­‐Boneschi,   B.   Taylor,   H.   F.   Harbo,   I.   Kockum,   J.   Hillert,   
T.   Olsson,   M.   Ban,   J.   R.   Oksenberg,   R.   Hintzen,   L.   F.   Barcellos,   C.   Wellcome   Trust   
Case   Control,   I.   B.   D.   G.   C.   International,   C.   Agliardi,   L.   Alfredsson,   M.   Alizadeh,   
C.   Anderson,   R.   Andrews,   H.   B.   Sondergaard,   A.   Baker,   G.   Band,   S.   E.   Baranzini,   
N.   Barizzone,   J.   Barrett,   C.   Bellenguez,   L.   Bergamaschi,   L.   Bernardinelli,   A.   
Berthele,   V.   Biberacher,   T.   M.   Binder,   H.   Blackburn,   I.   L.   Bomfim,   P.   Brambilla,   
S.   Broadley,   B.   Brochet,   L.   Brundin,   D.   Buck,   H.   Butzkueven,   S.   J.   Caillier,   W.   
Camu,   W.   Carpentier,   P.   Cavalla,   E.   G.   Celius,   I.   Coman,   G.   Comi,   L.   Corrado,   L.   
Cosemans,   I.   Cournu-­‐Rebeix,   B.   A.   Cree,   D.   Cusi,   V.   Damotte,   G.   Defer,   S.   R.   
Delgado,   P.   Deloukas,   A.   di   Sapio,   A.   T.   Dilthey,   P.   Donnelly,   B.   Dubois,   M.   
Duddy,   S.   Edkins,   I.   Elovaara,   F.   Esposito,   N.   Evangelou,   B.   Fiddes,   J.   Field,   A.   
Franke,   C.   Freeman,   I.   Y.   Frohlich,   D.   Galimberti,   C.   Gieger,   P.   A.   Gourraud,   C.   
Graetz,   A.   Graham,   V.   Grummel,   C.   Guaschino,   A.   Hadjixenofontos,   H.   
Hakonarson,   C.   Halfpenny,   G.   Hall,   P.   Hall,   A.   Hamsten,   J.   Harley,   T.   Harrower,   
C.   Hawkins,   G.   Hellenthal,   C.   Hillier,   J.   Hobart,   M.   Hoshi,   S.   E.   Hunt,   M.   Jagodic,   I.   
Jelcic,   A.   Jochim,   B.   Kendall,   A.   Kermode,   T.   Kilpatrick,   K.   Koivisto,   I.   Konidari,   
T.   Korn,   H.   Kronsbein,   C.   Langford,   M.   Larsson,   M.   Lathrop,   C.   Lebrun-­‐Frenay,   J.   
Lechner-­‐Scott,   M.   H.   Lee,   M.   A.   Leone,   V.   Leppa,   G.   Liberatore,   B.   A.   Lie,   C.   M.   Lill,   
M.   Linden,   J.   Link,   F.   Luessi,   J.   Lycke,   F.   Macciardi,   S.   Mannisto,   C.   P.   Manrique,   
R.   Martin,   V.   Martinelli,   D.   Mason,   G.   Mazibrada,   C.   McCabe,   I.   L.   Mero,   J.   
Mescheriakova,   L.   Moutsianas,   K.   M.   Myhr,   G.   Nagels,   R.   Nicholas,   P.   Nilsson,   F.   
Piehl,   M.   Pirinen,   S.   E.   Price,   H.   Quach,   M.   Reunanen,   W.   Robberecht,   N.   P.   
Robertson,   M.   Rodegher,   D.   Rog,   M.   Salvetti,   N.   C.   Schnetz-­‐Boutaud,   F.   
Sellebjerg,   R.   C.   Selter,   C.   Schaefer,   S.   Shaunak,   L.   Shen,   S.   Shields,   V.   Siffrin,   M.   
Slee,   P.   S.   Sorensen,   M.   Sorosina,   M.   Sospedra,   A.   Spurkland,   A.   Strange,   E.   
Sundqvist,   V.   Thijs,   J.   Thorpe,   A.   Ticca,   P.   Tienari,   C.   van   Duijn,   E.   M.   Visser,   S.   
Vucic,   H.   Westerlind,   J.   S.   Wiley,   A.   Wilkins,   J.   F.   Wilson,   J.   Winkelmann,   J.   
Zajicek,   E.   Zindler,   J.   L.   Haines,   M.   A.   Pericak-­‐Vance,   A.   J.   Ivinson,   G.   Stewart,   D.   
Hafler,   S.   L.   Hauser,   A.   Compston,   G.   McVean,   P.   De   Jager,   S.   J.   Sawcer,   J.   L.   
McCauley,   Analysis   of   immune-­‐related   loci   identifies   48   new   susceptibility   
variants   for   multiple   sclerosis.   Nature   genetics   45,   1353-­‐1360   (2013).   
6.   
C.   International   Multiple   Sclerosis   Genetics,   C.   Wellcome   Trust   Case   Control,   S.   
Sawcer,   G.   Hellenthal,   M.   Pirinen,   C.   C.   Spencer,   N.   A.   Patsopoulos,   L.   
Moutsianas,   A.   Dilthey,   Z.   Su,   C.   Freeman,   S.   E.   Hunt,   S.   Edkins,   E.   Gray,   D.   R.   
Booth,   S.   C.   Potter,   A.   Goris,   G.   Band,   A.   B.   Oturai,   A.   Strange,   J.   Saarela,   C.   
Bellenguez,   B.   Fontaine,   M.   Gillman,   B.   Hemmer,   R.   Gwilliam,   F.   Zipp,   A.   
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
23   
Jayakumar,   R.   Martin,   S.   Leslie,   S.   Hawkins,   E.   Giannoulatou,   S.   D'Alfonso,   H.   
Blackburn,   F.   Martinelli   Boneschi,   J.   Liddle,   H.   F.   Harbo,   M.   L.   Perez,   A.   
Spurkland,   M.   J.   Waller,   M.   P.   Mycko,   M.   Ricketts,   M.   Comabella,   N.   Hammond,   I.   
Kockum,   O.   T.   McCann,   M.   Ban,   P.   Whittaker,   A.   Kemppinen,   P.   Weston,   C.   
Hawkins,   S.   Widaa,   J.   Zajicek,   S.   Dronov,   N.   Robertson,   S.   J.   Bumpstead,   L.   F.   
Barcellos,   R.   Ravindrarajah,   R.   Abraham,   L.   Alfredsson,   K.   Ardlie,   C.   Aubin,   A.   
Baker,   K.   Baker,   S.   E.   Baranzini,   L.   Bergamaschi,   R.   Bergamaschi,   A.   Bernstein,   
A.   Berthele,   M.   Boggild,   J.   P.   Bradfield,   D.   Brassat,   S.   A.   Broadley,   D.   Buck,   H.   
Butzkueven,   R.   Capra,   W.   M.   Carroll,   P.   Cavalla,   E.   G.   Celius,   S.   Cepok,   R.   
Chiavacci,   F.   Clerget-­‐Darpoux,   K.   Clysters,   G.   Comi,   M.   Cossburn,   I.   Cournu-­‐
Rebeix,   M.   B.   Cox,   W.   Cozen,   B.   A.   Cree,   A.   H.   Cross,   D.   Cusi,   M.   J.   Daly,   E.   Davis,   P.   
I.   de   Bakker,   M.   Debouverie,   B.   D'Hooghe   M,   K.   Dixon,   R.   Dobosi,   B.   Dubois,   D.   
Ellinghaus,   I.   Elovaara,   F.   Esposito,   C.   Fontenille,   S.   Foote,   A.   Franke,   D.   
Galimberti,   A.   Ghezzi,   J.   Glessner,   R.   Gomez,   O.   Gout,   C.   Graham,   S.   F.   Grant,   F.   R.   
Guerini,   H.   Hakonarson,   P.   Hall,   A.   Hamsten,   H.   P.   Hartung,   R.   N.   Heard,   S.   
Heath,   J.   Hobart,   M.   Hoshi,   C.   Infante-­‐Duarte,   G.   Ingram,   W.   Ingram,   T.   Islam,   M.   
Jagodic,   M.   Kabesch,   A.   G.   Kermode,   T.   J.   Kilpatrick,   C.   Kim,   N.   Klopp,   K.   
Koivisto,   M.   Larsson,   M.   Lathrop,   J.   S.   Lechner-­‐Scott,   M.   A.   Leone,   V.   Leppa,   U.   
Liljedahl,   I.   L.   Bomfim,   R.   R.   Lincoln,   J.   Link,   J.   Liu,   A.   R.   Lorentzen,   S.   Lupoli,   F.   
Macciardi,   T.   Mack,   M.   Marriott,   V.   Martinelli,   D.   Mason,   J.   L.   McCauley,   F.   
Mentch,   I.   L.   Mero,   T.   Mihalova,   X.   Montalban,   J.   Mottershead,   K.   M.   Myhr,   P.   
Naldi,   W.   Ollier,   A.   Page,   A.   Palotie,   J.   Pelletier,   L.   Piccio,   T.   Pickersgill,   F.   Piehl,   
S.   Pobywajlo,   H.   L.   Quach,   P.   P.   Ramsay,   M.   Reunanen,   R.   Reynolds,   J.   D.   Rioux,   
M.   Rodegher,   S.   Roesner,   J.   P.   Rubio,   I.   M.   Ruckert,   M.   Salvetti,   E.   Salvi,   A.   
Santaniello,   C.   A.   Schaefer,   S.   Schreiber,   C.   Schulze,   R.   J.   Scott,   F.   Sellebjerg,   K.   
W.   Selmaj,   D.   Sexton,   L.   Shen,   B.   Simms-­‐Acuna,   S.   Skidmore,   P.   M.   Sleiman,   C.   
Smestad,   P.   S.   Sorensen,   H.   B.   Sondergaard,   J.   Stankovich,   R.   C.   Strange,   A.   M.   
Sulonen,   E.   Sundqvist,   A.   C.   Syvanen,   F.   Taddeo,   B.   Taylor,   J.   M.   Blackwell,   P.   
Tienari,   E.   Bramon,   A.   Tourbah,   M.   A.   Brown,   E.   Tronczynska,   J.   P.   Casas,   N.   
Tubridy,   A.   Corvin,   J.   Vickery,   J.   Jankowski,   P.   Villoslada,   H.   S.   Markus,   K.   Wang,   
C.   G.   Mathew,   J.   Wason,   C.   N.   Palmer,   H.   E.   Wichmann,   R.   Plomin,   E.   Willoughby,   
A.   Rautanen,   J.   Winkelmann,   M.   Wittig,   R.   C.   Trembath,   J.   Yaouanq,   A.   C.   
Viswanathan,   H.   Zhang,   N.   W.   Wood,   R.   Zuvich,   P.   Deloukas,   C.   Langford,   A.   
Duncanson,   J.   R.   Oksenberg,   M.   A.   Pericak-­‐Vance,   J.   L.   Haines,   T.   Olsson,   J.   
Hillert,   A.   J.   Ivinson,   P.   L.   De   Jager,   L.   Peltonen,   G.   J.   Stewart,   D.   A.   Hafler,   S.   L.   
Hauser,   G.   McVean,   P.   Donnelly,   A.   Compston,   Genetic   risk   and   a   primary   role   
for   cell-­‐mediated   immune   mechanisms   in   multiple   sclerosis.   Nature   476,   214-­‐
219   (2011).   
7.   
A.   Fogdell-­‐Hahn,   A.   Ligers,   M.   Gronning,   J.   Hillert,   O.   Olerup,   Multiple   sclerosis:   
a   modifying   influence   of   HLA   class   I   genes   in   an   HLA   class   II   associated   
autoimmune   disease.   Tissue   antigens   55,   140-­‐148   (2000).   
8.   
M.   A.   Friese,   K.   B.   Jakobsen,   L.   Friis,   R.   Etzensperger,   M.   J.   Craner,   R.   M.   
McMahon,   L.   T.   Jensen,   V.   Huygelen,   E.   Y.   Jones,   J.   I.   Bell,   L.   Fugger,   Opposing   
effects   of   HLA   class   I   molecules   in   tuning   autoreactive   CD8+   T   cells   in   multiple   
sclerosis.   Nature   medicine   14,   1227-­‐1235   (2008).   
9.   
R.   Hohlfeld,   K.   Dornmair,   E.   Meinl,   H.   Wekerle,   The   search   for   the   target   
antigens   of   multiple   sclerosis,   part   1:   autoreactive   CD4+   T   lymphocytes   as   
pathogenic   effectors   and   therapeutic   targets.   The   Lancet.   Neurology   15,   198-­‐
209   (2016).   
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
24   
10.   
A.   Ascherio,   K.   L.   Munger,   Environmental   risk   factors   for   multiple   sclerosis.   
Part   II:   Noninfectious   factors.   Annals   of   neurology   61,   504-­‐513   (2007).   
11.   
A.   Ascherio,   K.   L.   Munger,   J.   D.   Lunemann,   The   initiation   and   prevention   of   
multiple   sclerosis.   Nature   reviews.   Neurology   8,   602-­‐612   (2012).   
12.   
H.   Wekerle,   Brain   Autoimmunity   and   Intestinal   Microbiota:   100   Trillion   Game   
Changers.   Trends   in   immunology,      (2017).   
13.   
J.   Chen,   N.   Chia,   K.   R.   Kalari,   J.   Z.   Yao,   M.   Novotna,   M.   M.   Soldan,   D.   H.   Luckey,   E.   
V.   Marietta,   P.   R.   Jeraldo,   X.   Chen,   B.   G.   Weinshenker,   M.   Rodriguez,   O.   H.   
Kantarci,   H.   Nelson,   J.   A.   Murray,   A.   K.   Mangalam,   Multiple   sclerosis   patients   
have   a   distinct   gut   microbiota   compared   to   healthy   controls.   Scientific   reports   
6,   28484   (2016).   
14.   
S.   Jangi,   R.   Gandhi,   L.   M.   Cox,   N.   Li,   F.   von   Glehn,   R.   Yan,   B.   Patel,   M.   A.   Mazzola,   
S.   Liu,   B.   L.   Glanz,   S.   Cook,   S.   Tankou,   F.   Stuart,   K.   Melo,   P.   Nejad,   K.   Smith,   B.   D.   
Topcuolu,   J.   Holden,   P.   Kivisakk,   T.   Chitnis,   P.   L.   De   Jager,   F.   J.   Quintana,   G.   K.   
Gerber,   L.   Bry,   H.   L.   Weiner,   Alterations   of   the   human   gut   microbiome   in   
multiple   sclerosis.   Nature   communications   7,   12015   (2016).   
15.   
K.   Berer,   L.   A.   Gerdes,   E.   Cekanaviciute,   X.   Jia,   L.   Xiao,   Z.   Xia,   C.   Liu,   L.   Klotz,   U.   
Stauffer,   S.   E.   Baranzini,   T.   Kumpfel,   R.   Hohlfeld,   G.   Krishnamoorthy,   H.   
Wekerle,   
Gut   
microbiota   
from   
multiple   
sclerosis   
patients   
enables   
spontaneous   autoimmune   encephalomyelitis   in   mice.   Proceedings   of   the   
National   Academy   of   Sciences   of   the   United   States   of   America   114,   10719-­‐10724   
(2017).   
16.   
E.   Cekanaviciute,   B.   B.   Yoo,   T.   F.   Runia,   J.   W.   Debelius,   S.   Singh,   C.   A.   Nelson,   R.   
Kanner,   Y.   Bencosme,   Y.   K.   Lee,   S.   L.   Hauser,   E.   Crabtree-­‐Hartman,   I.   K.   Sand,   M.   
Gacias,   Y.   Zhu,   P.   Casaccia,   B.   A.   C.   Cree,   R.   Knight,   S.   K.   Mazmanian,   S.   E.   
Baranzini,   Gut   bacteria   from   multiple   sclerosis   patients   modulate   human   T   
cells   and   exacerbate   symptoms   in   mouse   models.   Proceedings   of   the   National   
Academy   of   Sciences   of   the   United   States   of   America   114,   10713-­‐10718   (2017).   
17.   
T.   C.   Fung,   C.   A.   Olson,   E.   Y.   Hsiao,   Interactions   between   the   microbiota,   
immune   and   nervous   systems   in   health   and   disease.   Nature   neuroscience   20,   
145-­‐155   (2017).   
18.   
D.   Erny,   A.   L.   Hrabe   de   Angelis,   D.   Jaitin,   P.   Wieghofer,   O.   Staszewski,   E.   David,   
H.   Keren-­‐Shaul,   T.   Mahlakoiv,   K.   Jakobshagen,   T.   Buch,   V.   Schwierzeck,   O.   
Utermohlen,   E.   Chun,   W.   S.   Garrett,   K.   D.   McCoy,   A.   Diefenbach,   P.   Staeheli,   B.   
Stecher,   I.   Amit,   M.   Prinz,   Host   microbiota   constantly   control   maturation   and   
function   of   microglia   in   the   CNS.   Nature   neuroscience   18,   965-­‐977   (2015).   
19.   
V.   Rothhammer,   I.   D.   Mascanfroni,   L.   Bunse,   M.   C.   Takenaka,   J.   E.   Kenison,   L.   
Mayo,   C.   C.   Chao,   B.   Patel,   R.   Yan,   M.   Blain,   J.   I.   Alvarez,   H.   Kebir,   N.   
Anandasabapathy,   G.   Izquierdo,   S.   Jung,   N.   Obholzer,   N.   Pochet,   C.   B.   Clish,   M.   
Prinz,   A.   Prat,   J.   Antel,   F.   J.   Quintana,   Type   I   interferons   and   microbial   
metabolites   of   tryptophan   modulate   astrocyte   activity   and   central   nervous   
system   inflammation   via   the   aryl   hydrocarbon   receptor.   Nature   medicine   22,   
586-­‐597   (2016).   
20.   
A.   Lutterotti,   M.   Sospedra,   R.   Martin,   Antigen-­‐specific   therapies   in   MS   -­‐   Current   
concepts   and   novel   approaches.   Journal   of   the   neurological   sciences   274,   18-­‐22   
(2008).   
21.   
S.   Shimoda,   M.   Nakamura,   H.   Ishibashi,   K.   Hayashida,   Y.   Niho,   HLA   DRB4   0101-­‐
restricted   immunodominant   T   cell   autoepitope   of   pyruvate   dehydrogenase   
complex   in   primary   biliary   cirrhosis:   evidence   of   molecular   mimicry   in   human   
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
25   
autoimmune   diseases.   The   Journal   of   experimental   medicine   181,   1835-­‐1845   
(1995).   
22.   
C.   Pinilla,   J.   R.   Appel,   P.   Blanc,   R.   A.   Houghten,   Rapid   identification   of   high   
affinity   peptide   ligands   using   positional   scanning   synthetic   peptide   
combinatorial   libraries.   BioTechniques   13,   901-­‐905   (1992).   
23.   
B.   Hemmer,   B.   Gran,   Y.   Zhao,   A.   Marques,   J.   Pascal,   A.   Tzou,   T.   Kondo,   I.   Cortese,   
B.   Bielekova,   S.   E.   Straus,   H.   F.   McFarland,   R.   Houghten,   R.   Simon,   C.   Pinilla,   R.   
Martin,   Identification   of   candidate   T-­‐cell   epitopes   and   molecular   mimics   in   
chronic   Lyme   disease.   Nature   medicine   5,   1375-­‐1382   (1999).   
24.   
Y.   Zhao,   B.   Gran,   C.   Pinilla,   S.   Markovic-­‐Plese,   B.   Hemmer,   A.   Tzou,   L.   W.   
Whitney,   W.   E.   Biddison,   R.   Martin,   R.   Simon,   Combinatorial   peptide   libraries   
and   biometric   score   matrices   permit   the   quantitative   analysis   of   specific   and   
degenerate   interactions   between   clonotypic   TCR   and   MHC   peptide   ligands.   
Journal   of   immunology   167,   2130-­‐2141   (2001).   
25.   
M.   Sospedra,   Y.   Zhao,   H.   zur   Hausen,   P.   A.   Muraro,   C.   Hamashin,   E.   M.   de   
Villiers,   C.   Pinilla,   R.   Martin,   Recognition   of   conserved   amino   acid   motifs   of   
common   viruses   and   its   role   in   autoimmunity.   PLoS   Pathog   1,   e41   (2005).   
26.   
R.   Planas,   I.   Metz,   Y.   Ortiz,   N.   Vilarrasa,   I.   Jelcic,   G.   Salinas-­‐Riester,   C.   Heesen,   
W.   Bruck,   R.   Martin,   M.   Sospedra,   Central   role   of   Th2/Tc2   lymphocytes   in   
pattern   II   multiple   sclerosis   lesions.   Annals   of   clinical   and   translational   
neurology   2,   875-­‐893   (2015).   
27.   
C.   Lucchinetti,   W.   Bruck,   J.   Parisi,   B.   Scheithauer,   M.   Rodriguez,   H.   Lassmann,   
Heterogeneity   of   multiple   sclerosis   lesions:   implications   for   the   pathogenesis   
of   demyelination.   Annals   of   neurology   47,   707-­‐717   (2000).   
28.   
M.   Sospedra,   Y.   Zhao,   M.   Giulianotti,   R.   Simon,   C.   Pinilla,   R.   Martin,   Combining   
positional   
scanning   
peptide   
libraries,   
HLA-­‐DR   
transfectants   
and   
bioinformatics   to   dissect   the   epitope   spectrum   of   HLA   class   II   cross-­‐restricted   
CD4+   T   cell   clones.   J   Immunol   Methods   353,   93-­‐101   (2010).   
29.   
V.   Judkowski,   A.   Bunying,   F.   Ge,   J.   R.   Appel,   K.   Law,   A.   Sharma,   C.   Raja-­‐Gabaglia,   
P.   Norori,   R.   G.   Santos,   M.   A.   Giulianotti,   M.   K.   Slifka,   D.   C.   Douek,   B.   S.   Graham,   
C.   Pinilla,   GM-­‐CSF   production   allows   the   identification   of   immunoprevalent   
antigens   recognized   by   human   CD4+   T   cells   following   smallpox   vaccination.   
PloS   one   6,   e24091   (2011).   
30.   
C.   The   UniProt,   UniProt:   the   universal   protein   knowledgebase.   Nucleic   acids   
research   45,   D158-­‐D169   (2017).   
31.   
R.   G.   Santos,   M.   A.   Giulianotti,   C.   T.   Dooley,   C.   Pinilla,   J.   R.   Appel,   R.   A.   Houghten,   
Use   and   implications   of   the   harmonic   mean   model   on   mixtures   for   basic   
research   and   drug   discovery.   ACS   Comb   Sci   13,   337-­‐344   (2011).   
32.   
M.   Sospedra,   P.   A.   Muraro,   I.   Stefanova,   Y.   Zhao,   K.   Chung,   Y.   Li,   M.   Giulianotti,   
R.   Simon,   R.   Mariuzza,   C.   Pinilla,   R.   Martin,   Redundancy   in   antigen-­‐presenting   
function   of   the   HLA-­‐DR   and   -­‐DQ   molecules   in   the   multiple   sclerosis-­‐associated   
HLA-­‐DR2   haplotype.   Journal   of   immunology   176,   1951-­‐1961   (2006).   
33.   
S.   Yousef,   R.   Planas,   K.   Chakroun,   S.   Hoffmeister-­‐Ullerich,   T.   M.   Binder,   T.   H.   
Eiermann,   R.   Martin,   M.   Sospedra,   TCR   bias   and   HLA   cross-­‐restriction   are   
strategies   of   human   brain-­‐infiltrating   JC   virus-­‐specific   CD4+   T   cells   during   
viral   infection.   Journal   of   immunology   189,   3618-­‐3630   (2012).   
34.   
B.   Bielekova,   M.   H.   Sung,   N.   Kadom,   R.   Simon,   H.   McFarland,   R.   Martin,   
Expansion   and   functional   relevance   of   high-­‐avidity   myelin-­‐specific   CD4+   T   
cells   in   multiple   sclerosis.   Journal   of   immunology   172,   3893-­‐3904   (2004).   
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
26   
35.   
H.   Zhou,   L.   Sun,   J.   Li,   C.   Xu,   F.   Yu,   Y.   Liu,   C.   Ji,   J.   He,   The   crystal   structure   of   
human   GDP-­‐L-­‐fucose   synthase.   Acta   biochimica   et   biophysica   Sinica   45,   720-­‐
725   (2013).   
36.   
M.   J.   Coyne,   B.   Reinap,   M.   M.   Lee,   L.   E.   Comstock,   Human   symbionts   use   a   host-­‐
like   pathway   for   surface   fucosylation.   Science   307,   1778-­‐1781   (2005).   
37.   
W.   S.   Somers,   M.   L.   Stahl,   F.   X.   Sullivan,   GDP-­‐fucose   synthetase   from   
Escherichia   coli:   structure   of   a   unique   member   of   the   short-­‐chain   
dehydrogenase/reductase   family   that   catalyzes   two   distinct   reactions   at   the   
same   active   site.   Structure   6,   1601-­‐1612   (1998).   
38.   
S.   Dai,   F.   Crawford,   P.   Marrack,   J.   W.   Kappler,   The   structure   of   HLA-­‐DR52c:   
comparison   to   other   HLA-­‐DRB3   alleles.   Proceedings   of   the   National   Academy   of   
Sciences   of   the   United   States   of   America   105,   11893-­‐11897   (2008).   
39.   
M.   El-­‐Behi,   B.   Ciric,   H.   Dai,   Y.   Yan,   M.   Cullimore,   F.   Safavi,   G.   X.   Zhang,   B.   N.   
Dittel,   A.   Rostami,   The   encephalitogenicity   of   T(H)17   cells   is   dependent   on   IL-­‐
1-­‐   and   IL-­‐23-­‐induced   production   of   the   cytokine   GM-­‐CSF.   Nature   immunology   
12,   568-­‐575   (2011).   
40.   
L.   Codarri,   G.   Gyulveszi,   V.   Tosevski,   L.   Hesske,   A.   Fontana,   L.   Magnenat,   T.   
Suter,   B.   Becher,   RORgammat   drives   production   of   the   cytokine   GM-­‐CSF   in   
helper   T   cells,   which   is   essential   for   the   effector   phase   of   autoimmune   
neuroinflammation.   Nature   immunology   12,   560-­‐567   (2011).   
41.   
Y.   Dan,   Y.   Katakura,   A.   Ametani,   S.   Kaminogawa,   Y.   Asano,   IL-­‐3   augments   TCR-­‐
mediated   responses   of   type   2   CD4   T   cells.   Journal   of   immunology   156,   27-­‐34   
(1996).   
42.   
S.   Ebner,   S.   Hofer,   V.   A.   Nguyen,   C.   Furhapter,   M.   Herold,   P.   Fritsch,   C.   Heufler,   
N.   Romani,   A   novel   role   for   IL-­‐3:   human   monocytes   cultured   in   the   presence   of   
IL-­‐3   and   IL-­‐4   differentiate   into   dendritic   cells   that   produce   less   IL-­‐12   and   shift   
Th   cell   responses   toward   a   Th2   cytokine   pattern.   Journal   of   immunology   168,   
6199-­‐6207   (2002).   
43.   
C.   J.   Holland,   D.   K.   Cole,   A.   Godkin,   Re-­‐Directing   CD4(+)   T   Cell   Responses   with   
the   Flanking   Residues   of   MHC   Class   II-­‐Bound   Peptides:   The   Core   is   Not   
Enough.   Front   Immunol   4,   172   (2013).   
44.   
B.   Bielekova,   B.   Goodwin,   N.   Richert,   I.   Cortese,   T.   Kondo,   G.   Afshar,   B.   Gran,   J.   
Eaton,   J.   Antel,   J.   A.   Frank,   H.   F.   McFarland,   R.   Martin,   Encephalitogenic   
potential   of   the   myelin   basic   protein   peptide   (amino   acids   83-­‐99)   in   multiple   
sclerosis:   results   of   a   phase   II   clinical   trial   with   an   altered   peptide   ligand.   
Nature   medicine   6,   1167-­‐1175   (2000).   
45.   
K.   Ota,   M.   Matsui,   E.   L.   Milford,   G.   A.   Mackin,   H.   L.   Weiner,   D.   A.   Hafler,   T-­‐cell   
recognition   of   an   immunodominant   myelin   basic   protein   epitope   in   multiple   
sclerosis.   Nature   346,   183-­‐187   (1990).   
46.   
M.   Pette,   K.   Fujita,   B.   Kitze,   J.   N.   Whitaker,   E.   Albert,   L.   Kappos,   H.   Wekerle,   
Myelin   basic   protein-­‐specific   T   lymphocyte   lines   from   MS   patients   and   healthy   
individuals.   Neurology   40,   1770-­‐1776   (1990).   
47.   
R.   Martin,   D.   Jaraquemada,   M.   Flerlage,   J.   Richert,   J.   Whitaker,   E.   O.   Long,   D.   E.   
McFarlin,   H.   F.   McFarland,   Fine   specificity   and   HLA   restriction   of   myelin   basic   
protein-­‐specific   cytotoxic   T   cell   lines   from   multiple   sclerosis   patients   and   
healthy   individuals.   Journal   of   immunology   145,   540-­‐548   (1990).   
48.   
R.   Martin,   M.   D.   Howell,   D.   Jaraquemada,   M.   Flerlage,   J.   Richert,   S.   Brostoff,   E.   O.   
Long,   D.   E.   McFarlin,   H.   F.   McFarland,   A   myelin   basic   protein   peptide   is   
recognized   by   cytotoxic   T   cells   in   the   context   of   four   HLA-­‐DR   types   associated   
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
27   
with   multiple   sclerosis.   The   Journal   of   experimental   medicine   173,   19-­‐24   
(1991).   
49.   
J.   E.   Libbey,   M.   F.   Cusick,   R.   S.   Fujinami,   Role   of   pathogens   in   multiple   sclerosis.   
International   reviews   of   immunology   33,   266-­‐283   (2014).   
50.   
T.   F.   Bergstrom,   R.   Erlandsson,   H.   Engkvist,   A.   Josefsson,   H.   A.   Erlich,   U.   
Gyllensten,   Phylogenetic   history   of   hominoid   DRB   loci   and   alleles   inferred   
from   intron   sequences.   Immunological   reviews   167,   351-­‐365   (1999).   
51.   
R.   Faner,   E.   James,   L.   Huston,   R.   Pujol-­‐Borrel,   W.   W.   Kwok,   M.   Juan,   Reassessing   
the   role   of   HLA-­‐DRB3   T-­‐cell   responses:   evidence   for   significant   expression   and   
complementary   antigen   presentation.   European   journal   of   immunology   40,   91-­‐
102   (2010).   
52.   
H.   H.   Oh,   S.   H.   Kwon,   C.   W.   Kim,   B.   H.   Choe,   C.   W.   Ko,   H.   D.   Jung,   J.   S.   Suh,   J.   H.   Lee,   
Molecular   
analysis   
of   
HLA   
class   
II-­‐associated   
susceptibility   
to   
neuroinflammatory   diseases   in   Korean   children.   Journal   of   Korean   medical   
science   19,   426-­‐430   (2004).   
53.   
D.   G.   Brum,   A.   A.   Barreira,   A.   C.   dos   Santos,   D.   R.   Kaimen-­‐Maciel,   M.   Matiello,   R.   
M.   Costa,   N.   H.   Deghaide,   L.   S.   Costa,   P.   Louzada-­‐Junior,   P.   R.   Diniz,   E.   R.   Comini-­‐
Frota,   C.   T.   Mendes-­‐Junior,   E.   A.   Donadi,   HLA-­‐DRB   association   in   neuromyelitis   
optica   is   different   from   that   observed   in   multiple   sclerosis.   Multiple   sclerosis   
16,   21-­‐29   (2010).   
54.   
M.   Varrin-­‐Doyer,   C.   M.   Spencer,   U.   Schulze-­‐Topphoff,   P.   A.   Nelson,   R.   M.   Stroud,   
B.   A.   Cree,   S.   S.   Zamvil,   Aquaporin   4-­‐specific   T   cells   in   neuromyelitis   optica   
exhibit   a   Th17   bias   and   recognize   Clostridium   ABC   transporter.   Annals   of   
neurology   72,   53-­‐64   (2012).   
55.   
D.   J.   Becker,   J.   B.   Lowe,   Fucose:   biosynthesis   and   biological   function   in   
mammals.   Glycobiology   13,   41R-­‐53R   (2003).   
56.   
B.   Ma,   J.   L.   Simala-­‐Grant,   D.   E.   Taylor,   Fucosylation   in   prokaryotes   and   
eukaryotes.   Glycobiology   16,   158R-­‐184R   (2006).   
57.   
J.   J.   Garcia-­‐Vallejo,   J.   M.   Ilarregui,   H.   Kalay,   S.   Chamorro,   N.   Koning,   W.   W.   
Unger,   M.   Ambrosini,   V.   Montserrat,   R.   J.   Fernandes,   S.   C.   Bruijns,   J.   R.   van   
Weering,   N.   J.   Paauw,   T.   O'Toole,   J.   van   Horssen,   P.   van   der   Valk,   K.   Nazmi,   J.   G.   
Bolscher,   J.   Bajramovic,   C.   D.   Dijkstra,   B.   A.   t   Hart,   Y.   van   Kooyk,   CNS   myelin   
induces   regulatory   functions   of   DC-­‐SIGN-­‐expressing,   antigen-­‐presenting   cells   
via   cognate   interaction   with   MOG.   The   Journal   of   experimental   medicine   211,   
1465-­‐1483   (2014).   
58.   
D.   Lutz,   G.   Loers,   R.   Kleene,   I.   Oezen,   H.   Kataria,   N.   Katagihallimath,   I.   Braren,   
G.   Harauz,   M.   Schachner,   Myelin   basic   protein   cleaves   cell   adhesion   molecule   
L1   and   promotes   neuritogenesis   and   cell   survival.   The   Journal   of   biological   
chemistry   289,   13503-­‐13518   (2014).   
59.   
H.   E.   Murrey,   C.   I.   Gama,   S.   A.   Kalovidouris,   W.   I.   Luo,   E.   M.   Driggers,   B.   Porton,   
L.   C.   Hsieh-­‐Wilson,   Protein   fucosylation   regulates   synapsin   Ia/Ib   expression   
and   neuronal   morphology   in   primary   hippocampal   neurons.   Proceedings   of   
the   National   Academy   of   Sciences   of   the   United   States   of   America   103,   21-­‐26   
(2006).   
60.   
S.   Yaji,   H.   Manya,   N.   Nakagawa,   H.   Takematsu,   T.   Endo,   R.   Kannagi,   T.   
Yoshihara,   M.   Asano,   S.   Oka,   Major   glycan   structure   underlying   expression   of   
the   Lewis   X   epitope   in   the   developing   brain   is   O-­‐mannose-­‐linked   glycans   on   
phosphacan/RPTPbeta.   Glycobiology   25,   376-­‐385   (2015).   
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
28   
61.   
Y.   Goto,   S.   Uematsu,   H.   Kiyono,   Epithelial   glycosylation   in   gut   homeostasis   and   
inflammation.   Nature   immunology   17,   1244-­‐1251   (2016).   
62.   
S.   Miyake,   S.   Kim,   W.   Suda,   K.   Oshima,   M.   Nakamura,   T.   Matsuoka,   N.   Chihara,   
A.   Tomita,   W.   Sato,   S.   W.   Kim,   H.   Morita,   M.   Hattori,   T.   Yamamura,   Dysbiosis   in   
the   Gut   Microbiota   of   Patients   with   Multiple   Sclerosis,   with   a   Striking   
Depletion   of   Species   Belonging   to   Clostridia   XIVa   and   IV   Clusters.   PloS   one   10,   
e0137429   (2015).   
63.   
H.   Tremlett,   D.   W.   Fadrosh,   A.   A.   Faruqi,   F.   Zhu,   J.   Hart,   S.   Roalstad,   J.   Graves,   S.   
Lynch,   E.   Waubant,   U.   S.   N.   o.   P.   M.   Centers,   Gut   microbiota   in   early   pediatric   
multiple   sclerosis:   a   case-­‐control   study.   European   journal   of   neurology   23,   
1308-­‐1321   (2016).   
64.   
K.   R.   Rumah,   J.   Linden,   V.   A.   Fischetti,   T.   Vartanian,   Isolation   of   Clostridium   
perfringens   type   B   in   an   individual   at   first   clinical   presentation   of   multiple   
sclerosis   provides   clues   for   environmental   triggers   of   the   disease.   PloS   one   8,   
e76359   (2013).   
65.   
J.   Ochoa-­‐Reparaz,   D.   W.   Mielcarz,   L.   E.   Ditrio,   A.   R.   Burroughs,   S.   Begum-­‐Haque,   
S.   Dasgupta,   D.   L.   Kasper,   L.   H.   Kasper,   Central   nervous   system   demyelinating   
disease   protection   by   the   human   commensal   Bacteroides   fragilis   depends   on   
polysaccharide   A   expression.   Journal   of   immunology   185,   4101-­‐4108   (2010).   
66.   
R.   Hebbandi   Nanjundappa,   F.   Ronchi,   J.   Wang,   X.   Clemente-­‐Casares,   J.   
Yamanouchi,   C.   Sokke   Umeshappa,   Y.   Yang,   J.   Blanco,   H.   Bassolas-­‐Molina,   A.   
Salas,   H.   Khan,   R.   M.   Slattery,   M.   Wyss,   C.   Mooser,   A.   J.   Macpherson,   L.   K.   Sycuro,   
P.   Serra,   D.   M.   McKay,   K.   D.   McCoy,   P.   Santamaria,   A   Gut   Microbial   Mimic   that   
Hijacks   Diabetogenic   Autoreactivity   to   Suppress   Colitis.   Cell   171,   655-­‐667   
e617   (2017).   
67.   
C.   H.   Polman,   S.   C.   Reingold,   B.   Banwell,   M.   Clanet,   J.   A.   Cohen,   M.   Filippi,   K.   
Fujihara,   E.   Havrdova,   M.   Hutchinson,   L.   Kappos,   F.   D.   Lublin,   X.   Montalban,   P.   
O'Connor,   
M.   
Sandberg-­‐Wollheim,   
A.   
J.   
Thompson,   
E.   
Waubant,   
B.   
Weinshenker,   J.   S.   Wolinsky,   Diagnostic   criteria   for   multiple   sclerosis:   2010   
revisions   to   the   McDonald   criteria.   Annals   of   neurology   69,   292-­‐302   (2011).   
68.   
T.   Guo,   P.   Kouvonen,   C.   C.   Koh,   L.   C.   Gillet,   W.   E.   Wolski,   H.   L.   Rost,   G.   
Rosenberger,   B.   C.   Collins,   L.   C.   Blum,   S.   Gillessen,   M.   Joerger,   W.   Jochum,   R.   
Aebersold,   Rapid   mass   spectrometric   conversion   of   tissue   biopsy   samples   into   
permanent   quantitative   digital   proteome   maps.   Nature   medicine   21,   407-­‐413   
(2015).   
69.   
C.   Pinilla,   J.   R.   Appel,   R.   A.   Houghten,   Investigation   of   antigen-­‐antibody   
interactions   using   a   soluble,   non-­‐support-­‐bound   synthetic   decapeptide   library   
composed   of   four   trillion   (4   x   10(12)   sequences.   The   Biochemical   journal   301   (   
Pt   3),   847-­‐853   (1994).   
70.   
R.   Geiger,   T.   Duhen,   A.   Lanzavecchia,   F.   Sallusto,   Human   naive   and   memory   
CD4+   T   cell   repertoires   specific   for   naturally   processed   antigens   analyzed   
using   libraries   of   amplified   T   cells.   The   Journal   of   experimental   medicine   206,   
1525-­‐1534   (2009).   
71.   
R.   Noster,   R.   Riedel,   M.   F.   Mashreghi,   H.   Radbruch,   L.   Harms,   C.   Haftmann,   H.   D.   
Chang,   A.   Radbruch,   C.   E.   Zielinski,   IL-­‐17   and   GM-­‐CSF   expression   are   
antagonistically   regulated   by   human   T   helper   cells.   Science   translational   
medicine   6,   241ra280   (2014).   
72.   
S.   Trifari,   C.   D.   Kaplan,   E.   H.   Tran,   N.   K.   Crellin,   H.   Spits,   Identification   of   a   
human   helper   T   cell   population   that   has   abundant   production   of   interleukin   
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
29   
22   and   is   distinct   from   T(H)-­‐17,   T(H)1   and   T(H)2   cells.   Nature   immunology   10,   
864-­‐871   (2009).   
73.   
C.   Schlapbach,   A.   Gehad,   C.   Yang,   R.   Watanabe,   E.   Guenova,   J.   E.   Teague,   L.   
Campbell,   N.   Yawalkar,   T.   S.   Kupper,   R.   A.   Clark,   Human   TH9   cells   are   skin-­‐
tropic   and   have   autocrine   and   paracrine   proinflammatory   capacity.   Science   
translational   medicine   6,   219ra218   (2014).   
74.   
P.   Wang,   J.   Sidney,   C.   Dow,   B.   Mothe,   A.   Sette,   B.   Peters,   A   systematic   
assessment   of   MHC   class   II   peptide   binding   predictions   and   evaluation   of   a   
consensus   approach.   PLoS   computational   biology   4,   e1000048   (2008).   
75.   
P.   Wang,   J.   Sidney,   Y.   Kim,   A.   Sette,   O.   Lund,   M.   Nielsen,   B.   Peters,   Peptide   
binding   predictions   for   HLA   DR,   DP   and   DQ   molecules.   BMC   bioinformatics   11,   
568   (2010).   
   
 
 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
30   
Acknowledgements: We thank Dr. G. Nepom and Dr. B. Kwok (University of Washington, 
Seattle) for BLS tranfectants and Dr. F. Sallusto (Institute for Research in Biomedicine, 
Bellinzona, Switzerland) for IL-2 hybridoma. We wish to acknowledge Dr. A. Willing and the 
inims outpatient clinic and day hospital at the University Medical Center Hamburg-Eppendorf 
and the clinical staff of nims, Neurology Clinic, University Hospital Zurich for clinical samples. 
Funding: This work was supported by DFG Clinical Research Group, KFO 228/1, DFG Center 
Grant - SFB 841 and SNF: 310030_146945. European Research Council Advanced Grant 
(340733) (RM), Clinical Research Priority Program MS (CRPPMS) of the University Zurich (RM 
and MS), Swiss National Science Foundation (Sinergia UnmetMS) (RM and MS) and the Swiss 
MS Society (RM). RP was supported by UZH FK-13-046. UK Multiple Sclerosis Tissue Bank 
was supported by the Multiple Sclerosis Society of Great Britain and Northern Ireland 
(registered charity 207495). This work was supported in part by Multiple Sclerosis National 
Research Institute (RS and CP). Author contributions: M.S. designed and supervised the 
study and wrote the manuscript. R.M. participated in study design and reviewed the manuscript. 
R.P. performed the experiments with T cells. R.S. and C.P. provided the peptide libraries and 
participated in the design and analysis of the results. P.T.O. and C.C. help in the expansion of 
the CSF-infiltrating cells. A.L. supervised the provision of clinical samples. W.F. and N.S.W. 
performed the proteomic analysis of the brain. C.E. and H.E. discussed and analyzed data and 
gave conceptual advice. All authors discussed the results and commented on the manuscript. 
Competing interests: All authors declare that they have no competing financial interests in the 
context of this work. A patent to   use GDP-L-Fucose Synthase in the treatment, diagnosis and/or 
prevention of multiple sclerosis (MS) is being filed. Data and materials availability: Peptide 
libraries are available under a material transfer agreement with Torrey Pines Institute for 
Molecular Studies.  
 
 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
31   
 
FIGURE LEGENDS 
Figure 1. Single and dual-defined decapeptide positional scanning mixtures in 
combination with biometric analysis to identify the specifity of TCC21.1. A GM-CSF 
production by TCC21.1 in response to 20 combinatorial peptide mixtures with AAs defined at 
position 5 and presented by BLS cells expressing only DRB1*15:01, DRB5*01:01 or 
DQB1*06:02 class II molecules. X-axes, single-letter AA code; Y-axes, cytokine production. B. 
GM-CSF (black histograms) and IL-10 (white histograms) production by TCC21.1 in response to 
a complete decapeptide positional scanning library (200 mixtures) presented by BLS cells 
expressing only DRB1*15:01. C. Score matrix designed with the log10 median of GM-CSF 
production of three independent experiments. Dark grey cells correspond to values equal or 
higher than 2 and light grey cells to values between 1.5 and 2. Bold borders show mixtures 
selected for dual defined mixtures, continuous borders based on GM-CSF results and dotted 
borders on IL-10 results. D. GM-CSF production by TCC21.1 in response to the 50 peptides 
with highest scores predicted using the GM-CSF based score matrix. E. GM-CSF production by 
TCC21.1 in response to 22 dual-defined mixtures. In green, mixtures with defined AAs of the 
TCR motif in frame 1 and in blue in frame 2. Stimulatory responses of mixtures shown with 
darker colors (Frame 1/2-HM) were integrated into the original matrix using the harmonic mean 
model. F. TCR motif and dual-defined mixture activity values selected based on the harmonic 
mean model and incorporated into the original matrix, Frame 1-HM in green and Frame 2-HM in 
blue. G. GM-CSF production by TCC21.1 in response to the 50 peptides with higher scores 
predicted using harmonic boost frame 1 and 2 score matrices. Complete decapeptide library, 
dual defined mixtures and individual decapeptides were presented by BLS cells expressing 
DRB1*15:01. Mixtures were tested at 200 µg/ml and individual decapeptides at 5 µg/ml. 
Histograms show mean ± standard error mean (SEM) and dot plots mean of three independent 
experiments. Cytokine released is always expressed as pg/ml released by TCC21.1 in response 
to stimuli minus pg/ml released in absence of stimulus (negative control). 
 
Figure 2. Characterization of TCC21.1 response to GDP-L-fucose synthase peptides. A. 
GM-CSF production by TCC21.1 in response to eleven decapeptides overlapping by nine AA 
and tested at 0.5 and 5 µg/ml. B-C. GM-CSF dose response of TCC21.1 to GDP-L-fucose 
synthase peptide (96-105) presented by BLS cells expressing DRA*01:01/DRB1*15:01, 
DRA*01:01/DRB5*01:01 or DQA1*01:02/DQB1*06:02 class II molecules. D. GM-CSF 
production by TCC21.1 in response to 13 alanine scan peptides presented by BLS cells 
expressing DRA*01:01/DRB1*15:01. Alanine substitution is shown in grey. E-F. Proliferative 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
32   
responses (white histograms) and production of cytokines (black histograms) by TCC21.1 in 
response to GDP-L-fucose synthase peptides presented by autologous PBMCs/BCL and 
unspecific stimulus. F. Proliferative response (white histograms) and GM-CSF and IL-3 
production (black histograms) by TCC21.1 and other TCCs with different functional phenotype 
in response to the corresponding specific peptides presented by autologous PBMCs, for 
TCC21.1 also autologous BCL, and to unspecific stimuli. Cytokine released is always expressed 
as pg/ml released by TCC21.1 in response to stimuli minus pg/ml released in absence of 
stimulus (negative control). All results show the mean ± SEM. Dotted lines show a putative 
threshold for positivity: SI=2 in proliferation histograms and the amount of IFNγ, IL-4, IL-17, IL-9 
and IL-22 released by T cells with Th1, Th2, Th17, Th9 Th22 functional phenotype respectively. 
G. Representative flow cytometry analysis of intracellular IL-4, IFN-γ, GM-CSF and IL-3 
production by TCC21.1 in response to GDP-L-fucose synthase peptide (96-105) and 
PMA/Ionomycin. Numbers represent the percentage of positive cells. H. Histograms 
representing the mean fluorescence intensity of CD28, CCR4, CCR6 and CRTh2 on the surface 
of resting TCC21.1 (black lines) in comparison to the isotype control staining (gray shaded). 
 
Figure 3. Recognition of GDP-L-fucose synthase peptides by TCC21.1 and CSF-
infiltrating CD4+ T cells from patient 1154SA. A. Proliferative responses expressed as SI of 
TCC21.1 and CSF-infiltrating CD4+ T cells after short- and long PHA expansion, to GDP-L-
fucose synthase-, myelin- and CEF peptides presented by autologous PBMCs as well as to 
control beads. TCC21.1 graph shows the mean SI ± SEM, while in the CSF graphs each dot 
represents one well. Positive peptides are shown in black. B. Proliferation of long expanded 
CSF-infiltrating CD4+ T to GDP-L-fucose synthase peptide (91-105), CEF pool and PHA using 
as APCs BLS DRA*01:01/DRB1*15:01 and assessed by EdU incorporation. Numbers represent 
the percentage of EdU-positive cells. C. Proliferative responses expressed as stimulation 
indexes (SI) of positive wells to GDP-L-fucose synthase peptide (191-205) for generation of 
TCL-39. D. TCRBV sequencing of TCCs present in TCL-39. E. Production of cytokines of long 
expanded CSF-infiltrating CD4+ T to GDP-L-fucose synthase peptides 91-105 and 191-205 
presented by autologous PBMCs as well as to control beads. Cytokine released is expressed as 
pg/ml released by stimulated cells minus pg/ml released in absence of stimulus (negative 
control). Results show the mean ± SEM. 
 
Figure 4. Recognition of GDP-L-fucose synthase peptides by CSF-infiltrating CD4+ T cells 
from moderate and high responder CIS/MS patients. A. Proliferative responses expressed 
as stimulation indexes (SI) of CSF-infiltrating CD4+ T cells (single round of PHA expansion) to 
 GDP-L-fucose synthase as putative autoantigen in MS 
   
   
33   
GDP-L-fucose synthase and CEF peptides presented by autologous PBMCs as well as to 
control beads. Each dot represents one well, and median SIs are shown as solid lines. Positive 
peptides (black dots and red line) are peptides with median of all SIs > 1.455 (dotted red line). 
All peptides have been tested in four wells, except for peptides 156-170 and/or 161-175 in 
748UR, 1129RE, 1005ME, 1173DI, 718MA and 776JE, which were tested also for bacterial 
peptides by seeding 8 wells. B. Number of CIS/MS patients with CSF-infiltrating CD4+ T cells 
that responded to GDP-L-fucose synthase peptides. Immunodominant peptides that were 
positive in at least three patients are shown in red. Solid red are high responder and light red 
moderate responder patients. C. Production of cytokines of CSF-infiltrating CD4+ T cells from 
three patients to GDP-L-fucose synthase immunodominant peptides presented by autologous 
PBMCs. 
 
Figure 5. Recognition of myelin peptides by CSF-infiltrating CD4+ T cells from CIS/MS 
patients. A. Proliferative responses expressed as stimulation indexes (SI) of CSF-infiltrating 
CD4+ T cells (single round of PHA expansion) to myelin peptides presented by autologous 
PBMCs. Each dot represents one well, and median SIs are shown as solid lines. Positive 
peptides (black wells and red line) are peptides with median of all SIs > 1.455 (dotted red line). 
B. Checkerboard graph illustrating GDP-L-fucose synthase immunodominant (red) and myelin 
(blue) peptides recognized by each CIS/MS patient. Solid colors are GDP-L-fucose synthase 
and myelin peptides showing significant correlation between them. P values for Fisher’s exact 
tests with Bonferroni-Holm correction are shown. 
 
Figure 6. Recognition of bacterial GDP-L-fucose synthase peptides by CSF-infiltrating 
CD4+ T cells from CIS/MS patients. Proliferative responses expressed as stimulation indexes 
(SI) of CSF-infiltrating CD4+ T cells (single round of PHA expansion) to eight bacterial GDP-L-
fucose synthase peptides, sharing with the human homologous peptide at least six of the 15 
amino acids (blue), presented by autologous PBMCs. Each dot represents one well and median 
SIs are shown as solid lines. Positive peptides (black wells and red line) are peptides with 
median of all SIs > 2 (dotted red line). 
 Table 1. GDP-L-fucose synthase transcripts and peptides identified in brain tissue. 
 
 
Transcriptome 
 
 
 
Proteome (PSM3) 
Distinct 
Protein 
 
Gene 
RPKM1 
UniProt 
 
 
MS 
Non-MS 
 
peptides 
coverage 
Protein 
ID 
LI2 
LII 
LIII 
ID 
Peptide sequence 
Residues 
WM 
GM 
WM 
GM 
Total 
# 
% 
GDP-L-fucose synthase 
TSTA3 
2.17 
2.02 
2.67 
Q13630 
ILVTGGSGLVGK 
10 - 21 
12 
12 
12 
12 
48 
17 
56.0 
 
 
 
 
 
 
VVADGAGLPGEDWVFVSSK 
26 - 44 
12 
12 
12 
12 
48 
 
 
 
 
 
 
 
 
DADLTDTAQTR 
45 - 55 
12 
12 
12 
12 
48 
 
 
 
 
 
 
 
 
VQPTHVIHLAAMVGGLFR 
61 - 78 
- 
9 
9 
9 
27 
 
 
 
 
 
 
 
 
YNLDFWR 
82 - 88 
12 
12 
12 
12 
48 
 
 
 
 
 
 
 
 
YNLDFWRK 
82 - 89 
- 
- 
- 
1 
1 
 
 
 
 
 
 
 
 
NVHMNDNVLHSAFEVGAR 
90 - 107 
- 
13 
13 
13 
39 
 
 
 
 
 
 
 
 
NVHMNDNVLHSAFEVGARK 
90 - 108 
- 
- 
- 
3 
3 
 
 
 
 
 
 
 
 
VVSCLSTCIFPDK 
109 - 121 
- 
- 
- 
3 
3 
 
 
 
 
 
 
 
 
 MIDVQNR 
149 - 155 
- 
2 
- 
2 
4 
 
 
 
 
 
 
 
 
RMIDVQNR 
148 - 155 
- 
- 
2 
2 
4 
 
 
 
 
 
 
 
 
SSGSALTVWGTGNPR 
200 - 214 
3 
- 
- 
- 
3 
 
 
 
 
 
 
 
 
SSGSALTVWGTGNPRR 
200 - 215 
- 
- 
1 
- 
1 
 
 
 
 
 
 
 
 
TTYPIDETMIHNGPPHNSNFGYSYAK 
222 - 247 
- 
- 
3 
- 
3 
 
 
 
 
 
 
 
 
EYNEVEPIILSVGEEDEVSIK 
233 - 253 
- 
3 
- 
- 
3 
 
 
 
 
 
 
 
 
  TYLPDFR 
291 - 297 
12 
12 
12 
12 
48 
 
 
 
 
 
 
 
 
LRTYLPDFR 
289 - 297 
- 
- 
- 
2 
2 
 
 
 
 
 
 
 
 
 
 
63 
87 
88 
95 
333 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myelin basic protein 
MBP 
37.20 
28.97 
59.21 
P02686 
 
 
993 
871 
985 
865 
3714 
80 
79.6 
Myelin proteolipid protein 
PLP1 
458.31 
341.43 
431.91 
P60201 
 
 
148 
153 
129 
157 
587 
13 
30.6 
Myelin-oligodendrocyte 
glycoprotein 
 
MOG 
- 
- 
- 
 
Q16653 
 
 
216 
199 
222 
216 
853 
28 
 
49.8 
Myelin-associated glycoprotein 
MAG 
16.29 
10.83 
26.84 
P20916 
 
 
243 
232 
221 
243 
939 
34 
36.9 
Myelin-associated 
oligodendrocyte basic protein 
 
MOBP 
14.48 
11.16 
19.82 
 
Q13875 
 
 
20 
12 
27 
14 
73 
6 
 
26.2 
Oligodendrocyte myelin 
glycoprotein 
 
OMG 
5.21 
5.07 
3.26 
 
P23515 
 
 
144 
155 
136 
155 
590 
13 
 
28.8 
2',3'-cyclic-nucleotide 
3'-
phosphodiesterase 
 
CNP 
- 
- 
- 
 
P09543 
 
 
1168 
985 
1157 1060 
4370 
112 
 
96.4 
1 RPKM, reads per kilobase of exon model per million mapped reads. 2 LI and LIII, active lesions in which TCC21.1 was clonally expanded. LII, inactive lesion in which TCC21.1 
was not idenfied. 3 PSM, peptide spectrum matches. Proteome data correspond to white matter (WM) and grey matter (GM) from multiple sclerosis patients (MS, n=15) and non-
MS controls (Non-MS, n=9). In bold are GDP-L-fucose synthase values. 
 Table 2. Demographical and clinical characteristics of CIS/MS patients and HLA-DR –DQ typing.  
 
Patient 
 
 
 
IgG 
CSF 
HLA 
 
ID 
Disease 
Sex 
Age 
Index 
# cells/uL 
DRB1* 
DRB1* 
DRB3* 
DRB3* 
DRB4* 
DRB4* 
DRB5* 
DRB5* 
DQA1* 
DQA1* 
DQB1* 
DQB1* 
UNRESPONDERS 
 
66JO 
RRMS 
F 
38 
2.89 
8 
15:01 
15:01 
 
 
 
 
01:01 
01:01 
01:02 
01:02 
06:02 
06:02 
 
103HR 
CIS 
M 
37 
0.68 
9 
15:01 
15:01 
 
 
 
 
01:01 
01:01 
01:02 
01:02 
06:02 
06:02 
 
0204AM 
RRMS 
F 
38 
1.04 
8 
15:01 
15:01 
 
 
 
 
01:01 
01:01 
01:02 
01:02 
06:02 
06:02 
 
0247PE 
SPMS 
F 
39 
1.5 
3 
15:01 
07:01 
 
 
01:03 
 
01:01 
 
01:02 
02:01 
06:02 
03:03 
 
0381MA 
SPMS 
F 
45 
0.5 
3 
15:01 
04:01 
 
 
01:01 
 
01:01 
 
01:02 
03:XX 
06:02 
03:02 
 
0702AN 
RRMS 
M 
45 
0.73 
5 
15:01 
01:03 
 
 
 
 
01:01 
 
01:02 
05:01 
03:01 
06:02 
 
0740RA 
CIS 
F 
35 
0.5 
3 
04:01 
07:01 
 
 
01:01 
01:01 
 
 
02:01 
03:01 
02:01 
03:01 
 
0936MA 
RRMS 
F 
31 
0.66 
2 
15:01 
15:01 
 
 
 
 
01:01 
01:01 
01:02 
01:02 
06:02 
06:02 
 
0973JO 
RRMS 
M 
22 
0.51 
18 
15:01 
04:02 
 
 
01:01 
 
01:01 
 
01:02 
03:01 
03:02 
06:02 
 
1125PA 
RRMS 
M 
41 
0.63 
6 
04:02 
14:54 
 
02:02 
01:01 
 
 
 
01:01 
03:01 
03:02 
05:03 
 
1292DI 
RRMS 
F 
27 
1.28 
10 
15:01 
16:01 
 
 
 
 
01:01 
02:02 
01:02 
01:02 
05:02 
06:02 
 
1300EV 
RRMS 
F 
37 
0.57 
2 
03:01 
08:01 
 
02:02 
 
 
 
 
04:01 
05:01 
02:01 
04:02 
 
0897UR 
RRMS 
F 
34 
1.97 
7 
15:01 
08:01 
 
 
 
 
01:01 
 
01:02 
04:01 
04:02 
06:02 
 
0127RO 
CIS 
M 
30 
1.38 
27 
15:01 
08:01 
 
 
 
 
01:01 
 
01:02 
04:01 
04:02 
06:02 
 
1290JA 
SPMS 
M 
27 
0.5 
8 
15:01 
04:04 
 
 
01:01 
 
01:01 
 
03:02 
06:02 
01:02 
03:XX 
 
0800TH 
RRMS 
M 
22 
0.52 
7 
15:01 
11:04 
 
02:02 
 
 
01:01 
 
01:02 
05:01 
03:01 
06:02 
 
0830OL 
CIS 
F 
36 
0.56 
4 
15:01 
11:01 
 
02:02 
 
 
01:01 
 
01:02 
05:01 
03:01 
06:02 
 
0818MA 
RRMS 
M 
37 
0.67 
3 
03:01 
04:07 
01:01 
 
01:01 
 
 
 
03:01 
05:01 
02:01 
03:01 
 
1206CO 
RRMS 
F 
37 
1.37 
5 
15:01 
04:01 
 
 
01:01 
 
01:01 
 
01:02 
03:01 
03:02 
06:02 
MODERATE RESPONDERS 
 
0780UR 
RRMS 
M 
27 
1.19 
8 
15:01 
09:01 
 
 
01:01 
 
01:01 
 
01:02 
03:01 
03:03 
06:02 
 
0866JE 
RRMS 
F 
30 
1.14 
10 
11:01 
13:01 
01:01 
02:02 
 
 
 
 
01:03 
05:01 
03:01 
06:03 
 
0748UR 
RRMS 
M 
53 
1.49 
7 
15:01 
15:01 
 
 
 
 
01:01 
01:01 
01:02 
01:02 
06:02 
06:02 
 
1346JU 
RRMS 
F 
21 
1.09 
12 
07:01 
13:01 
01:01 
 
01:01 
 
 
 
01:03 
02:01 
02:01 
06:03 
 
1081SA 
CIS 
F 
49 
0.71 
23 
01:01 
08:03 
 
 
 
 
 
 
01:01 
06:01 
03:01 
05:01 
 
0817JD 
RRMS 
M 
28 
0.53 
6 
15:01 
03:01 
01:01 
 
 
 
 
01:01 
01:02 
05:01 
02:01 
06:02 
HIGH RESPONDERS 
 
1129RE 
RRMS 
M 
32 
0.92 
3 
07:01 
11:03 
 
02:02 
01:03 
 
 
 
02:01 
05:01 
03:01 
03:03 
 
1005ME 
CIS 
F 
33 
0.76 
4 
15:03 
03:01 
 
02:02 
 
 
01:01 
 
01:02 
05:01 
02:01 
06:02 
 
1173DI 
RRMS 
M 
32 
0.51 
14 
04:04 
11:04 
 
02:02 
01:01 
 
 
 
03:01 
05:01 
03:02 
03:01 
 
0718MA 
RRMS 
F 
36 
0.54 
1 
15:01 
03:01 
 
02:02 
 
 
01:01 
 
05:01 
05:01 
02:01 
03:01 
 
0816DA 
CIS 
F 
52 
1.14 
12 
15:01 
13:01 
 
02:02 
 
 
01:01 
 
01:03 
01:02 
06:02 
06:03 
 
0776JE 
CIS 
F 
28 
0.7 
6 
03:01 
08:03 
 
02:02 
 
 
 
 
05:01 
06:01 
02:01 
03:01 
   
 Individual activity insufficient 
to explain mixture activity 
Individual activity now sufficient 
to explain mixture activity 
70
80
90
100
0
500
1000
5000
10000
15000
% Max Theoretical Score
GM-CSF (pg / mL) 
Original Matrix
Human proteins
D- Synthesize and test individual 
peptides based on mixture activity 
and biometrical analysis 
A C D E F GH I K L MN P QR S T VWY
0
50
100
150
200
GM-CSF (pg/ml)
HLA-DRB5*0101
A C D E F GH I K L MN P QR S T VWY
0
50
100
150
200
HLA-DRB1*1501
A C D E F GH I K L MN P QR S T VWY
0
50
100
150
200
HLA-DQB1*0602
B- Screen Positional Scanning Library 
C- Biometrical Analysis 
G- Synthesize and test of individual peptides based 
on new biometrical analysis 
70
80
90
100
0
500
1000
5000
10000
15000
% Max Theoretical Score
GM-CSF (pg / mL) 
Harmonic Boost Frame 1
Human proteins
70
80
90
100
0
500
1000
5000
10000
15000
% Max Theoretical Score
GM-CSF (pg / mL) 
Harmonic Boost Frame 2
Human proteins
Figure 1 
F- Motif with flanking residues  
0
100
200
300
400
500
GM-­‐CSF   (pg/ml)   
E- Synthesis and test of dual-defined mixtures 
1 2 3 4 5 6 7 8 9 10
Acetyl I K X X X X X X X X NH2
Acetyl X K L X X X X X X X NH2
Acetyl X R L X X X X X X X NH2
Acetyl X X K L X X X X X X NH2
Acetyl X X L H X X X X X X NH2
Acetyl X X X H S X X X X X NH2
Acetyl X X X L H X X X X X NH2
Acetyl X X X X H S X X X X NH2
Acetyl X X X X S S X X X X NH2
Acetyl X X X X X X F E X X NH2
Acetyl X X X X X X X E V
X NH2
Acetyl X X X X X X X F E
X NH2
Acetyl X X X X X X X X E V NH2
Acetyl X X X H X X X E X X NH2
Acetyl X X X K X X X F X X NH2
Acetyl X X X L X X X F X X NH2
Acetyl X X X H X X X X V
X NH2
Acetyl X X X L X X X X E
X NH2
Acetyl X X X X H X X F X X NH2
Acetyl X X X X S X X E X X NH2
Acetyl X X X X H X X X E
X NH2
Acetyl X X X X S X X X V
X NH2
Position
Frame 1
Frame 1-HM
Frame 2
Frame 2-HM
200 µg/ml 
pg/ml 
0
200
400
600
800
0
200
400
600
800
P1 
P2 
0
100
200
300
400
0
200
400
600
P3 
P4 
0
100
200
300
400
0
50
100
150
P5 
P6 
0
100
200
300
0
100
200
300
400
P7 
P8 
A C D E F G H I K L M N P Q R S T V W Y
0
100
200
300
400
500
A C D E F G H I K L M N P Q R S T V W Y
0
100
200
300
400
P9 
P10 
GM-CSF 
IL-10 
A- HLA Restriction 
 0
20000 0
20000
0
20000
0
60
BEADS
αCD3 αCD28
αCD3 PMA
0
20000
0
40
VLHSAFEVGA
NVLHSAFEVG
DNVLHSAFEV
0
2000
0
5000
0
6000
E 
IL-4 
IL-22 
TNFα 
 

IL-17A 
IL-9 
IL-21 
PBMCs 
IL-2 
IFNγ 
 

IL-5 
IL-13 
IL-17F 
SI 
pg/ml 
0
5000
0
5000
0
50000 0
30000
0
5000
IL-6 
IL-10 
0
5000 0
20000
0
20000
Th1 
Th2 
0
5000
Th17 
0
20000
Th22 
Th9 
0
5000 0
20000 0
5000
0
6000 0
20000 0
25000 0
5000
0
5000
0
2000 0
20000 0
5000
0
5000 0
20000
GDP-L-fucose synthase 
0
5000
0
5000 0
6000
0
20000 0
25000 0
5000
0
5000 0
2000
0
20000 0
5000
0
5000
0
20000
95-104�
96-105�
97-106�
95-104�
96-105�
97-106�
BCL 
52.8 
11.3 
1.55 
13.7 
47.7 
13.5 
42,7 
10.9 
0.37 
GDP-L-fucose 
synthase96-105 
30.2 
46.2 
7.00 
15.1 
77.7 
0.12 
62,4 
13.0 
0.33 
PMA+Io 
F 
IL-4 
IFNγ 

GM-CSF 
IL-4 

GM-CSF 
IL-3 

Unstimulated 
0
100
250
TCC3 BEADS
TCC3 VP134-49
TCC1 BEADS
TCC1 VP134-49
TCC5F6 BEADS
TCC5F6 MBP83-99
TCC3A6 BEADS
TCC3A6 MBP83-99
TCC21.1 BEADS
αCD3 αCD28
αCD3 PMA
TCC21.1 TSTA396-104
TCC21.1 TSTA396-104
BEADS�
MBP83-99�
TCC3A6(Th1*)�
BEADS�
MBP83-99�
TCC5F6(Th1)�
BEADS�
VP134-49�
TCC1(Th1)�
BEADS�
VP134-49�
TCC3(Th1/2)�
BCL�
PBMCs�
αCD3 PMA�
αCD3 αCD28�
BEADS�
SI 
GM-CSF 
IL-3 
TCC21.1(Th2)�
0
25000
TCC3 BEADS
TCC3 VP134-49
TCC1 BEADS
TCC1 VP134-49
TCC5F6 BEADS
TCC5F6 MBP83-99
TCC3A6 BEADS
TCC3A6 MBP83-99
TCC21.1 BEADS
αCD3 αCD28
αCD3 PMA
TCC21.1 TSTA396-104
TCC21.1 TSTA396-104
0
400 4000
TCC3 BEADS
TCC3 VP134-49
TCC1 BEADS
TCC1 VP134-49
TCC5F6 BEADS
TCC5F6 MBP83-99
TCC3A6 BEADS
TCC3A6 MBP83-99
TCC21.1 BEADS
αCD3 αCD28
αCD3 PMA
TCC21.1 TSTA396-104
TCC21.1 TSTA396-104
pg/ml 
H 
CCR4 
CRTh2 
CCR6 
CD28 
Counts 
MFI 
G 
 pg/ml 
A 
D 
0
20000
GM-CSF (pg/ml) 
0.5 µg/ml 
5 µg/ml  
10-4
10-3
10-2
10-1
100
101
102
0
10000
20000
NVLHSAFEVG (μg/ml)
C 
0
5000
10000
15000
DRB1*1501 
DRB5*0101 
DQB1*0602 
0.1 
1 
10 
10-4
10-3
10-2
10-1
100
101
102
0
10000
20000
NVLHSAFEVG (μg/ml)
B 
10 µg/ml 
5 µg/ml 
0.5 µg/ml 
GM-CSF (pg/ml) 
 pg/ml 
GDP-L-fucose synthase  
C 
D 
APCs 
96-105 / APCs 
Figure 2 
0
10
VLHSAFEVGA
NVLHSAFEVG
DNVLHSAFEV
0
20000
0
20000
Proliferation 
Proliferation 
 A 
CD4+ CSF-infiltrating T cells (Long PHA expansion) 
26.30 
FSC 
27.60 
26.40 
0.08 
0.00 
Vb21+ 
Vb21- 
All Vb 
0.21 
 9.22 
 0.01 
 2.66 
0.00 
0.00 
0.56 
- 
91-105 
CEF 
PHA 
EdU 
B 
0
70000
0
70000
0
70000
0
70000
0
70000
0
70000
0
70000
0
70000
0
70000
0
70000
0
70000
0
70000
0
70000
0
70000
0
600
0
600
0
600
0
600
0
600
0
600
0
600
0
600
0
600
0
600
0
600
0
600
0
600
0
600
IL-4 
IL-22 
TNFα 
 

IL-17A 
IL-9 
IL-21 
IL-2 
IFNγ 
 

IL-5 
IL-13 
IL-17F 
IL-6 
IL-10 
Th1 
Th2 
Th17 
Th22 
Th9 
GM-CSF 
0
12000
0
12000
0
12000
0
12000
0
12000
0
12000
0
12000
0
12000
0
12000
0
12000
0
12000
0
12000
0
12000
0
12000
91-105�
191-205�
BEADS�
pg/ml 
E 
D 
0
2
4
6
8
10
5th PHA expansion
3rd PHA expansion
1rst PHA expansion
TCL Generation
SI
C 
TCR sequencing 
Figure 3 
0
50
100
0
1
2
3
4
SI 
0
200
400
0
30
60
0
10
20
TCC21.1 
PHA-expanded 
CD4+ CSF-infiltrating T cells 
0
5
60
Short Exp 
Long Exp 
GDP-L-fucose synthase 
 0
150
300
0
6
12
0
75
150
0.0
2.5
5.0
0
50
100
0
2
4
120
240
0
2
4
SI 
0
50
100
0
200
400
0
50
100
0
50
100
0
50
100
0
100
200
0
100
200
0
50
100
0
2
4
0
2
4
0
2
4
0
2
4
0
3
6
780UR 
866JE 
1346JU 
1081SA 
817JD 
1129RE 
1005ME 
816DA 
MODERATE RESPONDERS 
HIGH RESPONDERS 
B 
>1000 
26-40 
51-65 
136-150 
161-175 
226-240 
246-260 
256-270 
296-310 
0 pg/ml 
A 
C 
GDP-L-fucose synthase 
Beads 
Figure   4   
Positive patients 
1-15 
26-40 
51-65 
76-90 
136-150 
156-170 
161-175 
226-240 
196-310 
236-250 
241-255 
246-260 
251-265 
256-270 
Immunodominant   Pep2des   
1173DI 
0
2
4
748UR 
0
5
10
0
4
8
40
718MA 
776JE 
 0
3
6
0
3
6
0
3
6
0
3
6
0
3
6
0
3
6
0
3
6
776JE
816DA
718MA
1173DI
1005ME
1129RE
817JD
1081SA
1346JU
748UR
866JE
780UR
1206CO
818MA
830OL
800TH
1290JA
127RO
897UR
1300EV
1292DI
1125PA
973JO
936MA
740RA
702AN
381MA
247PE
204AM
103FH
66JO
Figure 5 
Nonresponders 
High 
Responders 
A 
MOG1-20 
MOG35-55 
MBP13-32 
MBP111-129 
MBP146-170 
PLP139-154 
SI 
B 
Moderate 
Responders 
Nonresponders 
High 
Responders 
GDP-L-fucose synthase 
161-175 
51-65 
136-150 
251-265 
241-255 
246-260 
26-40 
156-170 
226-240 
236-250 
256-270 
296-310 
1-15 
76-90 
MOG1-20 
MOG35-55 
MBP13-32 
MBP83-99 
MBP111-129 
MBP146-170 
PLP139-154 
Immunodominant Peptides 
GDP-L-fucose synthase 
MBP83-99 
Moderate 
Responders 
66JO 
103FH 
204AM 
247PE 
381MA 
702AN 
740RA 
936MA 
973JO 
1125PA 
1292DI 
1300EV 
897UR 
127RO 
1290JA 
800TH 
830OL 
818MA 
1206CO 
780UR 
866JE 
748UR 
1346JU 
1081SA 
817JD 
1129RE 
1005ME 
1173DI 
718MA 
816DA 
776JE 
 0
2
4
6
SI 
1173DI 
Figure 6 
1489HE 
748UR 
776JE 
0
2
4
6
0
2
4
6
0
2
4
6
0
2
4
6
0
2
4
6
718MA 
1440AM 
1129RE 
1005ME 
0
5
10
15
0
2
4
6
0
2
4
6
 Figure S1. Integration of stimulatory response from testing dual-defined mixtures into the original scoring matrix using the harmonic mean model. 
In order to integrate the responses from testing dual-defined mixtures into the original scoring matrix using the harmonic mean model, we first retested single 
defined mixtures along with the dual defined mixtures and used them to normalize all activity values to a single scale using linear regression.  Then, all GM-
CSF (pg/ml) values for all single defined and dual defined at all doses were converted to Approximate EC50 values using the formula:  
Approximate EC50= [Tested Concentration] * (MaximumGMCSF / GMCSF-1) 
Next, the harmonic mean was taken of each pair of single-defined Approximate EC50 that had a corresponding dual defined mixture, and the value was 
compared to that of the dual defined mixture. For example, the Approximate EC50 of the dual defined mixture with L defined in the fourth position and H 
defined in the fifth position was compared to the harmonic mean of the  Approximate EC50 values of the two corresponding single defined mixtures: the first 
with L defined in the fourth position, and the second with H defined in the fifth position.  The harmonic mean model dictates that the dual defined mixture 
contains more active individual peptides than either of the single defined mixtures only if its activity is greater than the harmonic mean of the two single 
defined mixtures27 (i.e., when the fold over the harmonic mean is greater than one).  In total, five dual defined mixtures in Frame 1 (Green) and four in Frame 
2 (Blue) exhibited this property (the dual-defined mixtures in darker colors and bolded Fold Over Harmonic Mean).  All Approximate EC50 values were 
converted back to GM-CSF (pg/ml) values at 200 ug/ml, and then those amino acids and position corresponding to the five dual defined mixtures in Frame 1 
had added to them the log base 10 of the highest activity value among the dual defined mixtures with that position defined (Fig. S1, bold values in Log10 
median table, as opposed to the lower numerical values in grey).  For example, both the dual defined mixture with F defined in position seven and E in 
position eight, and the dual defined mixture with E in position eight and V in position nine, had activity values greater than their associated harmonic means.  
The value added to E in the eighth position of the matrix was the activity value for the dual defined mixture with F defined in position seven and E in position 
eight, because it was the higher of the two (2.5 versus 2.4).  Frame 2 was treated the same way, creating the two “updated” matrices shown that were then 
used to score peptides in the standard Biometrical Analysis fashion. 
 
Frame 1
Frame 1-HM
Frame 2
Frame 2-HM
 High Responders
Moderate Responders
Nonresponders
100
101
102
103
Log (Med SI )
Beads
High Responders
Moderate Responders
Nonresponders
10-1
100
101
Log (Med SI )
CEF
0
100
200
0
2
4
0
50
100
0
2
4
0
100
200
90
180
0
150
300
0
75
150
0
75
150
0
75
150
0
75
150
0
100
200
0
50
100
0
50
100
0
75
150
0
75
150
0
50
100
0
50
100
0
100
200
0
50
100
0
50
100
0
2
4
66JO 
0
2
4
103HR 
0
2
4
204AM 
0
2
4
247PE 
381MA 
0
2
4
0 1 2 3 4
8
702AN 
0
2
4
740RA 
0
2
4
936MA 
0
2
4
973JO 
0
2
4
1125PA 
1292DI 
1300EV 897UR 
127RO 
0
2
4
1290JA 
800TH 
830OL 
818MA 
0
3
6
0
5
10
0
2
4
0
2
4
15
0
2
4
0
2
4
SI   
A 
GDP-L-fucose synthase 
B 
Figure S2 
1206CO 
High Responders
Moderate Responders
Nonresponders
10-1
100
101
Log (SI )
Negative control
NONRESPONDERS 
 Figure S2. Response of CSF-infiltrating CD4+ T cells. A. Response of CSF-infiltrating CD4+ T cells from nonresponder CIS/
MS patients to GDP-L-fucose synthase peptides. Proliferative responses expressed as stimulation indexes (SI) of CSF-infiltrating 
CD4+ T cells (single round of PHA expansion) to GDP-L-fucose synthase and CEF peptides presented by autologous PBMCs as 
well as to control beads. Each dot represents one replicate well and median SIs are shown as solid lines. Positive peptides 
(black dots and red line) are peptides with median of  SIs > 1.455 (dotted red line). All peptides have been tested in four replicate 
wells. B. Graphs comparing the proliferative responses of CSF-infiltrating CD4+ T cells to CEF peptides, control beads and only 
medium (negative control) for the different responder groups. In the CEF peptide pool and control beads graphs, each dot 
represents the median SIs of four wells for one individual patient. In the negative control graph, each dot represents the SI of one 
individual well and it has been calculated as: cpm in one individual well without peptide / Median (all replicates cpm without 
peptide in the patient). Willcoxon statistical analysis and p values are shown for the three comparisons. 
 
 SI 
A 
C 
0 20 40 60 80
BEADS
0
3
6
CEF
296-310
251-265
241-255
161-175
136-150
51-65
0
3
6
CEF
296-310
251-265
241-255
161-175
136-150
51-65
1440AM 
RRMS 
1489AM 
CIS 
0 20 40 60 80
BEADS
GDP-L-fucose synthase 
B 
 Figure S3. New patients and phylogeny of bacterial species sharing GDP-L-fucose synthase peptides. A. 
Proliferative responses expressed as stimulation indexes (SI) of CSF-infiltrating CD4+ T cells (single round of PHA 
expansion) to GDP-L-fucose synthase and CEF peptides presented by autologous PBMCs as well as to control beads. 
Each dot represents one well, and median SIs are shown as solid lines. Positive peptides (black dots and red line) are 
peptides with median of all SIs > 1.455 (dotted red line). B. HLA class II typing. C. Phylogeny of bacterial species 
sharing GDP-L-fucose synthase peptides. In black are represented stimulatory peptides in four patients, in dark grey in 
one to three patients and in light grey non stimulatory. Genera common in gut microbiota are shown in red.  
 Table   S1.   Summary   of   human   decapeptides   predicted   with   the   biometrical   approached,   synthesized   and   tested   for   stimulatory   capacity
PEPTIDES   FROM   HUMAN   PROTEINS
Peptides   tested   at   5   mg/ml
Matrix
Uniprot   Database
Rank
Score
PercentMax
Matrix
Uniprot   Database
Rank
Database
Rank
Score
PercentMax
10mer
Protein
Mean   GM-­‐CSF   (pg/ml)
Original
Human
1
19.79
86.9%
HM   Boost   Frame   2
Human
4
Brain   Lesions
4
27.14
81.0%
RKKLHKFEET
|Q96PE3|INP4A_HUMAN   Type   I   inositol   3,4-­‐bisphosphate   4-­‐phosphatase   OS=Homo   sapiens   GN=INPP4A   PE=1   SV=1
3
Original
Human
2
19.27
84.6%
HM   Boost   Frame   2
Human
5
Brain   Lesions
5
26.96
80.4%
LKKLHDFEEQ
|Q9BX84|TRPM6_HUMAN   Transient   receptor   potential   cation   channel   subfamily   M   member   6   OS=Homo   sapiens   GN=TRPM6   PE=1   SV=2
9
Original
Human
3
19.21
84.3%
HM   Boost   Frame   2
Human
7
Brain   Lesions
7
26.90
80.3%
QKKLHDFEEQ
|Q96QT4|TRPM7_HUMAN   Transient   receptor   potential   cation   channel   subfamily   M   member   7   OS=Homo   sapiens   GN=TRPM7   PE=1   SV=1
9
Original
Human
4
18.99
83.4%
HM   Boost   Frame   2
Human
8
Brain   Lesions
8
26.90
80.3%
QKKLSSGEEK
|Q15858|SCN9A_HUMAN   Sodium   channel   protein   type   9   subunit   alpha   OS=Homo   sapiens   GN=SCN9A   PE=1   SV=3
4
Original
Human
5
18.89
82.9%
HM   Boost   Frame   1
Human
45
26.35
72.1%
RKLLHRFETE
|O15327|INP4B_HUMAN   Type   II   inositol   3,4-­‐bisphosphate   4-­‐phosphatase   OS=Homo   sapiens   GN=INPP4B   PE=2   SV=4
14
Original
Human
6
18.78
82.4%
HM   Boost   Frame   2
Human
1
Brain   Lesions
1
28.47
84.9%
RRKLHSFYEV
|Q5VST9|OBSCN_HUMAN   Obscurin   OS=Homo   sapiens   GN=OBSCN   PE=1   SV=3
13
Original
Human
7
18.71
82.1%
KKKKVAGEEE
|I3L1I4|I3L1I4_HUMAN   Chromodomain-­‐helicase-­‐DNA-­‐binding   protein   3   (Fragment)   OS=Homo   sapiens   GN=CHD3   PE=4   SV=1
0
Original
Human
8
18.54
81.4%
LKKVHDFEEQ
|Q9HCF6|TRPM3_HUMAN   Transient   receptor   potential   cation   channel   subfamily   M   member   3   OS=Homo   sapiens   GN=TRPM3   PE=2   SV=4
49
Original
Human
9
18.19
79.9%
KKLLLHVEEV
|Q8N8V2|GBP7_HUMAN   Guanylate-­‐binding   protein   7   OS=Homo   sapiens   GN=GBP7   PE=2   SV=2
64
Original
Human
10
18.18
79.8%
HM   Boost   Frame   1
Human
4
Brain   Lesions
4
28.28
77.3%
QKKHSGFEDE
|P10645|CMGA_HUMAN   Chromogranin-­‐A   OS=Homo   sapiens   GN=CHGA   PE=1   SV=7
9
Original
Human
11
18.12
79.5%
LKKKSHMEEK
|Q49MG5|MAP9_HUMAN   Microtubule-­‐associated   protein   9   OS=Homo   sapiens   GN=MAP9   PE=1   SV=3
6
Original
Human
12
18.01
79.1%
KKKKSALFEV
|Q9GZU0|CF062_HUMAN   Uncharacterized   protein   C6orf62   OS=Homo   sapiens   GN=C6orf62   PE=2   SV=1
4
Original
Human
13
18.01
79.1%
RKKKSALFEV
|Q9GZU0-­‐2|CF062_HUMAN   Isoform   2   of   Uncharacterized   protein   C6orf62   OS=Homo   sapiens   GN=C6orf62
0
Original
Human
14
18.00
79.0%
IWKKLSFEEV
|Q96JI7|SPTCS_HUMAN   Spatacsin   OS=Homo   sapiens   GN=SPG11   PE=1   SV=3
8
Original
Human
15
18.00
79.0%
HM   Boost   Frame   2
Human
13
Brain   Lesions
13
25.87
77.2%
LKRLHEFEEQ
|Q7Z4N2|TRPM1_HUMAN   Transient   receptor   potential   cation   channel   subfamily   M   member   1   OS=Homo   sapiens   GN=TRPM1   PE=1   SV=2
6
Original
Human
16
17.97
78.9%
HM   Boost   Frame   1
Human
3
Brain   Lesions
3
28.40
77.7%
LKLHSRFYEL
|O75838|CIB2_HUMAN   Calcium   and   integrin-­‐binding   family   member   2   OS=Homo   sapiens   GN=CIB2   PE=1   SV=1
55
Original
Human
17
17.89
78.5%
QKKLHKFELA
|O15514|RPB4_HUMAN   DNA-­‐directed   RNA   polymerase   II   subunit   RPB4   OS=Homo   sapiens   GN=POLR2D   PE=1   SV=1
27
Original
Human
18
17.74
77.9%
LGLHHHGEEA
|Q9BWH6|RPAP1_HUMAN   RNA   polymerase   II-­‐associated   protein   1   OS=Homo   sapiens   GN=RPAP1   PE=1   SV=3
7
Original
Human
19
17.74
77.9%
HM   Boost   Frame   1
Human
12
Brain   Lesions
11
27.63
75.6%
RRLHLHFERV
|Q6UXD5|SE6L2_HUMAN   Seizure   6-­‐like   protein   2   OS=Homo   sapiens   GN=SEZ6L2   PE=1   SV=2
3
Original
Human
20
17.72
77.8%
HM   Boost   Frame   2
Human
3
Brain   Lesions
3
27.26
81.3%
RRLLSSGFEE
|O60518|RNBP6_HUMAN   Ran-­‐binding   protein   6   OS=Homo   sapiens   GN=RANBP6   PE=1   SV=2
3
Original
Human
21
17.70
77.7%
KKKKHSTEGV
|P51003|PAPOA_HUMAN   Poly(A)   polymerase   alpha   OS=Homo   sapiens   GN=PAPOLA   PE=1   SV=4
6
Original
Human
22
17.66
77.5%
HM   Boost   Frame   1
Human
9
Brain   Lesions
8
27.89
76.3%
QRLHLHFEKV
|Q53EL9|SEZ6_HUMAN   Seizure   protein   6   homolog   OS=Homo   sapiens   GN=SEZ6   PE=1   SV=2
5
Original
Human
23
17.58
77.2%
SKKHHRGEVC
|Q8N7U6|EFHB_HUMAN   EF-­‐hand   domain-­‐containing   family   member   B   OS=Homo   sapiens   GN=EFHB   PE=2   SV=4
0
Original
Human
24
17.56
77.1%
HM   Boost   Frame   2
Human
2
Brain   Lesions
2
27.46
81.9%
RKLLSSGFEI
|Q8N8A2|ANR44_HUMAN   Serine/threonine-­‐protein   phosphatase   6   regulatory   ankyrin   repeat   subunit   B   OS=Homo   sapiens   GN=ANKRD44   PE=1   SV=3
5
Original
Human
25
17.54
77.0%
IKKKHLFENS
|Q8NBU5|ATAD1_HUMAN   ATPase   family   AAA   domain-­‐containing   protein   1   OS=Homo   sapiens   GN=ATAD1   PE=1   SV=1
0
Original
Human
26
17.53
77.0%
HM   Boost   Frame   2
Human
31
Brain   Lesions
28
24.72
73.7%
QKKLHHFFIG
|Q8IWB1|IPRI_HUMAN   Inositol   1,4,5-­‐trisphosphate   receptor-­‐interacting   protein   OS=Homo   sapiens   GN=ITPRIP   PE=1   SV=1
0
Original
Human
27
17.52
76.9%
AKLHHGFGEA
|Q9P2P6|STAR9_HUMAN   StAR-­‐related   lipid   transfer   protein   9   OS=Homo   sapiens   GN=STARD9   PE=1   SV=3
1
Original
Human
28
17.46
76.6%
LKHVSHGEEL
|Q9NZ53|PDXL2_HUMAN   Podocalyxin-­‐like   protein   2   OS=Homo   sapiens   GN=PODXL2   PE=1   SV=1
0
Original
Human
29
17.46
76.6%
QKKIHKFEEA
|Q8N8E3|CE112_HUMAN   Centrosomal   protein   of   112   kDa   OS=Homo   sapiens   GN=CEP112   PE=1   SV=2
0
Original
Human
30
17.45
76.6%
LHKKHYFEVL
|Q96JI7|SPTCS_HUMAN   Spatacsin   OS=Homo   sapiens   GN=SPG11   PE=1   SV=3
1
Original
Human
31
17.42
76.5%
LKKHLSGEEH
|Q96EU6|RRP36_HUMAN   Ribosomal   RNA   processing   protein   36   homolog   OS=Homo   sapiens   GN=RRP36   PE=1   SV=1
24
Original
Human
32
17.40
76.4%
HM   Boost   Frame   1
Human
8
Brain   Lesions
7
27.99
76.5%
QKLHLHFERL
|Q9BYH1|SE6L1_HUMAN   Seizure   6-­‐like   protein   OS=Homo   sapiens   GN=SEZ6L   PE=1   SV=1
10
Original
Human
33
17.37
76.3%
HM   Boost   Frame   1
Human
24
Brain   Lesions
18
27.05
74.0%
RKLKASFEVS
|Q8TDX9|PK1L1_HUMAN   Polycystic   kidney   disease   protein   1-­‐like   1   OS=Homo   sapiens   GN=PKD1L1   PE=1   SV=1
338
Original
Human
34
17.35
76.2%
HM   Boost   Frame   2
Human
25
25.03
74.7%
FSKLHTFEEV
|Q96JB1|DYH8_HUMAN   Dynein   heavy   chain   8,   axonemal   OS=Homo   sapiens   GN=DNAH8   PE=1   SV=2
0
Original
Human
35
17.32
76.0%
RKKLSLDEES
|O60296|TRAK2_HUMAN   Trafficking   kinesin-­‐binding   protein   2   OS=Homo   sapiens   GN=TRAK2   PE=1   SV=2
0
Original
Human
36
17.31
76.0%
HM   Boost   Frame   1
Human
17
27.23
74.5%
EKKVSSFEVF
|Q9UHG0|DCDC2_HUMAN   Doublecortin   domain-­‐containing   protein   2   OS=Homo   sapiens   GN=DCDC2   PE=1   SV=2
0
Original
Human
37
17.24
75.7%
HM   Boost   Frame   1
Human
29
Brain   Lesions
22
26.98
73.8%
RKLLSDFPVV
|Q4LDE5|SVEP1_HUMAN   Sushi,   von   Willebrand   factor   type   A,   EGF   and   pentraxin   domain-­‐containing   protein   1   OS=Homo   sapiens   GN=SVEP1   PE=1   SV=3
7
Original
Human
38
17.23
75.6%
MKKKSLGEVL
|O94827|PKHG5_HUMAN   Pleckstrin   homology   domain-­‐containing   family   G   member   5   OS=Homo   sapiens   GN=PLEKHG5   PE=1   SV=3
124
Original
Human
39
17.23
75.6%
RKKLVEAEEL
|O14578|CTRO_HUMAN   Citron   Rho-­‐interacting   kinase   OS=Homo   sapiens   GN=CIT   PE=1   SV=2
0
Original
Human
40
17.22
75.6%
RHKKSHTEEK
|Q03923|ZNF85_HUMAN   Zinc   finger   protein   85   OS=Homo   sapiens   GN=ZNF85   PE=2   SV=3
20
Original
Human
41
17.20
75.5%
IRKLSSGETV
|Q70EL2|UBP45_HUMAN   Ubiquitin   carboxyl-­‐terminal   hydrolase   45   OS=Homo   sapiens   GN=USP45   PE=1   SV=3
7
Original
Human
42
17.20
75.5%
KEKHHHFTEE
|Q6ZWH5|NEK10_HUMAN   Serine/threonine-­‐protein   kinase   Nek10   OS=Homo   sapiens   GN=NEK10   PE=2   SV=3
0
Original
Human
43
17.20
75.5%
KKRRHSFEHV
|Q9NR48|ASH1L_HUMAN   Histone-­‐lysine   N-­‐methyltransferase   ASH1L   OS=Homo   sapiens   GN=ASH1L   PE=1   SV=2
0
Original
Human
44
17.16
75.3%
QKRHDDFEEV
|O60229|KALRN_HUMAN   Kalirin   OS=Homo   sapiens   GN=KALRN   PE=1   SV=2
0
Original
Human
45
17.16
75.3%
QKRHEDFEEV
|O75962|TRIO_HUMAN   Triple   functional   domain   protein   OS=Homo   sapiens   GN=TRIO   PE=1   SV=2
0
Original
Human
46
17.15
75.3%
RKKQAHFEEE
|O95544|NADK_HUMAN   NAD   kinase   OS=Homo   sapiens   GN=NADK   PE=1   SV=1
0
Original
Human
47
17.13
75.2%
HM   Boost   Frame   2
Human
26
Brain   Lesions
23
24.91
74.3%
QAKLSSFEET
|Q5TB80|CE162_HUMAN   Centrosomal   protein   of   162   kDa   OS=Homo   sapiens   GN=KIAA1009   PE=1   SV=2
0
Original
Human
48
17.08
75.0%
KKMLIDGEEV
|Q6PP77|XKR2_HUMAN   XK-­‐related   protein   2   OS=Homo   sapiens   GN=XKRX   PE=2   SV=2
0
Original
Human
49
17.07
74.9%
KKKLVRSEEN
|Q8N157|AHI1_HUMAN   Jouberin   OS=Homo   sapiens   GN=AHI1   PE=1   SV=1
0
Original
Human
50
17.05
74.8%
KKKQVHFFVN
|Q96IY4|CBPB2_HUMAN   Carboxypeptidase   B2   OS=Homo   sapiens   GN=CPB2   PE=1   SV=2
0
HM   Boost   Frame   1
Human
1
Brain   Lesions
1
31.42
85.9%
NVLHSAFEVG
|Q13630|FCL_HUMAN   GDP-­‐L-­‐fucose   synthase   OS=Homo   sapiens   GN=TSTA3   PE=1   SV=1
12,111
HM   Boost   Frame   1
Human
2
Brain   Lesions
2
29.53
80.7%
RKLHSFYEVK
|Q5VST9|OBSCN_HUMAN   Obscurin   OS=Homo   sapiens   GN=OBSCN   PE=1   SV=3
56
Original
Human
16
17.97
78.9%
HM   Boost   Frame   1
Human
3
Brain   Lesions
3
28.40
77.7%
LKLHSRFYEL
|O75838|CIB2_HUMAN   Calcium   and   integrin-­‐binding   family   member   2   OS=Homo   sapiens   GN=CIB2   PE=1   SV=1
55
Original
Human
10
18.18
79.8%
HM   Boost   Frame   1
Human
4
Brain   Lesions
4
28.28
77.3%
QKKHSGFEDE
|P10645|CMGA_HUMAN   Chromogranin-­‐A   OS=Homo   sapiens   GN=CHGA   PE=1   SV=7
9
HM   Boost   Frame   1
Human
5
Brain   Lesions
5
28.22
77.2%
LALHSVFEGL
|Q9NY26|S39A1_HUMAN   Zinc   transporter   ZIP1   OS=Homo   sapiens   GN=SLC39A1   PE=1   SV=1
0
HM   Boost   Frame   1
Human
6
28.22
77.2%
RRLHSPPEVE
|A8MT33|SYC1L_HUMAN   Synaptonemal   complex   central   element   protein   1-­‐like   OS=Homo   sapiens   GN=SYCE1L   PE=2   SV=3
0
HM   Boost   Frame   1
Human
7
Brain   Lesions
6
28.12
76.9%
LSLHRMFEVV
|Q8WXF8|DEDD2_HUMAN   DNA-­‐binding   death   effector   domain-­‐containing   protein   2   OS=Homo   sapiens   GN=DEDD2   PE=1   SV=1
0
Original
Human
32
17.40
76.4%
HM   Boost   Frame   1
Human
8
Brain   Lesions
7
27.99
76.5%
QKLHLHFERL
|Q9BYH1|SE6L1_HUMAN   Seizure   6-­‐like   protein   OS=Homo   sapiens   GN=SEZ6L   PE=1   SV=1
10
Original
Human
22
17.66
77.5%
HM   Boost   Frame   1
Human
9
Brain   Lesions
8
27.89
76.3%
QRLHLHFEKV
|Q53EL9|SEZ6_HUMAN   Seizure   protein   6   homolog   OS=Homo   sapiens   GN=SEZ6   PE=1   SV=2
5
HM   Boost   Frame   1
Human
10
Brain   Lesions
9
27.86
76.2%
LLLHSIFELN
|H7C3K9|H7C3K9_HUMAN   Melanophilin   (Fragment)   OS=Homo   sapiens   GN=MLPH   PE=2   SV=1
0
HM   Boost   Frame   1
Human
11
Brain   Lesions
10
27.72
75.8%
NGLHSHSEVL
|Q9HCH5|SYTL2_HUMAN   Synaptotagmin-­‐like   protein   2   OS=Homo   sapiens   GN=SYTL2   PE=1   SV=3
0
Original
Human
19
17.74
77.9%
HM   Boost   Frame   1
Human
12
Brain   Lesions
11
27.63
75.6%
RRLHLHFERV
|Q6UXD5|SE6L2_HUMAN   Seizure   6-­‐like   protein   2   OS=Homo   sapiens   GN=SEZ6L2   PE=1   SV=2
3
HM   Boost   Frame   1
Human
13
27.59
75.4%
LRLHSPPEVT
|Q9NZ20|PA2G3_HUMAN   Group   3   secretory   phospholipase   A2   OS=Homo   sapiens   GN=PLA2G3   PE=1   SV=2
0
HM   Boost   Frame   1
Human
14
27.55
75.3%
SHLHSLFRVL
|Q8NGR2|OR1L6_HUMAN   Olfactory   receptor   1L6   OS=Homo   sapiens   GN=OR1L6   PE=2   SV=2
0
HM   Boost   Frame   1
Human
15
Brain   Lesions
12
27.27
74.6%
VELHSHSEVP
|Q92551|IP6K1_HUMAN   Inositol   hexakisphosphate   kinase   1   OS=Homo   sapiens   GN=IP6K1   PE=1   SV=3
0
HM   Boost   Frame   1
Human
16
27.25
74.5%
GHLHSQLEVS
|Q6ZTK2|YP015_HUMAN   Putative   uncharacterized   protein   LOC400499   OS=Homo   sapiens   PE=2   SV=1
0
Original
Human
36
17.31
76.0%
HM   Boost   Frame   1
Human
17
27.23
74.5%
EKKVSSFEVF
|Q9UHG0|DCDC2_HUMAN   Doublecortin   domain-­‐containing   protein   2   OS=Homo   sapiens   GN=DCDC2   PE=1   SV=2
0
HM   Boost   Frame   1
Human
18
27.22
74.4%
DGLHSSNEVL
|Q5TDP6|LGSN_HUMAN   Lengsin   OS=Homo   sapiens   GN=LGSN   PE=1   SV=1
0
HM   Boost   Frame   1
Human
19
Brain   Lesions
13
27.19
74.4%
LSLHSLFELR
|Q6U841|S4A10_HUMAN   Sodium-­‐driven   chloride   bicarbonate   exchanger   OS=Homo   sapiens   GN=SLC4A10   PE=2   SV=1
0
HM   Boost   Frame   1
Human
20
Brain   Lesions
14
27.17
74.3%
FTPHSRFEVL
|Q9P2E5|CHPF2_HUMAN   Chondroitin   sulfate   glucuronyltransferase   OS=Homo   sapiens   GN=CHPF2   PE=2   SV=2
0
HM   Boost   Frame   1
Human
21
Brain   Lesions
15
27.15
74.2%
IKLPSSFEKW
|Q0P6D6|CCD15_HUMAN   Coiled-­‐coil   domain-­‐containing   protein   15   OS=Homo   sapiens   GN=CCDC15   PE=2   SV=2
54
HM   Boost   Frame   1
Human
22
Brain   Lesions
16
27.08
74.0%
VMLLSLFEEE
|Q9P2P5|HECW2_HUMAN   E3   ubiquitin-­‐protein   ligase   HECW2   OS=Homo   sapiens   GN=HECW2   PE=1   SV=2
0
HM   Boost   Frame   1
Human
23
Brain   Lesions
17
27.07
74.0%
FALHSLFEAK
|Q96PN7|TREF1_HUMAN   Transcriptional-­‐regulating   factor   1   OS=Homo   sapiens   GN=TRERF1   PE=1   SV=1
0
Original
Human
33
17.37
76.3%
HM   Boost   Frame   1
Human
24
Brain   Lesions
18
27.05
74.0%
RKLKASFEVS
|Q8TDX9|PK1L1_HUMAN   Polycystic   kidney   disease   protein   1-­‐like   1   OS=Homo   sapiens   GN=PKD1L1   PE=1   SV=1
338
HM   Boost   Frame   1
Human
25
Brain   Lesions
19
27.04
73.9%
KALHSDFIVK
|P52333|JAK3_HUMAN   Tyrosine-­‐protein   kinase   JAK3   OS=Homo   sapiens   GN=JAK3   PE=1   SV=2
0
HM   Boost   Frame   1
Human
26
Brain   Lesions
20
27.01
73.9%
KKLRSSFESS
|Q5JTJ3|COA6_HUMAN   Cytochrome   c   oxidase   assembly   factor   6   homolog   OS=Homo   sapiens   GN=COA6   PE=1   SV=1
23
HM   Boost   Frame   1
Human
27
27.00
73.8%
LQLHSPFERG
|Q8TDY3|ACTT2_HUMAN   Actin-­‐related   protein   T2   OS=Homo   sapiens   GN=ACTRT2   PE=2   SV=2
0
HM   Boost   Frame   1
Human
28
Brain   Lesions
21
26.98
73.8%
RKCHSSGEVQ
|Q8N5D0|WDTC1_HUMAN   WD   and   tetratricopeptide   repeats   protein   1   OS=Homo   sapiens   GN=WDTC1   PE=1   SV=2
4
Original
Human
37
17.24
75.7%
HM   Boost   Frame   1
Human
29
Brain   Lesions
22
26.98
73.8%
RKLLSDFPVV
|Q4LDE5|SVEP1_HUMAN   Sushi,   von   Willebrand   factor   type   A,   EGF   and   pentraxin   domain-­‐containing   protein   1   OS=Homo   sapiens   GN=SVEP1   PE=1   SV=3
7
HM   Boost   Frame   1
Human
30
Brain   Lesions
23
26.95
73.7%
KKRHSYFEKP
|Q13123|RED_HUMAN   Protein   Red   OS=Homo   sapiens   GN=IK   PE=1   SV=3
11
HM   Boost   Frame   1
Human
31
26.94
73.7%
VHLHSFFAVG
|Q86VW1|S22AG_HUMAN   Solute   carrier   family   22   member   16   OS=Homo   sapiens   GN=SLC22A16   PE=1   SV=1
0
HM   Boost   Frame   1
Human
32
Brain   Lesions
24
26.89
73.5%
EALLSGFEVI
|O60503|ADCY9_HUMAN   Adenylate   cyclase   type   9   OS=Homo   sapiens   GN=ADCY9   PE=1   SV=4
0
HM   Boost   Frame   1
Human
33
Brain   Lesions
25
26.80
73.3%
EKLFSQFEVD
|Q9NXB0|MKS1_HUMAN   Meckel   syndrome   type   1   protein   OS=Homo   sapiens   GN=MKS1   PE=1   SV=2
0
HM   Boost   Frame   1
Human
34
Brain   Lesions
26
26.75
73.1%
GDLKSGFEEV
|Q1XH10|SKDA1_HUMAN   SKI/DACH   domain-­‐containing   protein   1   OS=Homo   sapiens   GN=SKIDA1   PE=2   SV=1
0
HM   Boost   Frame   1
Human
35
Brain   Lesions
27
26.69
73.0%
KGLHSKKEVP
|Q7KZF4|SND1_HUMAN   Staphylococcal   nuclease   domain-­‐containing   protein   1   OS=Homo   sapiens   GN=SND1   PE=1   SV=1
0
HM   Boost   Frame   1
Human
36
Brain   Lesions
28
26.61
72.8%
EFLASSFEVS
|Q15269|PWP2_HUMAN   Periodic   tryptophan   protein   2   homolog   OS=Homo   sapiens   GN=PWP2   PE=1   SV=2
0
HM   Boost   Frame   1
Human
37
Brain   Lesions
29
26.57
72.7%
GVLHSKFWVV
|Q96BZ4|PLD4_HUMAN   Phospholipase   D4   OS=Homo   sapiens   GN=PLD4   PE=2   SV=2
0
HM   Boost   Frame   1
Human
38
26.51
72.5%
KQLVHHFEVD
|F8WAS2|F8WAS2_HUMAN   Inter-­‐alpha-­‐trypsin   inhibitor   heavy   chain   H1   OS=Homo   sapiens   GN=ITIH1   PE=2   SV=1
0
HM   Boost   Frame   1
Human
39
26.50
72.5%
RHLHSVLEEL
|A1L168|CT202_HUMAN   Uncharacterized   protein   C20orf202   OS=Homo   sapiens   GN=C20orf202   PE=2   SV=2
0
HM   Boost   Frame   1
Human
40
Brain   Lesions
30
26.45
72.3%
RLLSSGFEEV
|O60518|RNBP6_HUMAN   Ran-­‐binding   protein   6   OS=Homo   sapiens   GN=RANBP6   PE=1   SV=2
24
HM   Boost   Frame   1
Human
41
Brain   Lesions
31
26.45
72.3%
QMLHPIFEEA
|Q9BS26|ERP44_HUMAN   Endoplasmic   reticulum   resident   protein   44   OS=Homo   sapiens   GN=ERP44   PE=1   SV=1
0
HM   Boost   Frame   1
Human
42
Brain   Lesions
32
26.42
72.2%
RRLHSTHEEL
|Q03001|DYST_HUMAN   Dystonin   OS=Homo   sapiens   GN=DST   PE=1   SV=4
7
HM   Boost   Frame   1
Human
43
Brain   Lesions
33
26.40
72.2%
RKLHWLFELL
|Q14997|PSME4_HUMAN   Proteasome   activator   complex   subunit   4   OS=Homo   sapiens   GN=PSME4   PE=1   SV=2
116
HM   Boost   Frame   1
Human
44
Brain   Lesions
34
26.40
72.2%
VELHSDMEVT
|P04275|VWF_HUMAN   von   Willebrand   factor   OS=Homo   sapiens   GN=VWF   PE=1   SV=4
0
Original
Human
5
18.89
82.9%
HM   Boost   Frame   1
Human
45
26.35
72.1%
RKLLHRFETE
|O15327|INP4B_HUMAN   Type   II   inositol   3,4-­‐bisphosphate   4-­‐phosphatase   OS=Homo   sapiens   GN=INPP4B   PE=2   SV=4
14
HM   Boost   Frame   1
Human
46
26.31
71.9%
NKLISEFEEE
|Q8NE09|RGS22_HUMAN   Regulator   of   G-­‐protein   signaling   22   OS=Homo   sapiens   GN=RGS22   PE=1   SV=3
357
HM   Boost   Frame   1
Human
47
Brain   Lesions
35
26.30
71.9%
SKLVSNKEVV
|Q15751|HERC1_HUMAN   Probable   E3   ubiquitin-­‐protein   ligase   HERC1   OS=Homo   sapiens   GN=HERC1   PE=1   SV=2
171
 HM   Boost   Frame   1
Human
48
Brain   Lesions
36
26.29
71.9%
LLLHSLFPVP
|Q9UJ68|MSRA_HUMAN   Mitochondrial   peptide   methionine   sulfoxide   reductase   OS=Homo   sapiens   GN=MSRA   PE=1   SV=1
0
HM   Boost   Frame   1
Human
49
Brain   Lesions
37
26.28
71.9%
RKLDSVFEER
|P14780|MMP9_HUMAN   Matrix   metalloproteinase-­‐9   OS=Homo   sapiens   GN=MMP9   PE=1   SV=3
0
HM   Boost   Frame   1
Human
50
Brain   Lesions
38
26.25
71.8%
RFKHSSTEVL
|A7KAX9|RHG32_HUMAN   Rho   GTPase-­‐activating   protein   32   OS=Homo   sapiens   GN=ARHGAP32   PE=1   SV=1   EXP=0.271770
0
Brain   Lesions
39
26.25
71.8%
QSVHHGFEVV
|O15198|SMAD9_HUMAN   Mothers   against   decapentaplegic   homolog   9   OS=Homo   sapiens   GN=SMAD9   PE=1   SV=1
0
Brain   Lesions
40
26.23
71.7%
HLLNSGFEVP
|A7KAX9|RHG32_HUMAN   Rho   GTPase-­‐activating   protein   32   OS=Homo   sapiens   GN=ARHGAP32   PE=1   SV=1   EXP=0.271770
0
HM   Boost   Frame   2
Human
1
Brain   Lesions
1
28.47
84.9%
RRKLHSFYEV
|Q5VST9|OBSCN_HUMAN   Obscurin   OS=Homo   sapiens   GN=OBSCN   PE=1   SV=3
13
Original
Human
24
17.56
77.1%
HM   Boost   Frame   2
Human
2
Brain   Lesions
2
27.46
81.9%
RKLLSSGFEI
|Q8N8A2|ANR44_HUMAN   Serine/threonine-­‐protein   phosphatase   6   regulatory   ankyrin   repeat   subunit   B   OS=Homo   sapiens   GN=ANKRD44   PE=1   SV=3
5
Original
Human
20
17.72
77.8%
HM   Boost   Frame   2
Human
3
Brain   Lesions
3
27.26
81.3%
RRLLSSGFEE
|O60518|RNBP6_HUMAN   Ran-­‐binding   protein   6   OS=Homo   sapiens   GN=RANBP6   PE=1   SV=2
3
Original
Human
1
19.79
86.9%
HM   Boost   Frame   2
Human
4
Brain   Lesions
4
27.14
81.0%
RKKLHKFEET
|Q96PE3|INP4A_HUMAN   Type   I   inositol   3,4-­‐bisphosphate   4-­‐phosphatase   OS=Homo   sapiens   GN=INPP4A   PE=1   SV=1
3
Original
Human
2
19.27
84.6%
HM   Boost   Frame   2
Human
5
Brain   Lesions
5
26.96
80.4%
LKKLHDFEEQ
|Q9BX84|TRPM6_HUMAN   Transient   receptor   potential   cation   channel   subfamily   M   member   6   OS=Homo   sapiens   GN=TRPM6   PE=1   SV=2
9
HM   Boost   Frame   2
Human
6
Brain   Lesions
6
26.91
80.3%
GLLLHSIFEL
|H7C3K9|H7C3K9_HUMAN   Melanophilin   (Fragment)   OS=Homo   sapiens   GN=MLPH   PE=2   SV=1
0
Original
Human
3
19.21
84.3%
HM   Boost   Frame   2
Human
7
Brain   Lesions
7
26.90
80.3%
QKKLHDFEEQ
|Q96QT4|TRPM7_HUMAN   Transient   receptor   potential   cation   channel   subfamily   M   member   7   OS=Homo   sapiens   GN=TRPM7   PE=1   SV=1
9
Original
Human
4
18.99
83.4%
HM   Boost   Frame   2
Human
8
Brain   Lesions
8
26.90
80.3%
QKKLSSGEEK
|Q15858|SCN9A_HUMAN   Sodium   channel   protein   type   9   subunit   alpha   OS=Homo   sapiens   GN=SCN9A   PE=1   SV=3
4
HM   Boost   Frame   2
Human
9
Brain   Lesions
9
26.85
80.1%
RKHLHSGQEA
|Q5JTD0|TJAP1_HUMAN   Tight   junction-­‐associated   protein   1   OS=Homo   sapiens   GN=TJAP1   PE=1   SV=1
0
HM   Boost   Frame   2
Human
10
Brain   Lesions
10
26.60
79.4%
QKLVHSLFES
|O15067|PUR4_HUMAN   Phosphoribosylformylglycinamidine   synthase   OS=Homo   sapiens   GN=PFAS   PE=1   SV=4
0
HM   Boost   Frame   2
Human
11
Brain   Lesions
11
26.51
79.1%
CYLLHSFEEF
|Q4LDE5|SVEP1_HUMAN   Sushi,   von   Willebrand   factor   type   A,   EGF   and   pentraxin   domain-­‐containing   protein   1   OS=Homo   sapiens   GN=SVEP1   PE=1   SV=3
0
HM   Boost   Frame   2
Human
12
Brain   Lesions
12
25.89
77.2%
SKTLHSVEEK
|Q8TBZ0|CC110_HUMAN   Coiled-­‐coil   domain-­‐containing   protein   110   OS=Homo   sapiens   GN=CCDC110   PE=2   SV=1
0
Original
Human
15
18.00
79.0%
HM   Boost   Frame   2
Human
13
Brain   Lesions
13
25.87
77.2%
LKRLHEFEEQ
|Q7Z4N2|TRPM1_HUMAN   Transient   receptor   potential   cation   channel   subfamily   M   member   1   OS=Homo   sapiens   GN=TRPM1   PE=1   SV=2
6
HM   Boost   Frame   2
Human
14
Brain   Lesions
14
25.86
77.1%
VKELHSAEEG
|O60941|DTNB_HUMAN   Dystrobrevin   beta   OS=Homo   sapiens   GN=DTNB   PE=1   SV=1
0
HM   Boost   Frame   2
Human
15
Brain   Lesions
15
25.59
76.3%
SLLLHSQEEK
|Q8IWZ3|ANKH1_HUMAN   Ankyrin   repeat   and   KH   domain-­‐containing   protein   1   OS=Homo   sapiens   GN=ANKHD1   PE=1   SV=1
0
HM   Boost   Frame   2
Human
16
Brain   Lesions
16
25.55
76.2%
AVHLHSGEEL
|Q92519|TRIB2_HUMAN   Tribbles   homolog   2   OS=Homo   sapiens   GN=TRIB2   PE=2   SV=1
0
HM   Boost   Frame   2
Human
17
Brain   Lesions
17
25.55
76.2%
HTRLHSGEEP
|Q6IV72|ZN425_HUMAN   Zinc   finger   protein   425   OS=Homo   sapiens   GN=ZNF425   PE=2   SV=1
0
HM   Boost   Frame   2
Human
18
Brain   Lesions
18
25.51
76.1%
MPLLHAIFEV
|O43592|XPOT_HUMAN   Exportin-­‐T   OS=Homo   sapiens   GN=XPOT   PE=1   SV=2
1
HM   Boost   Frame   2
Human
19
Brain   Lesions
19
25.38
75.7%
EKKRHSYFEK
|Q13123|RED_HUMAN   Protein   Red   OS=Homo   sapiens   GN=IK   PE=1   SV=3
0
HM   Boost   Frame   2
Human
20
25.32
75.5%
QAKLHSQEED
|Q4V328|GRAP1_HUMAN   GRIP1-­‐associated   protein   1   OS=Homo   sapiens   GN=GRIPAP1   PE=1   SV=1
0
HM   Boost   Frame   2
Human
21
Brain   Lesions
20
25.27
75.4%
QQKKHSGFED
|P10645|CMGA_HUMAN   Chromogranin-­‐A   OS=Homo   sapiens   GN=CHGA   PE=1   SV=7
2
HM   Boost   Frame   2
Human
22
Brain   Lesions
21
25.12
74.9%
LKKLHQQFEM
|Q9UQ26-­‐8|RIMS2_HUMAN   Isoform   8   of   Regulating   synaptic   membrane   exocytosis   protein   2   OS=Homo   sapiens   GN=RIMS2
0
HM   Boost   Frame   2
Human
23
25.05
74.7%
KLLLHSGVEN
|Q8N1W0|YF005_HUMAN   Transmembrane   protein   FLJ37396   OS=Homo   sapiens   PE=2   SV=2
2,779
HM   Boost   Frame   2
Human
24
Brain   Lesions
22
25.04
74.7%
DNVLHSAFEV
|Q13630|FCL_HUMAN   GDP-­‐L-­‐fucose   synthase   OS=Homo   sapiens   GN=TSTA3   PE=1   SV=1
7,817
Original
Human
34
17.35
76.2%
HM   Boost   Frame   2
Human
25
25.03
74.7%
FSKLHTFEEV
|Q96JB1|DYH8_HUMAN   Dynein   heavy   chain   8,   axonemal   OS=Homo   sapiens   GN=DNAH8   PE=1   SV=2
0
Original
Human
47
17.13
75.2%
HM   Boost   Frame   2
Human
26
Brain   Lesions
23
24.91
74.3%
QAKLSSFEET
|Q5TB80|CE162_HUMAN   Centrosomal   protein   of   162   kDa   OS=Homo   sapiens   GN=KIAA1009   PE=1   SV=2
0
HM   Boost   Frame   2
Human
27
Brain   Lesions
24
24.82
74.0%
SLALHSVFEG
|Q9NY26|S39A1_HUMAN   Zinc   transporter   ZIP1   OS=Homo   sapiens   GN=SLC39A1   PE=1   SV=1
0
HM   Boost   Frame   2
Human
28
Brain   Lesions
25
24.82
74.0%
EFALHSLFEA
|Q96PN7|TREF1_HUMAN   Transcriptional-­‐regulating   factor   1   OS=Homo   sapiens   GN=TRERF1   PE=1   SV=1
0
HM   Boost   Frame   2
Human
29
Brain   Lesions
26
24.75
73.8%
MRHLKSFFEA
|Q7Z7H5|TMED4_HUMAN   Transmembrane   emp24   domain-­‐containing   protein   4   OS=Homo   sapiens   GN=TMED4   PE=1   SV=1
0
HM   Boost   Frame   2
Human
30
Brain   Lesions
27
24.74
73.8%
QKKRHSFLES
|Q49MG5|MAP9_HUMAN   Microtubule-­‐associated   protein   9   OS=Homo   sapiens   GN=MAP9   PE=1   SV=3
0
Original
Human
26
17.53
77.0%
HM   Boost   Frame   2
Human
31
Brain   Lesions
28
24.72
73.7%
QKKLHHFFIG
|Q8IWB1|IPRI_HUMAN   Inositol   1,4,5-­‐trisphosphate   receptor-­‐interacting   protein   OS=Homo   sapiens   GN=ITPRIP   PE=1   SV=1
0
HM   Boost   Frame   2
Human
32
Brain   Lesions
29
24.72
73.7%
TLSLHSLFEL
|Q6U841|S4A10_HUMAN   Sodium-­‐driven   chloride   bicarbonate   exchanger   OS=Homo   sapiens   GN=SLC4A10   PE=2   SV=1
0
HM   Boost   Frame   2
Human
33
Brain   Lesions
30
24.69
73.7%
LRLFHSFEEL
|Q9UIY3|RWD2A_HUMAN   RWD   domain-­‐containing   protein   2A   OS=Homo   sapiens   GN=RWDD2A   PE=1   SV=1
0
HM   Boost   Frame   2
Human
34
24.67
73.6%
QKFLHSSFVA
|Q9UIV8|SPB13_HUMAN   Serpin   B13   OS=Homo   sapiens   GN=SERPINB13   PE=1   SV=2
0
HM   Boost   Frame   2
Human
35
Brain   Lesions
31
24.66
73.6%
AWLLHSGPEG
|O43299|AP5Z1_HUMAN   AP-­‐5   complex   subunit   zeta-­‐1   OS=Homo   sapiens   GN=AP5Z1   PE=1   SV=2
0
HM   Boost   Frame   2
Human
36
24.57
73.3%
TKLLHRTEEL
|Q68CJ6|SLIP_HUMAN   Nuclear   GTPase   SLIP-­‐GC   OS=Homo   sapiens   GN=NUGGC   PE=2   SV=3
0
HM   Boost   Frame   2
Human
37
Brain   Lesions
32
24.56
73.3%
FKTLSSKFEL
|Q8WWM7|ATX2L_HUMAN   Ataxin-­‐2-­‐like   protein   OS=Homo   sapiens   GN=ATXN2L   PE=1   SV=2
0
HM   Boost   Frame   2
Human
38
Brain   Lesions
33
24.50
73.1%
KRRLHLVFEY
|Q00532|CDKL1_HUMAN   Cyclin-­‐dependent   kinase-­‐like   1   OS=Homo   sapiens   GN=CDKL1   PE=1   SV=5
0
HM   Boost   Frame   2
Human
39
Brain   Lesions
34
24.47
73.0%
EHLLNSGFEV
|A7KAX9|RHG32_HUMAN   Rho   GTPase-­‐activating   protein   32   OS=Homo   sapiens   GN=ARHGAP32   PE=1   SV=1
0
HM   Boost   Frame   2
Human
40
24.42
72.9%
VMKLLSIFES
|Q3B7T1|EDRF1_HUMAN   Erythroid   differentiation-­‐related   factor   1   OS=Homo   sapiens   GN=EDRF1   PE=1   SV=1
0
HM   Boost   Frame   2
Human
41
Brain   Lesions
35
24.41
72.8%
KLELHSSEEA
|Q6TFL3|CC171_HUMAN   Coiled-­‐coil   domain-­‐containing   protein   171   OS=Homo   sapiens   GN=CCDC171   PE=2   SV=1
0
HM   Boost   Frame   2
Human
42
24.41
72.8%
KLPLHSSEEA
|P57721|PCBP3_HUMAN   Poly(rC)-­‐binding   protein   3   OS=Homo   sapiens   GN=PCBP3   PE=2   SV=2
0
HM   Boost   Frame   2
Human
43
Brain   Lesions
36
24.37
72.7%
LKRLLSNEEE
|O14976|GAK_HUMAN   Cyclin-­‐G-­‐associated   kinase   OS=Homo   sapiens   GN=GAK   PE=1   SV=2
0
HM   Boost   Frame   2
Human
44
24.24
72.3%
TTRLHSLEEK
|Q7Z3Z0|K1C25_HUMAN   Keratin,   type   I   cytoskeletal   25   OS=Homo   sapiens   GN=KRT25   PE=1   SV=1
0
HM   Boost   Frame   2
Human
45
Brain   Lesions
37
24.20
72.2%
HARLHSLEET
|Q5T160|SYRM_HUMAN   Probable   arginine-­‐-­‐tRNA   ligase,   mitochondrial   OS=Homo   sapiens   GN=RARS2   PE=1   SV=1
0
HM   Boost   Frame   2
Human
46
Brain   Lesions
38
24.20
72.2%
LPRLHGHFEQ
|Q9UPU7|TBD2B_HUMAN   TBC1   domain   family   member   2B   OS=Homo   sapiens   GN=TBC1D2B   PE=1   SV=2
0
HM   Boost   Frame   2
Human
47
Brain   Lesions
39
24.18
72.1%
VKTLHHKEEV
|Q6ZMW2|ZN782_HUMAN   Zinc   finger   protein   782   OS=Homo   sapiens   GN=ZNF782   PE=2   SV=1
0
HM   Boost   Frame   2
Human
48
Brain   Lesions
40
24.17
72.1%
SPSLHSREEA
|B7Z7H5|B7Z7H5_HUMAN   Coiled-­‐coil   domain-­‐containing   protein   116   OS=Homo   sapiens   GN=CCDC116   PE=2   SV=1
0
HM   Boost   Frame   2
Human
49
Brain   Lesions
41
24.16
72.1%
PRKLHWLFEL
|Q14997|PSME4_HUMAN   Proteasome   activator   complex   subunit   4   OS=Homo   sapiens   GN=PSME4   PE=1   SV=2
0
HM   Boost   Frame   2
Human
50
24.14
72.0%
LKKLLSFAEN
|Q5W041|ARMC3_HUMAN   Armadillo   repeat-­‐containing   protein   3   OS=Homo   sapiens   GN=ARMC3   PE=2   SV=2
0
 Table S2. GDP-L-fucose synthase, Myelin and CEF Peptides
GDP-L-fucose synthase
GDP-L-fucose synthase 1-15
MGEPQGSMRILVTGG 
GDP-L-fucose synthase 6-20
GSMRILVTGGSGLVG
GDP-L-fucose synthase 11-25
LVTGGSGLVGKAIQK
GDP-L-fucose synthase 16-30
SGLVGKAIQKVVADG
GDP-L-fucose synthase 21-35
KAIQKVVADGAGLPG
GDP-L-fucose synthase 26-40
VVADGAGLPGEDWVF
GDP-L-fucose synthase 31-45
AGLPGEDWVFVSSKD
GDP-L-fucose synthase 36-50
EDWVFVSSKDADLTD
GDP-L-fucose synthase 41-55
VSSKDADLTDTAQTR
GDP-L-fucose synthase 46-60
ADLTDTAQTRALFEK
GDP-L-fucose synthase 51-65
TAQTRALFEKVQPTH
GDP-L-fucose synthase 56-70
ALFEKVQPTHVIHLA
GDP-L-fucose synthase 61-75
VQPTHVIHLAAMVGG
GDP-L-fucose synthase 66-80
VIHLAAMVGGLFRNI
GDP-L-fucose synthase 71-85
AMVGGLFRNIKYNLD
GDP-L-fucose synthase 76-90
LFRNIKYNLDFWRKN
GDP-L-fucose synthase 81-95
KYNLDFWRKNVHMND
GDP-L-fucose synthase 86-100
FWRKNVHMNDNVLHS
GDP-L-fucose synthase 91-105
VHMNDNVLHSAFEVG
GDP-L-fucose synthase 96-110
NVLHSAFEVGARKVV
GDP-L-fucose synthase 101-115
AFEVGARKVVSCLST
GDP-L-fucose synthase 106-120
ARKVVSCLSTCIFPD
GDP-L-fucose synthase 111-125
SCLSTCIFPDKTTYP
GDP-L-fucose synthase 116-130
CIFPDKTTYPIDETM
GDP-L-fucose synthase 121-135
KTTYPIDETMIHNGP
GDP-L-fucose synthase 126-140
IDETMIHNGPPHNSN
GDP-L-fucose synthase 131-145
IHNGPPHNSNFGYSY
GDP-L-fucose synthase 136-150
PHNSNFGYSYAKRMI
GDP-L-fucose synthase 141-155
FGYSYAKRMIDVQNR
GDP-L-fucose synthase 146-160
AKRMIDVQNRAYFQQ
GDP-L-fucose synthase 151-165
DVQNRAYFQQYGCTF
GDP-L-fucose synthase 156-170
AYFQQYGCTFTAVIP
GDP-L-fucose synthase 161-175
YGCTFTAVIPTNVFG
GDP-L-fucose synthase 166-180
TAVIPTNVFGPHDNF
GDP-L-fucose synthase 171-185
TNVFGPHDNFNIEDG
GDP-L-fucose synthase 176-190
PHDNFNIEDGHVLPG
GDP-L-fucose synthase 181-195
NIEDGHVLPGLIHKV
GDP-L-fucose synthase 186-200
HVLPGLIHKVHLAKS
GDP-L-fucose synthase 191-205
LIHKVHLAKSSGSAL
GDP-L-fucose synthase 196-210
HLAKSSGSALTVWGT
GDP-L-fucose synthase 201-215
SGSALTVWGTGNPRR
GDP-L-fucose synthase 206-220
TVWGTGNPRRQFIYS
GDP-L-fucose synthase 211-225
GNPRRQFIYSLDLAQ
GDP-L-fucose synthase 216-230
QFIYSLDLAQLFIWV
GDP-L-fucose synthase 221-235
LDLAQLFIWVLREYN
GDP-L-fucose synthase 226-240
LFIWVLREYNEVEPI
GDP-L-fucose synthase 231-245
LREYNEVEPIILSVG
GDP-L-fucose synthase 236-250
EVEPIILSVGEEDEV
GDP-L-fucose synthase 241-255
ILSVGEEDEVSIKEA
GDP-L-fucose synthase 246-260
EEDEVSIKEAAEAVV
GDP-L-fucose synthase 251-265
SIKEAAEAVVEAMDF
GDP-L-fucose synthase 256-270
AEAVVEAMDFHGEVT
GDP-L-fucose synthase 261-275
EAMDFHGEVTFDTTK
 GDP-L-fucose synthase 266-280
HGEVTFDTTKSDGQF
GDP-L-fucose synthase 271-285
FDTTKSDGQFKKTAS
GDP-L-fucose synthase 276-290
SDGQFKKTASNSKLR
GDP-L-fucose synthase 281-295
KKTASNSKLRTYLPD
GDP-L-fucose synthase 286-300
NSKLRTYLPDFRFTP
GDP-L-fucose synthase 291-305
TYLPDFRFTPFKQAV
GDP-L-fucose synthase 296-310
FRFTPFKQAVKETCA
GDP-L-fucose synthase 301-315
FKQAVKETCAWFTDN
GDP-L-fucose synthase 306-321
KETCAWFTDNYEQARK
Myelin
MOG 1-20
GQFRVIGPRHPIRALVGDEV
MOG 35-55
MEVGWYRPPFSRVVHLYRNGK
MBP 13-32
KYLATASTMDHARHGFLPRH
MBP 83-99
ENPVVHFFKNIVTPRT
MBP 111-129
LSRFSWGAEGQRPGFGYGG
MBP 146-170
AQGTLSKIFKLGGRDSRSGSPMARR
PLP 139-154
HCLGKWLGHPDKFVGI
CEFT2 Mix (CEF)
Influenza A
FVFTLTVPSER
Influenza A
SGPLKAEIAQRLEDV
Influenza A
YDVPDYASLRSLVASS
Influenza B
PYYTGEHAKAIGN
Tetanus
GQIGNDPNRDIL
Influenza A
PKYVKQNTLKLA
Influenza A
PKYVKQNTLKLAT
Influenza A
DRLRRDQKS
EBV
AGLTLSLLVICSYLFISRG
Tetanus
QYIKANSKFIGITEL
Tetanus
QYIKANSKFIGITE
Tetanus
FNNFTVSFWLRVPKVSASHLE
EBV
TSLYNLRRGTALA
Tetanus
KFIIKRYTPNNEIDSF
Tetanus
VSIDKFRIFCKALNPK
EBV
VPGLYSPCRAFFNKEELL
HCMV
DKREMWMACIKELH
EBV
TGHGARTSTEPTTDY
EBV
KELKRQYEKKLRQ
Influenza A
RGYFKMRTGKSSIMRS
EBV
TVFYNIPPMPL
EBV
AEGLRALLARSHVER
EBV
PGPLRESIVCYFMVFLQTHI
 Table S3.  Peptides from brain proteins identified by proteomic analysis in brain tissue.
Protein
UniProt
Peptide Sequence
Residues
MS WM
MS GM
HD WM
HD GM
Myelin basic protein
P02686
ASTNSETNRGESEK
15 - 28
14
14
-
14
NLGELSR
31 - 37
-
3
-
-
NAWQDAHPADPGSRPHLIR
75 - 93
-
2
-
2
DAPGREDNTFK
98 - 108
4
4
-
4
DRPSESDELQTIQEDSAATSESLDVMASQK
109 - 138
-
6
-
6
HGSKYLATASTMDHAR
144 - 159
18
18
18
-
    YLATASTMDHAR
148 - 159
35
35
35
35
    YLATASTMDHARHGFLPR
148 - 165
46
46
46
46
    YLATASTMDHARHGFLPRHR
148 - 167
11
11
11
11
    YLATASTMDHARHGFLPRHRDTGILDSIGR
148 - 177
9
-
9
-
                HGFLPR
160 - 165
12
12
12
12
                HGFLPRHR
160 - 167
13
13
13
13
                HGFLPRHRDTGILDSIGR
160 - 177
16
-
16
16
                HGFLPRHRDTGILDSIGRFFGGDR
160 - 187
-
-
1
-
                HGFLPRHRDTGILDSIGRFFGGDRGAPK
160 - 191
4
-
4
-
                      HRDTGILDSIGR
166 - 177
29
29
29
29
                      HRDTGILDSIGRFFGGDR
166 - 187
20
20
20
20
                      HRDTGILDSIGRFFGGDRGAPK
166 - 191
25
25
25
25
                      HRDTGILDSIGRFFGGDRGAPKR
166 - 192
-
-
2
-
                        DTGILDSIGR
168 - 177
14
14
14
14
                        DTGILDSIGRFFGGDR
168 - 183
21
21
21
21
                        DTGILDSIGRFFGGDRGAPK
168 - 187
21
21
21
21
                        DTGILDSIGRFFGGDRGAPKR
168 - 188
2
-
2
-
                        DTGILDSIGRFFGGDRGAPKRGSGK
168 - 192
2
-
2
-
                                  FFGGDR
178 - 183
8
8
8
8
                                  FFGGDRGAPK
178 - 187
24
24
24
24
                                  FFGGDRGAPKR
178 - 188
5
-
5
-
                                  FFGGDRGAPKRGSGK
178 - 192
2
-
2
-
                                  FFGGDRGAPKRGSGKDSHHPAR
178 - 199
-
-
2
-
                                            RGSGKDSHHPAR
188 - 199
2
-
-
-
                                            RGSGKDSHHPARTAHYGSLPQK
188 - 209
9
9
9
9
                                             GSGKDSHHPARTAHYGSLPQK
189 - 209
2
-
2
-
                                                 DSHHPARTAHYGSLPQK
193 - 209
28
28
28
28
                                                 DSHHPARTAHYGSLPQKSHGR
193 - 213
3
-
3
-
                                                 DSHHPARTAHYGSLPQKSHGRTQDENPVVHFFK
193 - 225
1
-
-
-
                                                        TAHYGSLPQK
200 - 209
21
21
21
21
                                                        TAHYGSLPQKSHGR
200 - 213
21
21
21
21
                                                        TAHYGSLPQKSHGRTQDENPVVHFFK
200 - 225
11
-
11
11
                                                                  SHGRTQDENPVVHFFK
210 - 225
37
37
37
37
                                                                  SHGRTQDENPVVHFFKNIVTPR
210 - 231
4
-
4
-
                                                                  SHGRTQDENPVVHFFKNIVTPRTPPPSQGK
210 - 239
-
-
1
-
                                                                      TQDENPVVHFFK
214 - 225
34
34
34
34
                                                                      TQDENPVVHFFKNIVTPR
214 - 231
27
27
27
27
                                                                      TQDENPVVHFFKNIVTPRTPPPSQGK
214 - 239
9
9
9
9
                                                                                  NIVTPR
226 - 231
10
10
10
10
                                                                                  NIVTPRTPPPSQGK
226 - 239
62
62
62
62
                                                                                  NIVTPRTPPPSQGKGRGLSLSR
226 - 247
-
-
1
-
                                                                                        TPPPSQGK
232 - 239
3
-
-
-
                                                                                        TPPPSQGKGR
232 - 241
-
-
3
-
                                                                                        TPPPSQGKGRGLSLSR
232 - 247
-
-
1
-
                                                                                                GRGLSLSR
240 - 247
12
12
12
-
                                                                                                GRGLSLSRFSWGAEGQRPGFGYGGR
240 - 264
13
13
13
-
                                                                                                GRGLSLSRFSWGAEGQRPGFGYGGRASDYK
240 - 269
10
-
10
-
                                                                                                  GLSLSRFSWGAEGQRPGFGYGGR
242 -264
14
14
14
14
                                                                                                  GLSLSRFSWGAEGQRPGFGYGGRASDYK
242 - 269
6
6
6
-
                                                                                                        FSWGAEGQRPGFGYGGR
248 - 264
35
35
35
35
                                                                                                        FSWGAEGQRPGFGYGGRASDYK
248 - 269
35
35
35
35
                                                                                                        FSWGAEGQRPGFGYGGRASDYKSAHK
248 - 273
7
-
7
-
                                                                                                                         ASDYKSAHKGFK
265 - 276
3
-
3
-
                                                                                                                         ASDYKSAHKGFKGVDAQGTLSK
265 - 286
2
-
2
-
                                                                                                                              SAHKGFKGVDAQGTLSK
270 - 286
6
-
6
-
                                                                                                                              SAHKGFKGVDAQGTLSKIFK
270 - 289
-
-
1
-
                                                                                                                                  GFKGVDAQGTLSK
274 - 286
18
18
18
18
                                                                                                                                  GFKGVDAQGTLSKIFK
274 - 289
-
-
2
-
                                                                                                                                  GFKGVDAQGTLSKIFKLGGRDSR
274 - 296
-
-
1
-
                                                                                                                                     GVDAQGTLSK
277 - 286
24
24
24
24
                                                                                                                                     GVDAQGTLSKIFK
277 - 289
9
-
9
9
                                                                                                                                     GVDAQGTLSKIFKLGGR
277 - 293
-
-
1
-
                                                                                                                                     GVDAQGTLSKIFKLGGRDSR
277 - 296
3
-
3
-
                                                                                                                                                IFKLGGR
287 - 293 
5
-
5
-
                                                                                                                                               IFKLGGRDSR
287 - 296
4
-
4
-
                                                                                                                                               IFKLGGRDSRSGSPMAR
287 - 303
3
-
3
-
                                                                                                                                               IFKLGGRDSRSGSPMARR
287 - 304
3
-
3
-
                                                                                                                                                  LGGRDSR
292 - 296
2
-
2
-
                                                                                                                                                  LGGRDSRSGSPMAR
292 - 303
45
45
45
45
                                                                                                                                                  LGGRDSRSGSPMARR
292 - 304
10
-
10
10
                                                                                                                                                      DSRSGSPMAR
294 - 303
41
41
41
41
                                                                                                                                                      DSRSGSPMARR
294 - 304
11
11
11
11
                                                                                                                                                         SGSPMAR
297 - 303
24
24
24
24
                                                                                                                                                         SGSPMARR
297 - 304
9
9
9
9
993
871
985
865
Myelin proteolipid protein
P60201
LIETYFSK
46 - 53
12
12
12
12
QIFGDYK
99 - 105
15
15
15
15
GLSATVTGGQK
112 - 122
24
24
24
24
GLSATVTGGQKGR
112 - 124
14
14
14
14
GLSATVTGGQKGRGSR
112 - 127
4
-
4
-
           GRGSRGQHQAHSLER
123 - 137
4
4
-
4
             GSRGQHQAHSLER
125 - 137
-
9
-
9
                GQHQAHSLER
128 - 137
15
15
-
15
VCHCLGK
138 - 144
-
-
-
3
TSASIGSLCADAR
193 - 205
12
12
12
12
TSASIGSLCADARMYGVLPWNAFPGK
193 - 218
-
-
-
1
             MYGVLPWNAFPGK
206 - 218
48
48
48
48
VCGSNLLSICK
219 - 229
-
9
-
9
148
153
129
157
Myelin-oligodendrocyte glycoprotein
Q16653
VIGPRHPIR
34 - 42
3
-
3
3
VIGPRHPIRALVGDEVELPCR
34 - 54
1
-
-
-
     HPIRALVGDEVELPCR
39 - 54
-
-
-
3
         ALVGDEVELPCR
43 - 54
12
12
12
12
         ALVGDEVELPCRISPGK
43 - 59
-
-
-
1
VVHLYR
76 - 81
11
11
11
11
VVHLYRNGK
76 - 84
12
12
12
12
VVHLYRNGKDQDGDQAPEYR
76 - 95
15
15
15
15
VVHLYRNGKDQDGDQAPEYRGRTELLK
76 - 102
5
-
5
5
      NGKDQDGDQAPEYR
82 - 95
31
31
31
31
      NGKDQDGDQAPEYRGR
82 - 97
4
-
4
-
      NGKDQDGDQAPEYRGRTELLK
82 - 102
2
-
2
-
         DQDGDQAPEYR
85 - 95
12
12
12
12
         DQDGDQAPEYRGR
85 - 97
9
-
9
9
         DQDGDQAPEYRGRTELLK
85 - 102
4
-
4
4
                    GRTELLKDAIGEGK
96 - 109
-
2
-
-
                    GRTELLKDAIGEGKVTLR
96 - 113
-
-
1
-
                           DAIGEGKVTLR
103 - 113
9
9
9
-
                           DAIGEGKVTLRIR
103 - 115
-
-
2
-
FSDEGGFTCFFR
119 - 130
12
12
12
12
DHSYQEEAAMELK
131 - 143
24
24
24
24
LRAEIENLHR
186 - 195
13
13
13
13
  AEIENLHR
188 - 195
12
12
12
12
TFDPHFLR
196 - 203
5
5
-
5
RLAGQFLEELR
234 - 244
-
-
-
3
RLAGQFLEELRNPF
234 - 247
8
8
8
8
 LAGQFLEELR
235 - 244
-
9
9
9
 LAGQFLEELRNPF
235 - 247
12
12
12
12
216
199
222
216
Myelin-associated glycoprotein
P20916
FDFPDELRPAVVHGVWYFNSPYPK
44 - 67
12
12
12
12
NYPPVVFK
68 - 75
12
12
12
12
SRTQVVHESFQGR
76 - 88
10
10
10
10
SRTQVVHESFQGRSR
76 - 90
1
-
-
-
  TQVVHESFQGR
78 - 88
12
12
12
12
 LLGDLGLR
91 - 98
12
12
12
12
LREDEGTWVQVSLLHFVPTR
189 - 208
13
13
13
13
  EDEGTWVQVSLLHFVPTR
191 - 208
-
6
-
6
DGTVLR
276 - 281
4
4
4
4
DTVQCLCVVK
426 - 435
-
6
-
6
SNPEPSVAFELPSR
436 - 449
9
9
-
9
EFVYSER
459 - 465
8
8
8
8
SGLVLTSILTLR
466 - 477
12
12
12
12
SGLVLTSILTLRGQAQAPPR
466 - 485
3
-
-
-
            GQAQAPPR
478 - 485
12
12
12
12
VICTAR
486 - 491
-
-
-
2
NLYGAK
492 - 497
2
-
2
-
SLELPFQGAHR
498 - 508
12
12
12
12
NVTESPSFSAGDNPPVLFSSDFR
541 - 563
12
12
12
12
NVTESPSFSAGDNPPVLFSSDFRISGAPEK
541 - 570
7
7
7
7
                       ISGAPEK
564 - 570
3
-
-
-
                       ISGAPEKYESER
564 - 575
12
12
12
12
                       ISGAPEKYESERR
564 - 576
2
-
2
-
                       ISGAPEKYESERRLGSER
564 - 581
-
-
2
-
                              YESERRLGSER
571 - 581
6
6
6
6
                              YESERRLGSERR
571 - 582
-
-
-
1
                                   RLGSERRLLGLR
576 - 587
2
-
2
-
                                         RLLGLR
582 - 587
9
9
9
9
                                         RLLGLRGEPPELDLSYSHSDLGK
582 - 604
12
12
12
12
                                          LLGLRGEPPELDLSYSHSDLGK
583 - 604
10
10
10
10
                                          LLGLRGEPPELDLSYSHSDLGKRPTK
583 - 608
2
-
2
-
                                               GEPPELDLSYSHSDLGK
588 - 604
12
12
12
12
DSYTLTEELAEYAEIR
609 - 624
12
12
12
12
DSYTLTEELAEYAEIRVK
609 - 626
8
-
-
8
243
232
221
243
Myelin-associated oligodendrocyte basic protein
Q13875
QQPAAPPAVVR
82 - 92
12
12
12
12
QQPAAPPAVVRAPAKPR
82 - 98
-
-
3
-
QPRPRPEVRPPPAK
136 - 149
-
-
2
2
SSPLRGPGASR
162 - 172
2
-
2
-
SSPLRGPGASRGGSPVK
162 - 178
6
-
6
-
     GPGASRGGSPVK
167 - 178
-
-
2
-
20
12
27
14
Oligodendrocyte myelin glycoprotein
P23515
TLDISNNR
82 - 90
12
12
12
12
TLDISNNRLESLPAHLPR
82 - 99
18
18
18
18
        LESLPAHLPR
91 - 99
12
12
12
12
SDTAYQWNLK
117 - 126
12
12
12
12
YLDVSK
127 - 132
8
8
8
8
VVLIKNTLR
138 - 146
-
9
9
9
SLEVLNLSSNK
147 - 157
12
12
12
12
LWTVPTNMPSK
158 - 168
22
22
22
22
FTFIPDQSFDQLFQLQEITLYNNR
203 - 226
14
14
14
14
WSCDHK
227 - 232
-
2
-
2
WMMETK
241 - 246
17
17
17
17
AHVIGTPCSTQISSLK
247 - 262
9
9
-
9
ETTFGATLSK
311 - 320
8
8
-
8
144
155
136
155
Proteome data correspond to white matter (WM) and grey matter (GM) from multiple sclerosis patients (MS, n=15) and healthy donors (HD, n=9). In bold are GDP-L-fucose synthase values.
 Table S4. Patient Classification and HLA binding
A
Peptide
161-175
51-65
136-150
251-265
241-255
246-260
26-40
226-240
236-250
256-270
296-310
1-15
76-90
156-170
121-135
131-145
166-180
231-245
261-275
271-285
Log10 SI Wsum
66JO
0.96
1.12
0.92
0.78
0.59
0.70
1.08
1.00
0.69
0.91
0.47
1.02
0.81
0.94
0.96
1.03
0.61
0.73
0.70
0.60
0.00
Nonresponder
103FH
0.87
0.73
0.80
0.58
0.67
0.61
0.70
0.81
0.68
0.83
0.69
0.73
0.75
0.78
0.64
0.62
0.79
0.96
0.70
0.82
0.00
Nonresponder
204AM
0.87
0.77
0.69
0.87
0.86
0.76
0.70
1.10
0.79
0.94
0.44
0.89
1.14
0.94
0.64
0.97
0.84
0.89
0.72
0.93
0.00
Nonresponder
247PE
0.78
0.78
0.72
0.61
0.65
0.73
0.73
0.65
0.74
0.75
0.69
0.87
0.74
0.69
0.70
0.70
0.72
0.59
0.73
0.65
0.00
Nonresponder
381MA
1.31
0.76
1.13
1.00
1.00
1.06
0.82
1.27
0.93
0.98
0.95
0.85
0.72
1.23
1.00
1.03
1.06
0.99
0.84
1.24
0.00
Nonresponder
702AN
0.62
0.50
0.63
0.61
0.64
0.58
0.68
0.64
0.55
0.53
0.54
0.69
0.57
0.69
0.56
0.41
0.51
0.56
0.51
0.55
0.00
Nonresponder
740RA
0.99
0.78
0.70
0.81
0.77
0.80
0.89
0.86
0.75
0.59
0.66
0.86
0.82
0.81
0.67
0.68
0.84
0.81
0.64
0.95
0.00
Nonresponder
936MA
0.68
0.66
0.83
0.95
0.97
1.11
0.65
0.82
1.03
1.01
1.04
0.73
0.67
0.72
0.72
0.90
0.63
0.98
0.96
1.02
0.00
Nonresponder
973JO
0.85
0.91
0.37
0.50
0.68
0.57
0.56
0.90
0.62
0.56
0.70
0.83
0.47
0.85
0.61
0.50
1.02
0.72
0.49
0.69
0.00
Nonresponder
1125PA
0.81
1.07
0.43
0.57
0.63
0.49
0.99
0.49
0.54
0.73
0.41
0.74
0.43
0.58
0.74
0.61
0.93
0.71
0.65
0.50
0.00
Nonresponder
1292DI
1.09
0.76
0.47
0.93
0.81
0.66
0.63
0.54
0.92
0.40
0.72
0.87
0.57
0.86
0.65
0.75
0.90
1.06
0.64
0.93
0.00
Nonresponder
1300EV
1.21
0.90
0.89
0.97
0.59
0.70
0.51
0.73
0.88
0.61
0.75
0.59
0.70
0.86
0.90
0.91
1.11
0.92
0.74
0.98
0.00
Nonresponder
897UR
1.25
1.05
0.70
0.76
0.89
1.10
0.95
0.99
0.87
0.79
0.86
0.66
0.79
0.88
0.74
0.65
0.88
0.79
0.81
0.72
0.00
Nonresponder
127RO
0.86
0.67
0.63
1.08
1.03
1.15
0.62
0.65
0.86
0.98
0.94
0.62
0.65
0.70
0.80
0.70
0.54
0.88
0.84
1.01
0.00
Nonresponder
1290JA
1.17
0.91
1.06
1.08
1.19
1.34
0.88
0.98
1.34
1.18
1.10
1.02
0.72
1.13
0.87
0.98
0.74
1.01
0.94
1.41
0.00
Nonresponder
800TH
1.08
0.94
0.97
0.94
0.80
0.99
0.74
0.84
0.86
0.72
0.57
0.92
0.51
0.72
0.88
0.89
0.88
0.98
0.74
0.76
0.00
Nonresponder
830OL
0.67
0.81
0.99
0.71
0.98
0.93
0.68
0.43
0.81
0.67
0.85
1.06
0.69
0.85
0.89
0.93
0.73
0.79
0.69
0.84
0.00
Nonresponder
818MA
1.42
1.10
0.96
1.10
1.06
1.09
1.01
1.03
0.92
1.43
0.99
0.82
0.80
1.17
0.90
0.97
1.05
0.90
1.47
1.30
0.17
Nonresponder
1206CO
1.03
1.11
0.64
0.72
0.77
0.62
0.91
0.89
0.87
0.84
0.62
0.79
0.67
1.01
1.03
0.98
1.47
0.94
0.60
0.77
0.17
Nonresponder
780UR
1.09
0.84
0.90
0.76
0.88
0.76
1.11
1.54
0.91
0.91
0.68
1.05
0.78
0.94
0.90
0.90
0.85
0.76
0.84
0.82
0.79
Moderate Responder
866JE
1.32
0.87
1.03
1.60
0.87
0.81
0.97
0.97
1.03
1.11
0.79
0.80
0.68
0.98
0.92
0.92
0.93
0.93
0.92
1.12
0.98
Moderate Responder
748UR
1.48
0.83
1.11
1.42
0.94
1.01
0.80
1.02
0.88
0.98
0.92
0.83
0.89
1.24
0.87
1.05
0.97
0.83
1.10
1.13
1.01
Moderate Responder
1346JU
1.44
0.88
1.49
0.73
0.86
0.79
1.13
1.01
0.93
0.67
0.95
1.04
0.46
1.26
1.12
1.47
0.97
0.68
0.74
0.94
1.02
Moderate Responder
1081SA
1.63
0.81
1.32
1.10
1.30
1.45
1.01
0.95
1.47
1.30
1.09
1.25
0.95
1.25
1.48
1.28
1.27
1.63
1.38
1.47
1.34
Moderate Responder
817JD
1.53
1.31
1.12
1.09
0.06
1.01
4.09
0.98
0.95
1.23
1.05
0.97
0.87
1.25
1.10
1.06
0.97
0.82
0.84
0.82
1.43
Moderate Responder
1129RE
1.47
1.55
1.70
1.65
1.55
1.47
1.09
1.10
1.26
1.30
1.90
1.33
0.93
1.12
0.88
0.78
0.92
0.98
0.78
1.05
1.81
High Responder
1005ME
1.20
1.87
1.91
1.95
1.83
2.04
1.57
1.30
1.78
2.85
1.95
1.02
2.14
0.97
0.77
0.88
0.76
0.82
1.24
0.93
2.00
High Responder
1173DI
2.30
1.81
2.42
2.63
2.09
2.27
1.34
0.56
1.39
1.96
1.39
1.67
0.82
1.64
0.74
0.92
0.91
0.78
0.57
0.69
2.09
High Responder
718MA
4.57
1.56
0.89
0.79
0.80
0.95
0.69
25.93
0.73
0.65
0.91
1.22
0.69
0.75
1.03
1.14
1.25
0.80
0.62
0.90
2.16
High Responder
816DA
3.50
4.77
8.21
4.27
2.03
3.76
3.04
1.59
1.49
4.65
1.99
1.70
1.62
5.21
0.80
0.94
0.88
0.56
1.16
0.89
2.38
High Responder
776JE
2.35
4.37
7.40
6.99
6.24
7.04
4.76
2.44
4.52
6.41
4.81
2.50
1.53
4.55
1.01
0.95
0.93
0.93
1.01
1.05
2.50
High Responder
Peptide Sum
8
6
6
6
5
5
4
4
4
4
4
3
3
3
1
1
1
1
1
1
B
Binding Affinity (percentile-rank)*
37.47
13.48
29.81
68.2
29.81
75.22
16.25
21.74
39.16
43.26
39.06
61.74
4.67
10.49
2.79
11.29
60.77
33.2
20.11
41.85
8.36
2.14
74.35
61.77
74.52
94.52
83.08
91.67
19.12
86.02
43.48
77.96
10.58
51.08
65.44
93.75
86.86
19.8
70.27
82.89
Red cells med SI > 1.455.
* A lower number indicates higher binding affinity (http://tools.immuneepitope.org/mhcii/).
DRB3*0101
DRB3*0202
Immunodominant Peptides
 Table   S5.   Bacteria   selected   for   GDP-­‐L-­‐fucose   synthase   comparison
GDP   fucose   synthase
Bacterial   species
Relevance   in   MS
Reference
sequences   analyzed   (NCBI)
Acinetobacter   calcoaceticus
Gut   microbiota
Increased   in   MS   patients
Cekanaviciute   E,   Proceedings   of   ECTRIMS,   2016
Not   found
Adlercreutzia
Gut   microbiota
Decreased   in   RRMS   patients
Chen   J,   Sci   Rep,   2016
Not   found
Akkermansia   muciniphila
Gut   microbiota
Increased   in   MS   patients
Jangi   S,   Nat   Comm,   2016
Akkermansia   KLE1798,   1797,   1605,   CAG:304   (present   in   gut)
Anaerostipes   hadrus
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Bacteroides   coprocola
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Bacteroides   coprophilus
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Bacteroides   fragilis
Gut   microbiota
Oral   administration   lowers   clinical   score   in   EAE   by   polysaccharide   A
Ochoa-­‐Reparaz   J,   J   Immunol   2010
Bacteroides   fragilis
Bacteroides   stercoris
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Bacteroides   stercoris
Bifidobacterium
Gut   microbiota
Increased   in   pediatric   MS   patients
Tremlett   H,   Eur   J   Neurol,   2016
Not   found
Bilophilia
Gut   microbiota
Increased   in   pediatric   MS   patients
Tremlett   H,   Eur   J   Neurol,   2016
Not   found
Blautia
Gut   microbiota
Increased   in   RRMS   patients
Chen   J,   Sci   Rep,   2016
Blautia   obeum   and   Blautia   wexlerae   (present   in   gut)
butyrate-­‐producing   bacterium   A2-­‐175
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
butyrate-­‐producing   bacterium   SL7/1
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Butyricimonas   synergistica
Gut   microbiota
Decreased   in   MS   patients
Jangi   S,   Nat   Comm,   2016
Not   found
Christensenellaceae
Gut   microbiota
Increased   in   pediatric   MS   patients
Tremlett   H,   Eur   J   Neurol,   2016
Not   found
Clostridiaceae   bacterium   SH032
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Clostridium   perfringens   type   A
Gut   microbiota
Decreased   in   MS   patients
Rumah   KR,   Plos   one   2013
Not   found
Clostridium   perfringens   type   B
Gut   microbiota
Found   in   human   for   the   first   time   in   a   MS   patient   at   the   disease   onset
Rumah   KR,   Plos   one   2013
Not   found
Clostridium   sp.
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Clostridium   strain   KLE1755   (present   in   gut)
Clostridium   sp.   ID5
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Clostridium   sp.   RT8
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Collinsella   aerofaciens
Gut   microbiota
Decreased   in   MS   patients   untreated
Jangi   S,   Nat   Comm,   2016
Not   found
Desulfotomaculum   sp.   CYP1
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Desulfovibrio
Gut   microbiota
Increased   in   pediatric   MS   patients
Tremlett   H,   Eur   J   Neurol,   2016
Several   strains
Dorea
Gut   microbiota
Increased   in   RRMS   patients
Chen   J,   Sci   Rep,   2016
Not   found
Eubacterium   rectale   ATCC   33656
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Faecalibacterium   prausnitzii
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Fusobacterium
Gut   microbiota
Absence   associated   to   shorter   time   to   relapse   in   pediatric   MS
Tremlett   H,   J   Neurol   Sci,   2016
Not   found
Haemophilus
Gut   microbiota
Increased   in   RRMS   patients
Chen   J,   Sci   Rep,   2016
Not   found
Lachnospira   pectinoschiza
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Lachnospiraceae
Gut   microbiota
Decreased   in   pediatric   MS   patients
Tremlett   H,   Eur   J   Neurol,   2016
Lachnospiraceae   bacterium   3-­‐1   (present   in   gut)
Lactobacillus   rogosae
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Lepotrichia
Gut   microbiota
Absence   associated   to   shorter   time   to   relapse   in   pediatric   MS
Tremlett   H,   J   Neurol   Sci,   2016
Not   found
Megamonas   funiformis   YIT   11815
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Methanobrevibacter   smithii
Gut   microbiota
Increased   in   MS   patients
Jangi   S,   Nat   Comm,   2016
Not   found
Mycoplana
Gut   microbiota
Increased   in   RRMS   patients
Chen   J,   Sci   Rep,   2016
Not   found
Parabacteroides
Gut   microbiota
Decreased   in   RRMS   patients
Chen   J,   Sci   Rep,   2016
Parabacteroides   distastonis
Parabacteroides   distasonis
Gut   microbiota
Decreased   in   MS   patients
Baranzini   S   data
Parabacteroides   distastonis
Prevotella
Gut   microbiota
Decreased   in   RRMS   patients
Chen   J,   Sci   Rep,   2016
Several   strains
Prevotella   copri   DSM   18205
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Prevotella   stercorea
Gut   microbiota
Decreased   in   MS   patients   untreated
Jangi   S,   Nat   Comm,   2016
Not   found
Pseudomonas
Gut   microbiota
Increased   in   RRMS   patients
Chen   J,   Sci   Rep,   2016
Several   strains
Roseburia   sp.1120
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Ruminococcaceae
Gut   microbiota
Decreased   in   pediatric   MS   patients
Tremlett   H,   Eur   J   Neurol,   2016
Not   found
Sarcina   ventriculi
Gut   microbiota
Decreased   in   treated   vs   untreaded   MS   patients
Jangi   S,   Nat   Comm,   2016
Not   found
Slackia   isoflavoniconvertens
Gut   microbiota
Decreased   in   MS   patients   untreated
Jangi   S,   Nat   Comm,   2016
Not   found
Streptococcus   thermophiles/salivarius
Gut   microbiota
Increased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Sutterella   stercoricanis
Gut   microbiota
Increased   in   treated   vs   untreated   MS   patients
Jangi   S,   Nat   Comm,   2016
Not   found
Sutterella   wadsworthensis
Gut   microbiota
Increased   in   treated   vs   untreated   MS   patients
Jangi   S,   Nat   Comm,   2016
Not   found
Sutterella   wadsworthensis   2_1_59BFAA
Gut   microbiota
Decreased   in   Japanese   RRMS   patients
Miyake   S,   Plos   one,   2015
Not   found
Enterococcus faecium
Gut   microbiota   (Pathogen)
Enterococcus faecalis
Escherichia coli
Gut   microbiota   (Pathogen)
Escherichia coli
Helicobacter pylori
Gut   microbiota   (Pathogen)
Helicobacter pylori
Klebsiella pneumoniae
Gut   microbiota   (Pathogen)
Klebsiella pneumoniae
Campylobacter jejuni
Pathogen
Campylobacter jejuni
Mycobacterium avium
Pathogen
Mycobacterium avium
Mycobacterium tuberculosis
Pathogen
Mycobacterium tuberculosis
Porphyromonas gingivalis
Pathogen
Porphyromonas gingivalis
Pseudomonas sp
Pathogen
Pseudomonas sp
Salmonella enterica
Pathogen
Salmonella enterica
Shigella flexneri
Pathogen
Shigella flexneri
Shigella sonnei
Pathogen
Shigella sonnei
Vibrio cholerae
Pathogen
Vibrio cholerae
Yersinia pestis
Pathogen
Yersinia pestis
In red bacteria from which GDP-L-synthase sequence has been compared with the human homologous.
 Table S6. Sequence homology between human and bacterial GDP-L-fucose synthase peptides
A
GUT MICROBIOTA (MS)
51-
T A Q T R A L F E K V Q P T H
-65
%
136- P H N S N F G Y S Y A K R M I
-150
%
161- Y G C T F T A V I P T N V F G
-175
%
251- E E D E V S I K E A A E A V V
-265
%
Blautia
Blautia obeum
Q D A V E K F F A T E K P E Y
13.33
L E K T N E A Y A L A K I S G
26.67
Y G D D F I S C M P T N L Y G
46.67
T G K E L T I K E L T E L V A
40.00
Clostridium sp.
Clostriudium sp. KLE1755
Q A Q V R D F F E K E R P D V
46.67
L E E T N E A Y A I A K I A G
26.67
Y G D D F I S C M P T N L Y G
46.67
T G K E I T I K E L A E T V R
46.67
Lachnospiraceae
Lachnospiraceae bacterium 3-1 
Q A Q V T A F F E D E K P D V
33.33
L E A T N E A Y A I A K I A G
26.67
Y G D D F I S C M P T N L Y G
46.67
T G K E V T I R Q L A E T V Q
40.00
Blautia
Blautia wexlerae
Q D A V E K F F A T E K P E Y
13.33
L E K T N E A Y A L A K I S G
26.67
Y G T D Y I S V M P T N L Y G
46.67
T G K E L T I K E L T E L V A
40.00
Akkermansia muciniphila
Akkermansia sp KLE 1798
P A A V R E F F D R E K P E Y
26.67
L E Y T N E P Y A I A K I A G
26.67
Y G A N Y I A V M P T N L Y G
53.33
T G K E I S I R G L A E L I A
33.33
Akkermansia sp KLE 1797
P A A V R E F F D R E K P E Y
26.67
L E Y T N E P Y A I A K I A G
26.67
Y G A N Y I A V M P T N L Y G
53.33
T G K E I S I R G L A E L I A
33.33
Akkermansia sp KLE 1605
P A A V R E F F D R E K P E Y
26.67
L E Y T N E P Y A I A K I A G
26.67
Y G A N Y I A V M P T N L Y G
53.33
T G K E I S I R G L A E L I A
33.33
Akkermansia sp CAG:344
P A A V R E F F D R E K P E Y
26.67
L E Y T N E P Y A I A K I A G
26.67
Y G T N Y I A V M P T N L Y G
53.33
T G K E I S I G D L A R L I A
26.67
Bacteroides fragilis
G A A V K Q F F D E E M P E Y
20.00
L E Y T N E P Y A I A K I A G
26.67
Y G T N Y I A V M P T N L Y G
53.33
T G K E I T I R E L A G L I V
33.33
Bacteroides stercoris
G V A V R R F F D E E Q P E Y
26.67
L E Y T N E P Y A I A K I A G
26.67
Y G T N Y I A V M P T N L Y G
53.33
T G K E I T I R R L A E L I V
33.33
Parabacteroides distasonis
Parabacteroides distasonis
Q A A V N E F F A A E R P D Y
20.00
L E Y S N E P Y A I A K I A G
33.33
Y G T N Y I A V M P T N L Y G
53.33
T G I E L S I R E V A E L I R
40.00
PATHOGENS
GUT MICROBIOTA (NO MS) 
Enterococcus faecium
Q D A V E A F F A Q E K P D Y
20.00
L E K T N E A Y A L A K I S G
26.67
Y G T D Y I S V M P T N L Y G
46.67
T G K E L S I K E L T E M V A
46.67
Escherichia coli
S R A V H D F F A S E R I D Q
6.67
L E P T N E P Y A I A K I A G
26.67
Y G R D Y R S V M P T N L Y G
46.67
T G V D C T I R E L A Q T I A
20.00
Helicobacter pylori
K D N V Q A Y L K E Y K P T G
20.00
L E L T N E G Y A L A K L S V
33.33
K G V F Y K T L V P C N L Y G
26.67
S G V D Y S I E E Y Y E K V A
33.33
Klebsiella pneumoniae
A Q D V N N F F A N E R I D E
6.67
L E S T N E P Y A I A K I A G
26.67
Y N R D Y R S V M P T N L Y G
40.00
T G V D C S I K E L A E T I S
40.00
NO GUT MICROBIOTA
Campylobacter jejuni
Q Q A V I E F F K N E Q P E Y
20.00
L E Y N A T S F G V A K I S G
13.33
Y G T N F I T L A L N N L Y G
33.33
T G I D Y S I A E V A Q M V K
33.33
Mycobacterium avium
R A K T F D F V L E S R P Q V
20.00
L E S T N D A Y A I A K I A G
26.67
Y G L A W I S A M P T N L Y G
40.00
T G V D H T I R E I A E M V A
33.33
Mycobacterium tuberculosis
R A A T F D F V L E S R P Q V
20.00
L E P T N D A Y A I A K I A G
26.67
H G L P W I S A M P T N L Y G
33.33
T G I D H T I G E I A E M V A
33.33
Porphyromonas gingivalis
A V A V R E F F D K E E P Q Y
26.67
L E Y T N E P Y A I A K I A G
26.67
Y G T N Y I A V M P T N L Y G
53.33
T G E E I S I R D L A S L I A
26.67
Pseudomonas sp
P A A V Q A Y F A R H R V D Q
20.00
L E P T N E P Y A V A K I A G
26.67
H G R D Y R S V M P T N L Y G
40.00
T G V D C T I A E L A Q A L V
33.33
Salmonella enterica
G R A V Q A F F A G A G I D Q
13.33
L E P T N E P Y A I A K I A G
26.67
Y G R D Y R S V M P T N L Y G
46.67
T G V D C T I R E L A Q T I A
20.00
Shigella sonnei
S R A V H D F F A S E R I D Q
6.67
L E P T N E P Y A I A K I A G
26.67
Y G R D Y R S V M P T N L Y G
46.67
T G V D C T I R E L A Q T I A
20.00
Vibrio cholerae
Q K A V N A F F A T E R I D E
13.33
L E A T N E P Y A I A K I A G
26.67
Y G R D Y R S V M P T N L Y G
46.67
T G V D C T I R E M A E T M A
26.67
Yersinia pestis
Q S A V Q K F F A T E K I D E
6.67
L E P T N E P Y A I A K I A G
26.67
Y G R D Y R S V M P T N L Y G
46.67
T G V D C T I R E L A E T M A
26.67
Shigella flexneri
S R A V H D F F A S E R I D Q
6.67
L E P T N E P Y A I A K I A G
26.67
Y G R D Y R T V M P T N L Y G
46.67
T G V D C T I R E L A Q T I A
20.00
% - percentage of identidal amino acids. In red are identical amino acids. Identical peptide shared by different bacteria has the same cell color.
B
PEPTIDE   1
Y G D D F I S C M P T N L Y G
PEPTIDE   2
Y G T D Y I S V M P T N L Y G
PEPTIDE   3
Y G A N Y I A V M P T N L Y G
PEPTIDE   4
Y G T N Y I A V M P T N L Y G
PEPTIDE   5
Y G L A W I S A M P T N L Y G
PEPTIDE   6
Y G R D Y R S V M P T N L Y G
PEPTIDE   7
H G R D Y R S V M P T N L Y G
PEPTIDE   8
Y G R D Y R T V M P T N L Y G
 Table S7. Demographical and clinical characteristics of MS patients and non-MS controls
Post-mortem 
Disease Duration 
sex
age
cause of death
time (h)
MS type
(years)
Block
Type
MS Patients
MS 1
F
56
Breast carcinoma, Pneumothorax
8
SPMS
31
6
GM
MS 2
F
58
Peritonitis, inflamed caecal diverticulum
16
PPMS
22
9
WM
MS 3
F
78
Myocardial infection, acute abdomen
18
SPMS
33
1
WM
MS 6
F
58
Bronchopneumonia
6
PPMS
21
7
WM
MS 8
M
40
Dehydration / Multiple Sclerosis
18
SPMS
23
1
WM
3
WM
MS 14
F
78
Lung infection
9
PPMS
47
2
GM
MS 15
F
51
Multiple Sclerosis
15
SPMS
21
2
WM
MS 23
F
78
Metastatic carcinoma of bronchus
5
SPMS
42
1
WM
5
GM
MS 28
F
54
Bronchopneumonia
22
SPMS
20
1
WM
MS 32
F
39
Bronchopneumonia
18
PRMS
21
3
GM
MS 40
M
40
Respiratory failure, sepsis
10
SPMS
9
5
GM
MS 47
M
37
Intestinal obstruction
12
PPMS
27
2
GM
MS 51
F
49
Bronchopneumonia
12
PPMS
27
2
WM
Non-MS Controls
Non-MS 15
M
64
Cardiac failure
18
5
WM
Non-MS 18
M
35
Carcinoma of the tongue
22
3
GM
Non-MS 21
M
75
Aspiration pneumonia
17
1
GM
2
WM
Non-MS 28
F
60
heart failure, heart mestastasis
21
2
GM
1
WM
Non-MS 39
M
na.
Acute cardial death
10
5
GM
Non-MS 46
M
68
Metastatic colon cancer
10
1
GM
Non-MS 30
M
69
pericardial tamponade
7
1
GM
Brain Tissue
